Form 10-Q

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

0001193125-12-340701.txt : 20120807 0001193125-12-340701.hdr.sgml : 20120807 20120807153111 ACCESSION NUMBER: 0001193125-12-340701 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20120630 FILED AS OF DATE: 20120807 DATE AS OF CHANGE: 20120807 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MELA SCIENCES, INC. /NY CENTRAL INDEX KEY: 0001051514 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 133986004 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-51481 FILM NUMBER: 121013072 BUSINESS ADDRESS: STREET 1: 50 SOUTH BUCKHOUT STREET STREET 2: SUITE 1 CITY: IRVINGTON STATE: NY ZIP: 10533 BUSINESS PHONE: 914-591-3783 MAIL ADDRESS: STREET 1: 50 SOUTH BUCKHOUT STREET STREET 2: SUITE 1 CITY: IRVINGTON STATE: NY ZIP: 10533 FORMER COMPANY: FORMER CONFORMED NAME: ELECTRO OPTICAL SCIENCES INC /NY DATE OF NAME CHANGE: 19971216 10-Q 1 d366040d10q.htm FORM 10-Q Form 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2012

¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 000 — 51481

MELA SCIENCES, INC.

(Exact name of Registrant as specified in its charter)


Delaware		13-3986004
(State or Other Jurisdiction of Incorporation or Organization)		(I.R.S. Employer Identification No.)

50 South Buckhout Street, Suite 1 Irvington, New York		10533
(Address of Principal Executive offices)		(Zip Code)

Registrant’s Telephone Number, including area code:

(914) 591-3783

(Former name if changed since last report)

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of “accelerated filer” “large accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

As of July 31, 2012, 30,519,319 shares of the Registrant’s common stock were outstanding.

MELA Sciences, Inc.

Table of Contents


	Page
PART I. FINANCIAL INFORMATION

ITEM 1. Financial Statements

Condensed Balance Sheets as of June 30, 2012 (unaudited) and December 31, 2011		2

Condensed Statements of Operations (unaudited) for the three and six month periods ended June 30, 2012 and 2011		3

Condensed Statements of Cash Flows (unaudited) for the six month periods ended June 30, 2012 and 2011		4

Notes to Condensed Financial Statements (unaudited)		5

ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations		14

ITEM 3. Quantitative and Qualitative Disclosures about Market Risk		22

ITEM 4. Controls and Procedures		23

PART II. OTHER INFORMATION

ITEM 1. Legal Proceedings		23

ITEM 1A. Risk Factors		24

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds		25

ITEM 3. Defaults Upon Senior Securities		25

ITEM 4. Mine Safety Disclosures		25

ITEM 5. Other Information		25

ITEM 6. Exhibits		26

SIGNATURES		27

EXHIBIT INDEX		28

MELA SCIENCES, INC.

CONDENSED BALANCE SHEETS


	June 30, 2012			December 31, 2011
	(unaudited)			*
ASSETS
Current Assets:
Cash and cash equivalents	$	17,211,098		$	27,996,871
Accounts receivable		68,360			—
Inventory		473,454			—
Prepaid expenses and other current assets		664,463			1,061,550

Total Current Assets		18,417,375			29,058,421
Property and equipment, net		3,214,932			1,626,791
Patents and trademarks, net		53,258			59,208
Deferred financing costs		—			62,391
Deferred public offering cost		144,199			—
Other assets		71,235			586,498

Total Assets	$	21,900,999		$	31,393,309


LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities:
Accounts payable (includes related parties of $50,000 and $36,027- as of June 30, 2012 and December 31, 2011, respectively)	$	1,328,742		$	670,950
Accrued expenses		976,775			745,754
Deferred revenue (ST)		47,334			—
Other current liabilities		43,270			30,993

Total Current Liabilities		2,396,121			1,447,697

Long Term Liabilities:
Deferred rent		140,994			138,216
Deferred revenue (LT)		40,640			—

Total Long Term Liabilities		181,634			138,216

Total Liabilities		2,577,755			1,585,913


COMMITMENTS, CONTINGENCIES and LITIGATION (Note 8)

Stockholders’ Equity
Preferred stock — $.10 par value; authorized 10,000,000 shares; issued and outstanding: none
Common stock — $.001 par value; authorized 45,000,000 shares; issued and outstanding 30,332,217 shares at June 30, 2012 and 30,307,538 at December 31, 2011		30,332			30,308
Additional paid-in capital		150,057,460			149,304,424
Accumulated deficit		(130,764,548	)		(119,527,336	)

Stockholders’ Equity		19,323,244			29,807,396

Total Liabilities and Stockholders’ Equity	$	21,900,999		$	31,393,309

*	Derived from the audited balance sheet as of December 31, 2011

See accompanying notes to the financial statements

MELA SCIENCES, INC.

CONDENSED STATEMENTS OF OPERATIONS

(unaudited)


	Three months ended June 30,						Six months ended June 30,
	2012			2011			2012			2011

Revenue	$	75,757		$	—		$	87,007		$	—
Cost of revenue		372,048			—			502,458			—

Gross profit		(296,291	)		—			(415,451	)		—

Operating expenses:
Research and development		1,673,338			2,620,554			4,108,096			5,196,682
General and administrative		3,528,575			2,208,059			6,746,066			4,601,179

Operating loss		(5,498,204	)		(4,828,613	)		(11,269,613	)		(9,797,861	)

Interest income		9,021			13,934			22,405			34,465
Other income		4,996			5,022			9,996			11,670

Net loss:	$	(5,484,187	)	$	(4,809,657	)	$	(11,237,212	)	$	(9,751,726	)

Basic and diluted net loss per common share	$	(0.18	)	$	(0.19	)	$	(0.37	)	$	(0.39	)


Basic and diluted weighted average number of common shares outstanding		30,332,217			25,262,538			30,323,061			25,262,538

See accompanying notes to the financial statements

MELA SCIENCES, INC.

CONDENSED STATEMENTS OF CASH FLOWS

(unaudited)


	Six Months Ended June 30,
	2012			2011
Cash flows from operating activities:
Net loss	$	(11,237,212	)	$	(9,751,726	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		330,395			283,785
Noncash compensation		774,493			734,222
Write off of unamortized financing costs		62,391			—
Changes in operating assets and liabilities:
Increase in accounts receivable		(68,360	)		—
Increase in inventory		(383,181	)		—
Decrease (increase) in prepaid expenses and other current assets		306,814			(410,357	)
Increase (decrease) in accounts payable and accrued expenses		888,813			(419,525	)
Increase in deferred rent		2,778			16,956
Increase in other assets		(6,751	)		—
Increase in deferred revenue		87,974			—
Increase (decrease) in other current liabilities		12,277			(647	)

Net cash used in operating activities		(9,229,569	)		(9,547,292	)

Cash flows from investing activities:
Purchases of property and equipment		(1,390,572	)		(30,811	)

Net cash used in investing activities		(1,390,572	)		(30,811	)

Cash flows from financing activities:
Proceeds from exercise of stock options		33,310			—
Expenses related to Public Offerings		(198,942	)		—

Net cash used in financing activities		(165,632	)		—

Net decrease in cash and cash equivalents		(10,785,773	)		(9,578,103	)
Cash and cash equivalents at beginning of period		27,996,871			30,520,812

Cash and cash equivalents at end of period	$	17,211,098		$	20,942,709


Supplemental disclosure of cash flow information:
Non-cash investing activity:
Re-classification of MelaFind^® components from other assets to property and equipment	$	522,014		$	—

See accompanying notes to the financial statements

MELA SCIENCES, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(In thousands, except for share and per share data)

(unaudited)

1. ORGANIZATION AND BASIS OF PRESENTATION

MELA Sciences, Inc., a Delaware corporation (the “Company”), is a medical device company focused on the commercialization of our flagship product, MelaFind^®, and the further design and development of MelaFind^® and our technology. MelaFind^® is a non-invasive, point-of-care (in the doctor’s office) instrument to aid in the detection of melanoma. MelaFind^® features a hand-held component that emits light of multiple wavelengths to capture digital data from clinically atypical pigmented skin lesions. The data are then analyzed utilizing sophisticated classification algorithms, ‘trained’ on our proprietary database of melanomas and benign lesions, to provide information to assist in the management of the patient’s disease, including information useful in the decision of whether to biopsy the lesion.

The Company received the Food and Drug Administration’s (“FDA”) approval of the Pre-Market Approval (“PMA”) application for Melafind^® in November 2011 and in September 2011 the Company received Conformite Europeenne (“CE”) Mark approval for MelaFind^®. The Company initiated a controlled launch of MelaFind^® in selected U.S. and German markets in March 2012. Prior to March of 2012 the Company had not generated any revenues from MelaFind^®.

During the second quarter of 2012, the Company continued the MelaFind^® controlled launch with additional installations of MelaFind^® systems in both the U.S. and Germany. In the U.S., MelaFind^® systems were placed principally in the Northeast with additional installations in certain Southeastern, Southwestern and Middle-Atlantic states.

The Company anticipates that it will continue to incur net losses for the foreseeable future in the commercialization of the Melafind^® device, the conduct of a Post Approval Study (“PAS”) evaluating the sensitivity of physicians in diagnosing melanomas and high-grade lesions and the false positive rate after using MelaFind^®, the further development of Melafind^® and the Company’s technology and the expansion of its corporate infrastructure. From inception, the Company has financed operations initially through the sale of convertible preferred stock prior to becoming a public company in 2005 and subsequently through the sale of common stock

On June 15, 2012, the Company entered into a sales agreement (the “Sales Agreement”) with Cowen and Company, LLC (“Cowen”) to sell shares of its common stock with aggregate gross proceeds of up to $20,000,000, from time to time, through an “at-the-market” equity offering program (“ATM Program”) under which Cowen will act as sales agent. There were no shares of the Company’s common stock sold through the ATM Program as of June 30, 2012.

The Company faces certain risks and uncertainties which are present in many emerging medical device companies regarding future profitability, ability to obtain future capital, protection of patents and intellectual property rights, competition, rapid technological change, government regulations, changing health care marketplace, recruiting and retaining key personnel, and reliance on third party manufacturing organizations.

As of June 30, 2012, the Company’s total of cash and cash equivalents was approximately $17.2 million. Management believes that this cash balance along with anticipated revenues and the utilization of the Company’s ATM Program will be sufficient to fund the Company’s anticipated level of operations for at least the next twelve months. However, the Company will need substantial funds to broaden the commercial expansion of MelaFind^®, including further development of a direct sales force and expansion of the Company’s contract manufacturing capacity.

The net proceeds anticipated from the ATM Program are intended to be used to continue the commercial launch of MelaFind^® in the U.S. and the European Union, for continued research & development activities and for general corporate purposes, including working capital. There can be no assurances that the Company will be able to obtain additional financing in the future. Additional funds may not become available on acceptable terms, and there can be no assurance that any additional funding that the Company does obtain will be sufficient to meet the Company’s needs in the long term. In the event that the Company is unable to raise additional funds, the Company has the ability and intent to reduce certain discretionary expenditures.

The unaudited condensed financial statements included herein have been prepared from the books and records of the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for reporting on Form 10-Q. The information and note disclosures normally included in complete financial statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) have been condensed or omitted pursuant to such rules and regulations. The interim financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2011.

The Company’s management is responsible for the financial statements included in this document. The Company’s interim financial statements are unaudited. Interim results may not be indicative of the results that may be expected for the year. However, the Company believes all adjustments considered necessary for a fair presentation of these interim financial statements have been included and are of a normal and recurring nature.

2. REVENUE RECOGNITION

The Company considers revenue to be earned when all of the following criteria are met: persuasive evidence a sales arrangement exists; delivery has occurred or services have been rendered; the price is fixed or determinable; and collectability is reasonably assured. The Company’s agreements with dermatologists regarding the MelaFind^® system combines the elements noted above with a future service obligation. While the Company is required to place the MelaFind^® system with dermatologists for their exclusive use, ownership of the MelaFind^® system remains with the Company.

In the U.S., the Company generates revenue primarily from the sale of single-use electronic patient record cards. These cards activate the MelaFind^® system, capture data and store the data for each patient visit. Additionally, the Company typically charges an initial installation fee for each MelaFind^® system which covers training, delivery, supplies, maintenance and the right to use MelaFind^®. In accordance with the accounting guidance regarding multiple-element arrangements, the Company defers revenue for the undelivered service element based upon the relative standalone selling prices, and recognizes the associated revenue over the related service period, generally expected to be two years.

In Germany, the typical contract with dermatologists calls for a fixed monthly fee and a per patient usage charge. Revenue generated from German contracts is recognized when earned.

3. INVENTORIES

Inventories are stated at the lower of cost (first-in, first-out) or market value. Inventory costs only include material purchases as the Company does not manufacture its products.

4. USE OF ESTIMATES

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires the use of estimates and assumptions by management that affect reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to stock-based compensation arrangements and accrued expenses. Actual results could differ from these estimates.

5. RECENT ACCOUNTING PRONOUNCEMENTS

In June, 2011, the FASB issued Accounting Standard Update No 2011-05 “Presentation of Comprehensive Income” (ASU 2011-05). Under ASU 2011-05, an entity has the option to present the total of comprehensive income either in a single continuous statement of comprehensive income or in two separate but continuous statements of income and comprehensive income. The option of presentation of the components of other comprehensive income as part of the statement of change in the stockholders’ equity has been eliminated. This update was applied retrospectively and was effective for the Company for the fiscal year beginning January 1, 2012. For the periods ended June 30, 2011 and June 30, 2012, comprehensive loss was equal to net loss as the Company had no other comprehensive income or loss to report in either period.

6. NET LOSS PER COMMON SHARE

Basic net loss per common share excludes dilution for potentially dilutive securities and is computed by dividing loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share gives effect to dilutive options, warrants and other potential common shares outstanding during the period. Diluted net loss per common share is equal to the basic net loss per common share since all potentially dilutive securities are anti-dilutive for each of the periods presented. Potential common stock equivalents excluded consist of stock options and warrants which are summarized as follows:


	June 30,
	2012		2011
Common stock options		2,195,306		2,107,429
Warrants		546,781		546,781

Total		2,742,087		2,654,210

7. STOCK-BASED COMPENSATION

The Company has one stock-based compensation plan, the 2005 Stock Incentive Plan (“2005 Plan”), under which the Board of Directors may currently grant incentives to employees, consultants, directors, officers and collaborating scientists in the form of incentive stock options, nonqualified stock options and restricted stock awards. The Company also has one other stock-based compensation plan pursuant to which stock options are outstanding but no new grants may be made.

Stock awards under the Company’s stock option plans have been granted at prices which are no less than the market value of the stock on the date of the grant. Options granted under the 2005 Plan are generally time-based or performance-based, and vesting varies accordingly. Options under this plan expire in up to a maximum of ten years from the date of grant.

The compensation expense recognized in the Statement of Operations in the second quarter of 2012 and 2011 for stock options amounted to $426 (of which $199 relates to performance milestones) and $564 (of which $13 relates to performance milestones), respectively. For the six months ended June 2012 and 2011, compensation expense for stock options amounted to $774 (of which $345 relates to performance milestones) and $734 (of which $28 relates to performance milestones), respectively. No cash was received from options and warrants exercised under all share-based payment arrangements for the three month periods ended June 30, 2012 and 2011, respectively, and for the six month periods ended June 30, 2012 and 2011 cash received was $33 and $0, respectively.

The fair value of each option award granted is estimated on the date of grant using the Black-Scholes option valuation model and assumptions as noted in the following table:


	For the Six Months Ended June 30, 2012	For the Six Months Ended June 30, 2011
Expected life	6.5 years	6.5 years
Expected volatility	73.55-79.68%	70.54-76.32%%
Risk-free interest rate	0.93-1.60%	2.47-3.34%
Dividend yield	0%	0%

The expected life of the options is based on the expected time to full-vesting, forfeiture and exercise. The expected volatility assumptions were determined based upon the historical volatility of the Company’s daily closing stock price. The risk-free interest rate is based on the continuous rates provided by the U.S. Treasury with a term equal to the expected life of the option. The expected dividend yield is zero as the Company has never paid dividends and does not currently anticipate paying any in the foreseeable future.

At June 30, 2012, stock options to purchase 2,195,306 shares of common stock at exercise prices ranging from $1.00 to $11.11 per share are outstanding and exercisable at various dates through 2022.

During the three months and six months ended June 30, 2012, the weighted average fair value of options granted, estimated as of the grant date using the Black-Scholes option valuation model, was $2.71 and $2.68, respectively. For the three month and six month periods ended June 30, 2011, the weighted average fair value of options granted was $2.18 and $2.20, respectively. There were no options exercised in the three month period ended June 30, 2012. For the six months ended June 30, 2012 the total intrinsic value of options exercised was $74. For the three month and six month periods ended June 30, 2011 no options were exercised.

The status of the Company’s stock option plans at June 30, 2012 is summarized in the following:


	Number of Shares			Weighted Average Exercise Price per Share		Weighted Average Remaining Contractual Term in Years		Aggregate Intrinsic Value
Outstanding at December 31, 2011		2,057,104		$	4.35		6.6
Granted		350,563			3.93		—
Exercised		(53,123	)		—		—
Forfeited or expired		(159,238	)		6.12		—

Outstanding at June 30, 2012		2,195,306		$	4.18		7.0	$	211

Vested and exercisable at June 30, 2012		1,562,681		$	4.01		6.4	$	149


	Number Outstanding		Options Outstanding Weighted- Average Remaining Contractual Life	Weighted Average Exercise Price		Options Exercisable
Range of Exercise Prices	Number Outstanding			Weighted Average Exercise Price		Number Exercisable		Weighted- Average Exercise Price
$.01-$1.00		43,329	0.6 years	$	1.00		43,329	$	1.00
$1.01-$4.50		1,696,502	7.4 years	$	3.58		1,346,152	$	3.63
$4.51-$11.11		455,475	6.2 years	$	6.70		173,200	$	7.73

$.01-$11.11		2,195,306	7.0 years	$	4.18		1,562,681	$	4.01

As of June 30, 2012, of the total 2,195,306 options outstanding, 632,625 have not vested. Of this total unvested amount, 235,425 options will vest upon the attainment of certain milestones, and the balance will vest over the requisite service period. The weighted average vesting period for the non-milestone, non-vested awards not yet recognized is 1.9 years.

As of June 30, 2012, of the $986 of total unrecognized compensation cost related to unvested options to be recognized, $433 is to be recognized over a period to be determined by performance-based milestones, and $553 is to be recognized over the requisite service period through 2016.

As of June 30, 2012, there were 1,462,639 shares available for future grants under the Company’s 2005 Plan.

8. COMMITMENTS, CONTINGENCIES and LITIGATION

The Company is obligated under a non-cancelable operating lease for office, lab, and manufacturing space expiring December 2016. The lease is subject to escalations for increases in operating expenses. The approximate aggregate minimum future payments due under this lease are as follows:


Year ended December 31,

2012 Remaining six months	$	216
2013		461
2014		478
2015		478
2016		478

	$	2,111

Rental payments are recognized as rent expense on a straight-line basis over the term of the lease. In April 2012, the Company entered into an agreement, effective May 1, 2012, which amended the existing lease for laboratory, assembly and office space which runs through December 2016. This amendment increases the previously leased space by 1,700 square feet at an annual rental of $22.

ASKION GmbH (“ASKION”), located in Gera Germany, which specializes in precision optics, is an integral member of the MelaFind^® manufacturing and development team. ASKION produced the MelaFind^® hand-held devices used in our pivotal clinical trials. In January of 2012, the Company entered into an expanded manufacturing agreement with ASKION to continue developmental engineering, production and testing of our hand-held device, and to assemble and test the integrated finished MelaFind^® system to be placed within the European Union.

The Company, primarily through ASKION, engages Carl Zeiss Jena GmbH (“Zeiss”) to build the lenses and assemblies, as well as provide certain technical consulting, for the MelaFind^® units that had been used in the Company’s clinical trials and the commercial units currently being manufactured. This work is expected to continue on commercial MelaFind^® units beyond 2012.

In addition, we are utilizing Nexcore Technology Inc., an FDA GMP compliant and ISO 9001 certified and ISO 13485 original equipment manufacturer of medical devices in New Jersey, to provide the assembled and tested MelaFind^® systems for installation in the U.S.

The Company has an employment agreement with its President and Chief Executive Officer, Dr. Gulfo, which provides for an annual base salary, stock options and discretionary performance bonuses. The agreement, which provides for automatic one-year renewal terms, currently runs through the end of 2012.

The securities class action plaintiffs assert violations of the Securities Exchange Act of 1934, alleging, among other things, that defendants made misstatements and omissions regarding the Company’s product, MelaFind^®, and its prospects for FDA approval, on behalf of stockholders who purchased the Company’s common stock during the period from February 13, 2009 through November 16, 2010, and seek unspecified damages. On May 2, 2011, the securities class action plaintiffs filed their amended consolidated complaint, alleging similar claims to their prior complaints. On July 29, 2011, defendants filed a motion to dismiss the consolidated amended complaint in its entirety. Plaintiff’s opposition to the motion to dismiss was filed on September 23, 2011. In light of the Company’s receipt of the Approvable Letter from the FDA for the MelaFind^® PMA Application on September 22, 2011, the parties filed a stipulation on October 19, 2011 in which plaintiff stated its intention to file a motion seeking leave to amend its complaint. Defendants withdrew the outstanding motion to dismiss the current Amended Complaint without prejudice to renew it at a later date. On November 18, 2011, plaintiffs filed their motion for leave to amend the consolidated amended complaint. On December 18, 2011, defendants filed an opposition to plaintiff’s motion for leave to amend the consolidated amended complaint. On February 8, 2012, plaintiffs filed their reply to defendants’ opposition to the motion. On March 16, 2012, plaintiffs filed a revised proposed second amended complaint. On March 30, 2012, defendants filed a surreply in further opposition to the motion. On April 16, 2012, plaintiffs filed a surreply in further support of the motion.

The Company believes that it has meritorious defenses and intends to vigorously defend against the securities class action; however, as with any litigation, we cannot predict with any degree of certainty the eventual outcome of this litigation. An adverse outcome could have a material adverse effect on our business and our business could be materially harmed.

From time to time, we may be a party to certain legal proceedings, incidental to the normal course of our business. These may include controversies relating to contract claims and employment related matters, some of which claims may be material in which case we will make separate disclosure as required.

9. STOCKHOLDERS’ EQUITY

In May 2009, the Company entered into a committed equity financing facility (“CEFF”) with Kingsbridge Capital Limited, pursuant to which Kingsbridge committed to purchase from time to time at the Company’s sole discretion, up to the lesser of $45 million or 3,327,000 shares of the Company’s common stock, prior to May 25, 2012. In connection with this CEFF, the Company issued a 5 year warrant, exercisable as of November 7, 2009, to Kingsbridge to purchase up to 200,000 shares of the Company’s common stock at an exercise price of $11.35 per share.

The CEFF terminated in May 2012 with 1,095,315 shares of common stock remaining unsold. Legal, accounting, and other costs associated with this agreement approximating $62 have been charged to operations in the quarter ended June 30, 2012 as the CEFF expired. The 200,000 warrants held by Kingsbridge remain outstanding and, if not exercised, will expire in May 2014.

In May 2010, the Company filed a Form S-3 shelf registration statement for an indeterminate number of shares of common stock, warrants to purchase shares of common stock and units consisting of a combination thereof having an aggregate initial offering price not to exceed $75 million. The registration statement was declared effective by the SEC on June 1, 2010. On June 30, 2010, the Company entered into an underwriting agreement, relating to the public offering of 2,200,000 shares of the Company’s common stock, at a price to the public of $7.50 per share less underwriting discounts and commissions. The common stock was offered and sold pursuant to the Company’s Prospectus dated June 1, 2010 and the Company’s Prospectus Supplement filed with the SEC on June 30, 2010, in connection with a takedown from the Company’s effective shelf registration statement.

On December 15, 2011, the Company entered into an underwriting agreement, relating to the public offering of 5,000,000 shares of the Company’s common stock, at a price to the public of $3.25 per share less underwriting discounts and commissions. The common stock was offered and sold pursuant to the Company’s Prospectus dated June 1, 2010 and the Company’s Prospectus Supplement filed with the SEC on December 16, 2011, in connection with a takedown from the Company’s effective shelf registration statement. The gross proceeds to the Company from the sale of the common stock totaled approximately $16.3 million. After deducting the underwriters’ discounts and commissions and other offering expenses payable by the Company, net proceeds were approximately $15 million. This offering closed on December 21, 2011. Approximately $42.2 million remained available under the Company’s 2010 shelf registration at December 31, 2011.

On June 15, 2012 the Company entered into a sales agreement with Cowen and Company, LLC to sell shares of its common stock with aggregate gross proceeds of up to $20 million, from time to time, through an ATM Program. The common stock was offered and will be sold pursuant to the Company’s Prospectus dated June 1, 2010 and the Company’s Prospectus Supplement filed with the SEC on June 15, 2012, in connection with a takedown from the Company’s effective shelf registration statement, leaving $22.2 million available under the shelf registration. There were no shares of Company common stock sold through this ATM Program as of June 30, 2012. During July 2012, there were 187,102 shares of Company common stock sold through the ATM for gross proceeds of approximately $0.7 million.

As of June 30, 2012, the Company had 45,000,000 shares of $0.001 par value common stock authorized and 30,332,217 shares issued and outstanding; and had 10,000,000 shares of $0.10 par value preferred stock authorized with no preferred shares issued and outstanding.

10. WARRANTS


	Issued		Issued
	2007		2009		Total

Outstanding at December 31, 2011		346,781		200,000		546,781

Outstanding at June 30, 2012		346,781		200,000		546,781

In connection with the Company’s private placement in August 2007, the Company issued 5-year warrants to purchase up to 500,041 shares of the Company’s common stock. At June 30, 2012, 346,781 of the 2007 warrants were outstanding and exercisable at a price of $8.00 per share. At August 3, 2012, 60 months from their effective date, all 346,781 of the outstanding 2007 warrants expired.

In addition, in connection with the May 7, 2009 CEFF with Kingsbridge Capital, the Company issued a 5-year warrant to Kingsbridge to purchase up to 200,000 shares of the Company’s common stock at an exercise price of $11.35 per share. These 200,000 warrants are outstanding at June 30, 2012 and, if not exercised, will expire in May of 2014.

No warrants were exercised during the three and six month periods ended June 30, 2012 and June 30, 2011, respectively.

11. RELATED PARTY CONSULTING AGREEMENTS

The Company has in place the following consulting agreements with related parties:

Consulting Agreement with Breaux Castleman

In June 2003, the Company entered into a consulting agreement with Breaux Castleman, a former member and the former Chairman of the Company’s Board of Directors, for consulting services related to the FDA approval of MelaFind^® PMA application and the Company’s business and financial strategy. Under this agreement, Mr. Castleman received compensation for each month of services rendered. The Company made payments pursuant to this consulting agreement of $6 and $12 in the three and six month periods ended June 30, 2011. This consulting agreement was terminated in December 2011 at the time of Mr. Castleman’s resignation from the Company’s Board of Directors.

Consulting Agreement with Gerald Wagner, Ph.D

In January 2007, Dr. Wagner, Ph.D., a former member of the Company’s Board of Directors, entered into an amended and restated consulting contract with the Company for consulting services related to the Company’s operations. Under the terms of the amended contract, Dr. Wagner is paid a monthly retainer of $2.5 and will be paid $2.5 for each additional consulting day. This amended agreement may terminate at the option of Dr. Wagner or the Company at any time, by providing fifteen days’ prior written notice, or immediately upon the mutual agreement of the Company and Dr. Wagner. The Company paid consulting costs pursuant to this agreement of $7.5 and $15 in the three and six month periods ended June 30, 2012 and June 30, 2011, respectively. Dr. Wagner resigned from the Company’s Board of Directors in December 2011, with his consulting contract remaining in effect.

Consulting Agreement with Anne Egger

In March 2009, the Company entered into a consulting agreement with Anne Egger for certain consulting services primarily focusing on physician advocacy. The agreement was for an initial term of three months, and has subsequently been extended to run through September 2012, and may be terminated by either party with 30 days’ notice. Under the terms of the agreement, Ms. Egger is entitled to receive a consulting fee of $1.6 per day. The Company did not pay any amount to Ms. Egger for consulting in the three and six month periods ended June 30, 2012 and June 30, 2011, respectively. Ms. Egger was appointed to the Company’s Board of Directors in June 2009.

12. OTHER INCOME

During April 2005, the Company discontinued all operations associated with its DIFOTI^® product in order to focus its resources and attention on the development and commercialization of MelaFind^®. During December 2006, the Company entered into a sale and exclusive licensing agreement with KaVo Dental GmbH (“KaVo”), a leading dental equipment manufacturer, which provides for KaVo to further develop and commercialize DIFOTI^®. Beginning in July 2008, KaVo is required to pay to the Company a royalty stream based upon the worldwide aggregate net sales of the licensed product, as defined in the license agreement, or a set minimum. During the three and six months ended June 30, 2012 and June 30, 2011, respectively, the Company earned $5 and $10 as the pro-rated portion of the minimum royalty as KaVo has not re-launched the product as of June 30, 2012.

13. SUBSEQUENT EVENTS

During July 2012, 187,102 shares of Company common stock, for gross proceeds of approximately $0.7 million, were sold through the Company’s ATM Program. Approximately $19.3 million remains available under the ATM Program as of July 31, 2012. The Company had 30,519,319 shares of common stock issued and outstanding as of July 31, 2012.

In connection with the Company’s private placement in August 2007, the Company issued 5-year warrants to purchase up to 500,041 shares of the Company’s common stock. At June 30, 2012, there were 346,781 of the 2007 warrants outstanding and exercisable at a price of $8.00 per share. On August 3, 2012, 5 years after their effective date, all 346,781 of the 2007 outstanding warrants expired.

ITEM 2.

MELA SCIENCES, INC.

MANAGEMENT’S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This management’s discussion and analysis of financial condition and results of operations is intended to provide information to help you better understand and evaluate our financial condition and results of operations. We recommend that you read this section in conjunction with our unaudited condensed financial statements and accompanying notes included under Part I, Item 1 of this Quarterly Report and our financial statements and accompanying notes in our Annual Report on Form 10-K for the year ended December 31, 2011 (“Form 10-K”).

This quarterly report on Form 10-Q, including the following discussion and analysis of financial condition and results of operations, contains forward-looking statements that you should read in conjunction with the financial statements and notes to financial statements that we have included elsewhere in this report. These statements are based on our current expectations, assumptions, estimates and projections about our business and our industry, and involve known and unknown risks, uncertainties, and other factors that may cause our or our industry’s results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied in, or contemplated by, the forward-looking statements. Words such as “believe”, “anticipate,” “expect,” “intend,” “plan,” “will,” “may,” “should,” “estimate,” “predict,” “potential,” “continue,” or the negative of such terms or other similar expressions, identify forward-looking statements. Our actual results and the timing of events may differ significantly from the results discussed in the forward-looking statements, and you should not place undue reliance on these statements. Factors that might cause such a difference include whether MelaFind^® achieves market acceptance, as well as those discussed below under the heading “Risk Factors” in our Form 10-K and elsewhere in this quarterly report on Form 10-Q. We disclaim any intent or obligation to update any forward-looking statements as a result of developments occurring after the period covered by this report or otherwise.

Overview

We are a medical device company focused on the commercialization of our flagship product, MelaFind^®, and the further design and development of MelaFind^® and our technology. MelaFind^® is a non-invasive, point-of-care (in the doctor’s office) instrument to aid in the detection of melanoma. MelaFind^® features a hand-held component that emits light of multiple wavelengths to capture digital data from clinically atypical pigmented skin lesions. The data are then analyzed utilizing sophisticated classification algorithms, ‘trained’ on our proprietary database of melanomas and benign lesions, to provide information to assist in the management of the patient’s disease, including information useful in the decision of whether to biopsy the lesion.

We commenced operations in December 1989 as a New York corporation, re-incorporated as a Delaware corporation in September 1997, and changed our name from Electro-Optical Sciences, Inc. to MELA Sciences, Inc. on April 30, 2010. Since our inception, we have generated significant losses. As of June 30, 2012, we had an accumulated deficit of approximately $130.8 million. We expect to continue to spend significant amounts on the commercialization and further development of MelaFind^® and the development of our technology.

In the first quarter of 2012, the Company supported MelaFind^® pre-launch studies conducted by selected dermatologists in the U.S. and Germany. Enhancements to the MelaFind^® system were effected based on information gathered in these pre-launch studies. The Company initiated a controlled launch of MelaFind^® in selected U.S. and German markets in March 2012. Prior to March of 2012 the Company had not generated any revenues from MelaFind^®.

During the second quarter of 2012, the Company continued the MelaFind^® controlled launch with additional installations of MelaFind^® systems in both the U.S. and Germany. Additions were made to the direct sales force and field technical support capabilities of the Company commensurate with these additional installations and an increasing demand for MelaFind^®. Also during the quarter, the production levels of our contract manufacturers were ramped up to address the increasing demand for MelaFind^® systems. In the U.S., MelaFind^® systems were placed principally in the Northeast with additional installations in certain Southeastern, Southwestern and Middle-Atlantic states.

Liquidity and Capital Resources

The Company did not sell any stock to Kingsbridge Capital Limited under the CEFF in the three or six months ended June 30, 2012 and June 30, 2011, respectively. The CEFF terminated in May 2012 with 1,095,315 shares of common stock remaining unsold. Legal, accounting, and other costs associated with this agreement approximating $62 have been charged to operations in the quarter ended June 30, 2012 as the CEFF expired. The 200,000 warrants held by Kingsbridge remain outstanding and, if not exercised, will expire in May 2014.

On June 15, 2012 the Company entered into a sales agreement with Cowen and Company, LLC to sell shares of its common stock with aggregate gross proceeds of up to $20,000,000, from time to time, through an ATM Program. The common stock was offered and will be sold pursuant to the Company’s Prospectus dated June 1, 2010 and the Company’s Prospectus Supplement filed with the SEC on June 15, 2012, in connection with a takedown from the Company’s effective shelf registration statement, leaving $22.2 million available under the shelf registration. There were no shares of Company common stock sold through this ATM Program as of June 30, 2012. During July 2012, there were 187,102 shares of Company common stock sold through the ATM for gross proceeds of approximately $0.7 million.

Most of our expenditures prior to commercialization in March 2012 had been for research and development activities and general and administrative expenses. Research and development expenses represented costs incurred for product development, clinical trials, activities related to regulatory filings, and manufacturing development efforts. Subsequent to the commercial launch of MelaFind^®, certain costs previously classified as research and development expenses are now classified as cost of sales or general and administrative expenses.

We expense all of our research and development costs as they are incurred.

To date, we have not borrowed (other than by issuing convertible notes, all of which have been converted into equity) or financed our operations through equipment leases, financing loans or other debt instruments.

As of June 30, 2012, the Company’s total of cash and cash equivalents was approximately $17.2 million. The Company will require additional funds to achieve significant commercialization of MelaFind^®. However, there can be no assurances that the Company will be able to obtain additional financing in the future. Additional funds may not become available on acceptable terms, and there can be no assurance that any additional funding that the Company does obtain will be sufficient to meet the Company’s needs in the long term. In the event that the Company is unable to raise additional funds, the Company has the ability and intent to reduce certain discretionary expenditures.

Our cash and cash equivalents at June 30, 2012 are liquid investments in money market accounts and deposits with commercial banks, which are held in amounts that substantially exceed FDIC limits.

Cash Flows from Operating Activities (in thousands)

Net cash used in operations was $9,230 for the six months ended June 30, 2012. For the corresponding period in 2011, net cash used in operations was $9,547. In both periods, cash used in operations was attributable to net losses after an adjustment for non-cash charges related to depreciation/amortization, share-based compensation, deferred rent, deferred revenue, the acquisition of MelaFind^® related inventory and other changes in operating assets and liabilities.

Cash Flows from Investing Activities

For the six months ended June 30, 2012, there was $1,391 net cash used in our investing activities, principally for the purchase of MelaFind^® systems and components. For the corresponding period in 2011, $31 net cash was used in our investing activities, principally for the purchase of fixed assets.

Cash Flows from Financing Activities

For the six months ended June 30, 2012, there was $166 used in our financing activities representing the net of expenses related to our ATM Program, additional costs from our December 2011 public offering offset, in part, by the proceeds from the exercise of stock options. For the six months ended June 30, 2011, no net cash was provided by or used in our financing activities.

Operating Capital and Capital Expenditure Requirements

We face certain risks and uncertainties, which are present in many emerging medical device companies. At June 30, 2012, we had an accumulated deficit of approximately $130.8 million. We anticipate that we will continue to incur net losses for the foreseeable future as we proceed with the MelaFind^® commercialization process, the conduct of a Post Approval Study (“PAS”) evaluating the sensitivity of physicians in diagnosing melanomas and high-grade lesions and the false positive rate after using MelaFind^®, the further development of Melafind^® and the Company’s technology and the expansion of its corporate infrastructure. However, we will need substantial funds to broaden the commercial expansion of Melafind^®. The timing and amount of any additional funding the Company may require to broaden the commercial expansion of Melafind^® will be affected by the commercial success of the product. The funding could be in the form of either additional equity or debt financing. We believe that our current cash and cash equivalents, anticipated revenue and the utilization of the Company’s ATM Program will be sufficient to meet our anticipated cash needs for working capital and capital expenditures for at least the next twelve months. However, if our existing cash is insufficient to satisfy our liquidity requirements, or if we develop additional products, we may seek to sell additional equity or debt securities or obtain a credit facility, which will be even more difficult due to the lack of available capital as a result of the recent global economic crisis. If additional funds are raised through the issuance of debt securities, these securities would have rights senior to those associated with our common stock and could contain covenants that would restrict our operations. Any additional financing may not be available in amounts or on terms acceptable to us, or at all. If we are unable to obtain this additional financing, we may be required to reduce the scope of, delay or eliminate some or all of planned product research development and commercialization activities, which could harm our business.

Because of the numerous risks and uncertainties associated with the development and commercialization of medical devices such as MelaFind^® and operating our Company, we are unable to estimate the exact amounts of capital outlays and operating expenditures. Our future funding requirements will depend on many factors, including, but not limited to:

•

the cost of commercialization activities, including product marketing and building a domestic direct sales force;

•

the amount of direct payments we are able to obtain from physicians utilizing MelaFind^®;

•

the costs of maintaining regulatory approval;

•

reimbursement amounts for the use of MelaFind^® that we are able to obtain from Medicare and third party payers;

•

the success of our research and development efforts in product creation and enhancement, and meeting competitive services and technologies;

•

the schedule, costs, and results of our clinical trials;

•

the costs of maintaining or potentially building our inventory and other manufacturing expenses;

•

our ability to establish and maintain any collaborative, licensing or other arrangements, and the terms and timing of any such arrangements;

•

the costs involved in defending any patent infringement actions or other litigation claims brought against us by third parties; and

•

the costs of filing, prosecuting, defending and enforcing any patent claims or other rights.

Contractual Obligations (in thousands)

The following table summarizes our outstanding contractual obligations as of June 30, 2012, and the effect those obligations are expected to have on our liquidity and cash flows in future periods:


	Total		Less than 1 year		1-3 years		4-5 years
Operating leases	$	2,111	$	447	$	947	$	717

Our long-term obligations represent a non-cancelable operating lease for our laboratory, assembly, and office space which expires in December of 2016. The lease is for approximately 21,700 square feet of space including 1,700 square feet which became effective May 1, 2012. This amendment increased the annual rental by $22.

Results of Operations (in thousands)

In the six months ended June 30, 2012, the Company evolved from being exclusively an R&D company prior to the MelaFind^® launch to a commercial company with the controlled installation of MelaFind^® systems in the U.S. and Germany. Additions were made to the direct sales force and field technical support capabilities of the Company commensurate with these additional installations and increasing demand for MelaFind^®. Also during the quarter, the production levels of our contract manufacturers were accelerated to address the increasing demand for MelaFind^® systems. For the first two months of 2012 the Company continued to record all transactions as an R&D company, as it had in 2011. Subsequent to the commercial launch of MelaFind^®, certain costs previously classified as research and development expenses are now classified as cost of sales or general administrative expenses. Sales and marketing efforts have been increased in the first six months of 2012 leading up to and subsequent to the commercial launch of MelaFind^®.

Three Months Ended June 30, 2012 Compared to Three Months Ended June 30, 2011

Sales

Invoicing for the quarter totaled $147, with revenue of $76 and deferred revenue of $71 recorded in the three months ended June 30, 2012 as the Company continued its controlled commercial launch of the MelaFind^® product which commenced during March 2012. Prior to the commercial launch of MelaFind^®, the Company had not recorded any product revenue or deferred revenue since the discontinuance of our Difoti product in 2005. In general, the Company signs a user agreement with its customers that includes an installation fee for the placement of the MelaFind^® system and for the sale of its electronic patient record cards and consumables which are needed to operate the system. The Company is addressing unique aspects of the European marketplace through variations of the user agreement. Deferred revenue reflects the timed recognition of the installation fee revenue over the term of the user agreement, which is generally 2 years.

Cost of Sales

Costs of $372 were recorded as associated with the realization of MelaFind^® revenue and deferred revenue during the three months ended June 30, 2012. These costs were made up of direct costs associated with the placement of the MelaFind^® system in the doctor’s office, the cost of consumables delivered at installation, the cost of the electronic record cards, and depreciation costs of the MelaFind^® system placed with the customer which remains the property of the Company. Certain manufacturing overhead costs associated with supporting the contract manufacturers of MelaFind^® along with technical support and quality costs are also recorded to cost of goods sold.

Research and Development Expense

Research and development (“R&D”) expenses experienced an overall decrease of $947 or 36% in the three months ended June 30, 2012 below the comparable period a year earlier. This decrease was principally due to the decrease in R&D labor and materials at Askion in Germany of $265 and the re-classification to general and administrative (“G&A”) expense of approximately $263 of regulatory expenses and $336 of clinical expenses, and the re-classification of approximately $75 of quality expenses to cost of sales.

General and Administrative Expense

General and administrative (“G&A”) expenses experienced an overall increase of $1,321 or 60% for the three months ended June 30, 2012 above the comparable period a year earlier. Within G&A, marketing costs represented $624 of the increase as compensation related costs increased by $259 with the expansion of our field and in-house sales force, expenses for consulting in Germany increased by $167, conference expenses increased by $82 and travel expenses increased by $103.

Other year-to-year increases in general and administrative costs for the three months ended June 30, 2012 include the re-classification to G&A of approximately $ 336 in clinical and $263 of regulatory expenses which would have been classified as R&D if incurred prior to launch, while non-marketing travel expense increased by $124.

Interest Income

Interest income for the three months ended June 30, 2012 decreased to $9 from $14 in the comparable period of 2011. Interest income decreased as a result of the deterioration of interest rates and smaller cash balances during the period in 2012.

Other Income

Other income for the three months ended June 30, 2012 and 2011, respectively, was principally the $5 royalty minimum we earn each quarter from Kavo on the sale/licensing of our discontinued DEFOTI product.

Six Months Ended June 30, 2012 Compared to Six Months Ended June 30, 2011

Sales

Invoicing in the first two quarters totaled $175, with revenue of $87 and deferred revenue of $88 recorded in the six months ended June 30, 2012 as the Company commenced its controlled commercial launch of the MelaFind^® product during March 2012. Prior to the launch of MelaFind^®, the Company had not recorded any product revenue or deferred revenue since the discontinuance of our Difoti product in 2005. In general, the Company signs a user agreement with its customers that includes an installation fee for the placement of the MelaFind^® system and for the sale of its electronic patient record cards and consumables which are needed to operate the system. The Company is addressing unique aspects of the European marketplace through variations of the user agreement. Deferred revenue reflects the timed recognition of the installation fee revenue over the term of the user agreement, which is generally 2 years.

Cost of Sales

Costs of $502 were recorded as associated with the realization of MelaFind^® revenue and deferred revenue during the six months ended June 30, 2012. These costs were made up of direct costs associated with the placement of the MelaFind^® system in the doctor’s office, the cost of consumables sold, the cost of the system access cards, and depreciation costs of the MelaFind^® system placed with the customer which remains the property of the Company. Certain manufacturing overhead costs associated with supporting the contract manufacturers of MelaFind^® along with technical support and quality costs are also recorded to cost of goods sold.

Research and Development Expense

Research and development (“R&D”) expenses experienced an overall decrease of $1,089 or 21% in the six months ended June 30, 2012 below the comparable period a year earlier. This decrease was principally due to the decrease in R&D labor and materials at Askion in Germany of $719, the re-classification to general and administrative expenses of approximately $486 of regulatory expenses and $482 of clinical expenses, and of approximately $118 of quality expenses to cost of sales. These decreases were offset by an increase of $311 in software development costs and an increase of $384 in expenses related to clinical studies initiated in Germany prior to commercial launch.

General and Administrative Expense

General and administrative expenses experienced an overall increase of $2,145 or 47% for the six months ended June 30, 2012 above the comparable period a year earlier. Within G&A, marketing costs represented $902 of the increase as compensation related costs increased by $398 with the expansion of our sales force, expenses for consulting in Germany increased by $247, conference expenses increased by $121 and travel expenses increased by $154.

Other year-to-year increases in general and administrative costs for the six months ended June 30, 2012 include the re-classification to G&A of approximately $ 482 in clinical and $486 of regulatory expense which would have been classified as R&D if incurred prior to launch, while non-marketing travel expense increased by $136.

Interest Income

Interest income for the six months ended June 30, 2012 decreased to $22 from $34 in the comparable period of 2011. Interest income decreased as a result of the deterioration of interest rates and smaller cash balances during the period in 2012.

Other Income

Other income for the six months ended June 30, 2012 and 2011, respectively, was the $10 royalty minimum we earned from Kavo on the sale/licensing of our discontinued DIFOTI product.

Critical Accounting Policies and Significant Judgments and Estimates

Our management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with generally accepted accounting principles (“GAAP”). The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate our judgments related to accounting estimates. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

We believe that the following accounting policies and significant judgments and estimates relating to revenue recognition, stock-based compensation charges, and accrued expenses are most critical to aid you in fully understanding and evaluating our reported financial results.

Revenue Recognition

In Germany, the typical contract with dermatologists calls for a fixed monthly fee and a per patient usage charge. Revenue generated from German contracts is recognized when earned.

Stock-Based Compensation

We account for non-employee stock-based awards in which goods or services are the consideration received for the equity instruments issued based on the fair value of the equity instruments issued in accordance with FASB ASC 505-50, “Equity Based Payments to Non-Employees.”

We record compensation expense associated with stock options and other forms of equity compensation in accordance with FASB ASC 718, Compensation-Stock Compensation, as interpreted by SEC Staff Accounting Bulletins No. 107 and No. 110. A compensation charge is recorded when it is probable that performance conditions will be satisfied, over the period estimated to satisfy the performance condition. The probability of vesting is updated at each reporting period and compensation is adjusted prospectively.

Accrued Expenses

As part of the process of preparing financial statements, we are required to estimate accrued expenses. This process involves identifying services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for such service where we have not been invoiced or otherwise notified of the actual cost. Examples of estimated accrued expenses include:

•

professional service fees;

•

contract clinical service fees;

•

fees paid to contract manufacturers in conjunction with the production of clinical components or materials; and

•

fees paid to third party data collection organizations and investigators in conjunction with the clinical trials.

In connection with such service fees, our estimates are most affected by our projections of the timing of services provided relative to the actual level of services incurred by such service providers. The majority of our service providers invoice us monthly in arrears for services performed. In the event that we do not identify certain costs that have begun to be incurred or we are under or over our estimate of the level of services performed or the costs of such services, our actual expenses could differ from such estimates. The date on which certain services commence, the level of services performed on or before a given date, and the cost of such services are often subjective determinations. We make these judgments based upon the facts and circumstances known to us in accordance with U.S. GAAP. This is done as of each balance sheet date in our financial statements.

Off-Balance Sheet Arrangements

We do not currently have, nor have we ever had, any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. In addition, we do not engage in trading activities involving non-exchange traded contracts. As such, we are not materially exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in these relationships.

Recent Accounting Pronouncements

In June, 2011, the FASB issued Accounting Standard Update No 2011-05 “Presentation of Comprehensive Income” (ASU 2011-05). Under ASU 2011-05, an entity has the option to present the total of comprehensive income either in a single continuous statement of comprehensive income or in two separate but continuous statements of income and comprehensive income. The option of presentation of the components of other comprehensive income as part of the statement of change in the stockholders’ equity has been eliminated. This update was applied retrospectively and was effective for the Company for the fiscal year beginning January 1, 2012. For the year ended December 31, 2011 and as of June 30, 2012, comprehensive loss was equal to net loss as the Company had no other comprehensive income or loss to report in either period.

ITEM 3.

Quantitative and Qualitative Disclosures about Market Risk

Our exposure to market risk is confined to our cash, cash equivalents, and short-term investments. We invest in high-quality financial instruments, primarily money market funds, with the average effective duration of the portfolio within one year which we believe are subject to limited credit risk. We currently do not hedge interest rate exposure. Due to the short-term nature of our investments, we do not believe that we have any material exposure to interest rate risk arising from our investments. The Company is exposed to credit risks in the event of default by the financial institutions or issuers of investments in excess of FDIC insured limits. The Company performs periodic evaluations of the relative credit standing of these financial institutions and limits the amount of credit exposure with any institution.

ITEM 4.

Controls and Procedures

Evaluation of disclosure controls and procedures

Based on their evaluation as of June 30, 2012, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended, were effective to ensure that the information required to be disclosed by us in this Quarterly Report on Form 10-Q was recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and Form l0-Q, and that such information was accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Change in internal control over financial reporting

There were no changes in our internal control over financial reporting during the quarter ended June 30, 2012 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Limitations on the effectiveness of controls

Our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within a company have been detected.

PART II. OTHER INFORMATION

Item 1.

Legal Proceedings

On November 19, 2010, a purported securities class action complaint was filed in the U.S. District Court for the Southern District of New York, naming as defendants the Company and certain of its officers and directors, entitled Randall J. Pederson, Individually and on Behalf of All Others Similarly Situated v. MELA Sciences, Inc., Joseph V. Gulfo, Richard I. Steinhart, and Breaux Castleman, No. 7:10-cv-08774-JFM. Two similar complaints were also filed, one on December 2, 2010 and the other on January 20, 2011, in the same District Court, entitled Amy Steigman, Individually and on Behalf of All Others Similarly Situated v. MELA Sciences, Inc., Joseph V. Gulfo, Richard I. Steinhart, and Breaux Castleman, No. 7:10-cv-09024-JFM; and Martin Slove and Linda Slove, Individually and on Behalf of All Others Similarly Situated v. MELA Sciences, Inc., Joseph V. Gulfo, Richard I. Steinhart, and Breaux Castleman, No. 1:11-cv-00429-JFM. These three securities class actions were consolidated into one action on February 15, 2011, entitled In re MELA Sciences, Inc. Securities Litigation, No. 10-Civ-8774-JFM (“securities class action”). The securities class action plaintiffs assert violations of the Securities Exchange Act of 1934, alleging, among other things, that defendants made misstatements and omissions regarding the Company’s product, MelaFind^®, and its prospects for FDA approval, on behalf of stockholders who purchased the Company’s common stock during the period from February 13, 2009 through November 16, 2010, and seek unspecified damages. On May 2, 2011, the securities class action plaintiffs filed their amended consolidated complaint, alleging similar claims to their prior complaints. On July 29, 2011, defendants filed a motion to dismiss the consolidated amended complaint in its entirety. Plaintiff’s opposition to the motion to dismiss was filed on September 23, 2011. In light of the Company’s receipt of the Approvable Letter from the FDA for the MelaFind^® PMA Application on September 22, 2011, the parties filed a stipulation on October 19, 2011 in which plaintiff stated its intention to file a motion seeking leave to amend its complaint. Defendants withdrew the outstanding motion to dismiss the current Amended Complaint without prejudice to renew it at a later date. On November 18, 2011, plaintiffs filed their motion for leave to amend the consolidated amended complaint. On December 18, 2011, defendants filed an opposition to plaintiff’s motion for leave to amend the consolidated amended complaint. On February 8, 2012, plaintiffs

filed their reply to defendants’ opposition to the motion. On March 16, 2012, plaintiffs filed a revised proposed second amended complaint. On March 30, 2012, defendants filed a surreply in further opposition to the motion. On April 16, 2012, plaintiffs filed a surreply in further support of the motion.

Item 1A.

Risk Factors

Our business and operations entail a variety of serious risks and uncertainties, including those described in Item 1A of our Form 10-K for the year ended December 31, 2011. In addition, the following risk factors have materially changed during the three months ended June 30, 2012:

We have incurred losses for a number of years, and anticipate that we will incur continued losses for the foreseeable future.

Since 1999, we have primarily financed our operations through the sale of our equity securities and have devoted substantially all of our resources to research and development relating to MelaFind^®. Our net loss for the six months ended June 30, 2012 was approximately $5.5 million, and as of June 30, 2012, we had an accumulated deficit of approximately $130.8 million. Our research and development expenses may increase in connection with our continued commercialization and development activities related to MelaFind^®. Having commenced commercialization in March 2012, we expect to incur significant sales, marketing, contract manufacturing and inventory build-up expenses which will require additional funding. As a result, we expect to continue to incur significant and increasing operating losses for the foreseeable future. These losses, among other things, have had and will continue to have an adverse effect on our stockholders’ equity.

We may be unable to continue commercialization and continue development of MelaFind^® enhancements or other products without additional funding and we will not be able to achieve significant commercialization without additional funding.

As of June 30, 2012 we had approximately $17.2 million in cash and cash equivalents. Our operations have consumed substantial amounts of cash for each of the last ten years and we expect that our cash used by operations will increase significantly in each of the next several years. We currently believe that our available cash and cash equivalents, utilization of our ATM and anticipated revenue will be sufficient to fund our anticipated levels of operations for at least the next twelve months. However, we will need substantial funds to broaden the commercial expansion of MelaFind^®, including further development of a direct sales force and expansion of our contract manufacturing capacity. We also expect to continue to spend funds on research and development and product enhancements. Our business or operations may change in a manner that would consume available resources more rapidly than we anticipate. The amount of funding we will need will depend on many factors, including:

•

the cost of commercialization activities, including product marketing and building a domestic direct sales force and conducting activities in Germany and ultimately throughout the European Union (“EU”);

•

the costs of maintaining regulatory approval;

•

the amount of direct payments we are able to obtain from physicians utilizing MelaFind^®;

•

reimbursement amounts for the use of MelaFind^® that physicians are able to obtain from Medicare and third party payers;

•

the success of our research and development efforts in product creation and enhancement, and meeting competitive services and technologies;

•

the schedule, costs and results of any clinical trials and studies;

•

the costs of maintaining inventory and other manufacturing expenses;

•

our ability to establish and maintain any collaborative, licensing or other arrangements, and the terms and timing of any such arrangements;

•

the costs involved in defending any patent infringement actions or other litigation claims brought against us by third parties; and

•

the costs of filing, prosecuting, defending and enforcing any patent claims and other rights.

Additional financing may not be available to us when we need it, or it may not be available on favorable terms. If we are unable to obtain adequate financing on a timely basis, we may be required to significantly curtail or cease one or more of our development and marketing programs. We also may have to reduce marketing, customer support and other resources devoted to our products. We could be required to seek funds through arrangements with collaborators or others that may require us to relinquish rights to some of our technologies, product candidates or products that we would otherwise pursue on our own, or that may require us to grant a security interest in our assets. If we raise additional funds by issuing equity securities, our then-existing stockholders will experience ownership dilution, could experience declines in our share price and the terms of any new equity securities may have preferences over our common stock.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

None

Item 3.

Defaults Upon Senior Securities

Not applicable

Item 4.

Mine Safety Disclosures

Not applicable

Item 5.

Other Information

(a)

Not applicable

(b)

Not applicable

Item 6. Exhibits


Exhibit Number		Exhibit Title

31.1#		Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.

31.2#		Certification of Chief Financial Officer Pursuant to Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.

32.1#		Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.1#		Interactive Data File

#		Filed herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


MELA SCIENCES, INC.

By:		/s/ Richard I. Steinhart
		Richard I. Steinhart
		Senior Vice President and Chief Financial Officer (Principal Accounting and Financial Officer)

Date: August 7, 2012

EXHIBIT INDEX


Exhibit No.		Description

31.1		Certification by the Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.

31.2		Certification by the Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.

32.1		Certification Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.1		Interactive Data File

EX-31.1 2 d366040dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO RULE 13A-14(A) or RULE 15D-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

I, Joseph V. Gulfo, certify that:

1.	I have reviewed this report on Form 10-Q of MELA Sciences, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the financial statements for external purposes in accordance with generally accepted accounting principles;

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):

all significant deficiencies and material weaknesses in the design or operations of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

any fraud whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 7, 2012

/s/ Joseph V. Gulfo, M.D.

Joseph V. Gulfo, M.D.

Chairman, President and Chief Executive Officer

(Principal Executive Officer)

EX-31.2 3 d366040dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

CERTIFICATION BY THE CHIEF FINANCIAL OFFICER PURSUANT TO RULE 13A-14(A) or RULE 15D-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

I, Richard I. Steinhart, certify that:

1.	I have reviewed this report on Form 10-Q of MELA Sciences, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):

any fraud whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 7, 2012

/s/ Richard I. Steinhart

Richard I. Steinhart

Senior Vice President and Chief Financial Officer

(Principal Accounting and Financial Officer)

EX-32.1 4 d366040dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

MELA SCIENCES, INC.

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Each of the undersigned officers of MELA Sciences, Inc. (the “Company”) hereby certifies to his knowledge that the Company’s quarterly report on Form 10-Q for the period ended June 30, 2012 (the “Report”), as filed with the Securities and Exchange Commission on the date hereof, fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended, and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Joseph V. Gulfo

Joseph V. Gulfo

Chairman, President and Chief Executive Officer

(Principal Executive Officer)

August 7, 2012

/s/ Richard I. Steinhart

Richard I. Steinhart

Senior Vice President & Chief Financial Officer

(Principal Accounting and Financial Officer)

August 7, 2012

A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to MELA Sciences, Inc. and will be retained by MELA Sciences, Inc. and furnished to the Securities and Exchange Commission or its staff upon request. This written statement accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission, and will not be incorporated by reference into any filing of MELA Sciences, Inc. under the Securities Act of 1933 or the Securities Exchange Act of 1934, irrespective of any general incorporation language contained in such filing.

EX-101.INS 5 mela-20120630.xml XBRL INSTANCE DOCUMENT 0001051514 mela:RangeTwoMember 2012-01-01 2012-06-30 0001051514 mela:RangeThreeMember 2012-01-01 2012-06-30 0001051514 mela:RangeOneMember 2012-01-01 2012-06-30 0001051514 mela:NetRangeMember 2012-01-01 2012-06-30 0001051514 mela:RangeTwoMember 2012-06-30 0001051514 mela:RangeThreeMember 2012-06-30 0001051514 mela:RangeOneMember 2012-06-30 0001051514 mela:NetRangeMember 2012-06-30 0001051514 2011-01-01 2011-12-31 0001051514 mela:IssuedOnTwoThousandAndNineMember 2012-06-30 0001051514 mela:IssuedOnTwoThousandAndSevenMember 2011-12-31 0001051514 mela:IssuedOnTwoThousandAndNineMember 2011-12-31 0001051514 mela:IssuedOnTwoThousandAndNineMember 2012-01-01 2012-06-30 0001051514 us-gaap:PerformanceSharesMember us-gaap:StockCompensationPlanMember 2012-04-01 2012-06-30 0001051514 us-gaap:PerformanceSharesMember us-gaap:StockCompensationPlanMember 2012-01-01 2012-06-30 0001051514 us-gaap:PerformanceSharesMember us-gaap:StockCompensationPlanMember 2011-04-01 2011-06-30 0001051514 us-gaap:PerformanceSharesMember us-gaap:StockCompensationPlanMember 2011-01-01 2011-06-30 0001051514 us-gaap:PerformanceSharesMember us-gaap:StockCompensationPlanMember 2012-06-30 0001051514 us-gaap:StockCompensationPlanMember 2012-06-30 0001051514 us-gaap:StockCompensationPlanMember 2012-04-01 2012-06-30 0001051514 us-gaap:StockCompensationPlanMember 2011-04-01 2011-06-30 0001051514 us-gaap:StockCompensationPlanMember 2011-01-01 2011-06-30 0001051514 mela:CommittedEquityFinancingMember 2012-06-30 0001051514 2011-06-30 0001051514 2010-12-31 0001051514 us-gaap:WarrantMember 2012-01-01 2012-06-30 0001051514 us-gaap:StockOptionsMember 2012-01-01 2012-06-30 0001051514 us-gaap:WarrantMember 2011-01-01 2011-06-30 0001051514 us-gaap:StockOptionsMember 2011-01-01 2011-06-30 0001051514 2012-06-30 0001051514 2011-12-31 0001051514 mela:IssuedOnTwoThousandAndSevenMember 2007-08-01 2007-08-31 0001051514 2007-08-01 2007-08-31 0001051514 mela:IssuedOnTwoThousandAndSevenMember 2012-08-01 2012-08-31 0001051514 mela:IssuedOnTwoThousandAndSevenMember 2012-06-30 0001051514 mela:CommittedEquityFinancingMember 2009-11-07 0001051514 mela:IssuedOnTwoThousandAndNineMember 2009-05-07 0001051514 2012-07-01 2012-07-31 0001051514 mela:ShelfRegistrationStatementMember 2011-12-15 0001051514 mela:ShelfRegistrationStatementMember 2010-06-30 0001051514 mela:RelatedPartyMember 2012-04-01 2012-06-30 0001051514 mela:RelatedPartyMember 2012-01-01 2012-06-30 0001051514 mela:RelatedPartyMember 2011-04-01 2011-06-30 0001051514 mela:RelatedPartyMember 2011-01-01 2011-06-30 0001051514 mela:CommittedEquityFinancingMember 2012-01-01 2012-06-30 0001051514 2012-04-30 0001051514 mela:AtmProgramMember 2012-06-15 0001051514 mela:ShelfRegistrationStatementMember 2010-06-01 0001051514 us-gaap:StockCompensationPlanMember 2012-01-01 2012-06-30 0001051514 mela:CommittedEquityFinancingMember 2012-05-31 0001051514 mela:AtmProgramMember 2012-07-01 2012-07-31 0001051514 mela:CommittedEquityFinancingMember 2012-05-25 0001051514 2012-04-01 2012-06-30 0001051514 2011-04-01 2011-06-30 0001051514 2011-01-01 2011-06-30 0001051514 mela:FormerDirectorMember 2012-04-01 2012-06-30 0001051514 mela:FormerDirectorMember 2012-01-01 2012-06-30 0001051514 mela:FormerDirectorMember 2011-04-01 2011-06-30 0001051514 mela:BoardOfDirectorsFormerChairmanMember 2011-04-01 2011-06-30 0001051514 mela:FormerDirectorMember 2011-01-01 2011-06-30 0001051514 mela:BoardOfDirectorsFormerChairmanMember 2011-01-01 2011-06-30 0001051514 mela:AtmProgramMember 2012-06-30 0001051514 mela:AtmProgramMember 2011-12-31 0001051514 mela:BoardOfDirectorsFormerChairmanMember 2012-01-01 2012-06-30 0001051514 2012-07-31 0001051514 2012-01-01 2012-06-30 xbrli:pure iso4217:USD mela:Unit iso4217:USD xbrli:shares utr:sqft xbrli:shares iso4217:USD

1. ORGANIZATION AND BASIS OF PRESENTATION MELA Sciences, Inc., a Delaware corporation (the “Company”), is a medical device company focused on the commercialization of our flagship product, MelaFind®, and the further design and development of MelaFind ® and our technology. MelaFind ® is a non-invasive, point-of-care (in the doctor’s office) instrument to aid in the detection of melanoma. MelaFind ® features a hand-held component that emits light of multiple wavelengths to capture digital data from clinically atypical pigmented skin lesions. The data are then analyzed utilizing sophisticated classification algorithms, ‘trained’ on our proprietary database of melanomas and benign lesions, to provide information to assist in the management of the patient’s disease, including information useful in the decision of whether to biopsy the lesion. The Company received the Food and Drug Administration’s (“FDA”) approval of the Pre-Market Approval (“PMA”) application for Melafind ® in November 2011 and in September 2011 the Company received Conformite Europeenne (“CE”) Mark approval for MelaFind ®. The Company initiated a controlled launch of MelaFind ® in selected U.S. and German markets in March 2012. Prior to March of 2012 the Company had not generated any revenues from MelaFind ®. During the second quarter of 2012, the Company continued the MelaFind® controlled launch with additional installations of MelaFind ® systems in both the U.S. and Germany. In the U.S., MelaFind ® systems were placed principally in the Northeast with additional installations in certain Southeastern, Southwestern and Middle-Atlantic states. The Company anticipates that it will continue to incur net losses for the foreseeable future in the commercialization of the Melafind ® device, the conduct of a Post Approval Study (“PAS”) evaluating the sensitivity of physicians in diagnosing melanomas and high-grade lesions and the false positive rate after using MelaFind®, the further development of Melafind® and the Company’s technology and the expansion of its corporate infrastructure. From inception, the Company has financed operations initially through the sale of convertible preferred stock prior to becoming a public company in 2005 and subsequently through the sale of common stock On June 15, 2012, the Company entered into a sales agreement (the “Sales Agreement”) with Cowen and Company, LLC (“Cowen”) to sell shares of its common stock with aggregate gross proceeds of up to $20,000,000, from time to time, through an “at-the-market” equity offering program (“ATM Program”) under which Cowen will act as sales agent. There were no shares of the Company’s common stock sold through the ATM Program as of June 30, 2012. The Company faces certain risks and uncertainties which are present in many emerging medical device companies regarding future profitability, ability to obtain future capital, protection of patents and intellectual property rights, competition, rapid technological change, government regulations, changing health care marketplace, recruiting and retaining key personnel, and reliance on third party manufacturing organizations. As of June 30, 2012, the Company’s total of cash and cash equivalents was approximately $17.2 million. Management believes that this cash balance along with anticipated revenues and the utilization of the Company’s ATM Program will be sufficient to fund the Company’s anticipated level of operations for at least the next twelve months. However, the Company will need substantial funds to broaden the commercial expansion of MelaFind®, including further development of a direct sales force and expansion of the Company’s contract manufacturing capacity.   The net proceeds anticipated from the ATM Program are intended to be used to continue the commercial launch of MelaFind® in the U.S. and the European Union, for continued research & development activities and for general corporate purposes, including working capital. There can be no assurances that the Company will be able to obtain additional financing in the future. Additional funds may not become available on acceptable terms, and there can be no assurance that any additional funding that the Company does obtain will be sufficient to meet the Company’s needs in the long term. In the event that the Company is unable to raise additional funds, the Company has the ability and intent to reduce certain discretionary expenditures. The unaudited condensed financial statements included herein have been prepared from the books and records of the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for reporting on Form 10-Q. The information and note disclosures normally included in complete financial statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) have been condensed or omitted pursuant to such rules and regulations. The interim financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2011. The Company’s management is responsible for the financial statements included in this document. The Company’s interim financial statements are unaudited. Interim results may not be indicative of the results that may be expected for the year. However, the Company believes all adjustments considered necessary for a fair presentation of these interim financial statements have been included and are of a normal and recurring nature.

2. REVENUE RECOGNITION The Company considers revenue to be earned when all of the following criteria are met: persuasive evidence a sales arrangement exists; delivery has occurred or services have been rendered; the price is fixed or determinable; and collectability is reasonably assured. The Company’s agreements with dermatologists regarding the MelaFind ® system combines the elements noted above with a future service obligation. While the Company is required to place the MelaFind® system with dermatologists for their exclusive use, ownership of the MelaFind ® system remains with the Company. In the U.S., the Company generates revenue primarily from the sale of single-use electronic patient record cards. These cards activate the MelaFind ® system, capture data and store the data for each patient visit. Additionally, the Company typically charges an initial installation fee for each MelaFind ® system which covers training, delivery, supplies, maintenance and the right to use MelaFind ®. In accordance with the accounting guidance regarding multiple-element arrangements, the Company defers revenue for the undelivered service element based upon the relative standalone selling prices, and recognizes the associated revenue over the related service period, generally expected to be two years. In Germany, the typical contract with dermatologists calls for a fixed monthly fee and a per patient usage charge. Revenue generated from German contracts is recognized when earned.

3. INVENTORIES   Inventories are stated at the lower of cost (first-in, first-out) or market value. Inventory costs only include material purchases as the Company does not manufacture its products.

4. USE OF ESTIMATES The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires the use of estimates and assumptions by management that affect reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to stock-based compensation arrangements and accrued expenses. Actual results could differ from these estimates.

5. RECENT ACCOUNTING PRONOUNCEMENTS   In June, 2011, the FASB issued Accounting Standard Update No 2011-05 “Presentation of Comprehensive Income” (ASU 2011-05). Under ASU 2011-05, an entity has the option to present the total of comprehensive income either in a single continuous statement of comprehensive income or in two separate but continuous statements of income and comprehensive income. The option of presentation of the components of other comprehensive income as part of the statement of change in the stockholders’ equity has been eliminated. This update was applied retrospectively and was effective for the Company for the fiscal year beginning January 1, 2012. For the periods ended June 30, 2011 and June 30, 2012, comprehensive loss was equal to net loss as the Company had no other comprehensive income or loss to report in either period.

6. NET LOSS PER COMMON SHARE Basic net loss per common share excludes dilution for potentially dilutive securities and is computed by dividing loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share gives effect to dilutive options, warrants and other potential common shares outstanding during the period. Diluted net loss per common share is equal to the basic net loss per common share since all potentially dilutive securities are anti-dilutive for each of the periods presented. Potential common stock equivalents excluded consist of stock options and warrants which are summarized as follows:   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="76%"> </td> <td valign="bottom" width="3%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="3%"> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000">June 30,</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">2012</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">2011</td> <td valign="bottom"> </td> </tr>   <tr bgcolor="#cceeff"> <td valign="top"> Common stock options </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,195,306</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,107,429</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Warrants </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">546,781</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">546,781</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Total </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,742,087</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,654,210</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr>  </table>

7. STOCK-BASED COMPENSATION The Company has one stock-based compensation plan, the 2005 Stock Incentive Plan (“2005 Plan”), under which the Board of Directors may currently grant incentives to employees, consultants, directors, officers and collaborating scientists in the form of incentive stock options, nonqualified stock options and restricted stock awards. The Company also has one other stock-based compensation plan pursuant to which stock options are outstanding but no new grants may be made. Stock awards under the Company’s stock option plans have been granted at prices which are no less than the market value of the stock on the date of the grant. Options granted under the 2005 Plan are generally time-based or performance-based, and vesting varies accordingly. Options under this plan expire in up to a maximum of ten years from the date of grant. The compensation expense recognized in the Statement of Operations in the second quarter of 2012 and 2011 for stock options amounted to $426 (of which $199 relates to performance milestones) and $564 (of which $13 relates to performance milestones), respectively. For the six months ended June 2012 and 2011, compensation expense for stock options amounted to $774 (of which $345 relates to performance milestones) and $734 (of which $28 relates to performance milestones), respectively. No cash was received from options and warrants exercised under all share-based payment arrangements for the three month periods ended June 30, 2012 and 2011, respectively, and for the six month periods ended June 30, 2012 and 2011 cash received was $33 and $0, respectively.     The fair value of each option award granted is estimated on the date of grant using the Black-Scholes option valuation model and assumptions as noted in the following table:   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="62%"> </td> <td valign="bottom" width="11%"> </td> <td> </td> <td valign="bottom" width="11%"> </td> <td> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="center" style="border-bottom:1px solid #000000">For the Six Months Ended  June 30, 2012</td> <td valign="bottom"> </td> <td valign="bottom" align="center" style="border-bottom:1px solid #000000">For the Six Months Ended  June 30, 2011</td> </tr>   <tr bgcolor="#cceeff"> <td valign="top"> Expected life </td> <td valign="bottom"> </td> <td valign="bottom" align="center">6.5 years</td> <td valign="bottom"> </td> <td valign="bottom" align="center">6.5 years</td> </tr> <tr> <td valign="top"> Expected volatility </td> <td valign="bottom"> </td> <td valign="bottom" align="center">73.55-79.68%</td> <td valign="bottom"> </td> <td valign="bottom" align="center">70.54-76.32%%</td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Risk-free interest rate </td> <td valign="bottom"> </td> <td valign="bottom" align="center">0.93-1.60%</td> <td valign="bottom"> </td> <td valign="bottom" align="center">2.47-3.34%</td> </tr> <tr> <td valign="top"> Dividend yield </td> <td valign="bottom"> </td> <td valign="bottom" align="center">0%</td> <td valign="bottom"> </td> <td valign="bottom" align="center">0%</td> </tr>  </table> The expected life of the options is based on the expected time to full-vesting, forfeiture and exercise. The expected volatility assumptions were determined based upon the historical volatility of the Company’s daily closing stock price. The risk-free interest rate is based on the continuous rates provided by the U.S. Treasury with a term equal to the expected life of the option. The expected dividend yield is zero as the Company has never paid dividends and does not currently anticipate paying any in the foreseeable future. At June 30, 2012, stock options to purchase 2,195,306 shares of common stock at exercise prices ranging from $1.00 to $11.11 per share are outstanding and exercisable at various dates through 2022. During the three months and six months ended June 30, 2012, the weighted average fair value of options granted, estimated as of the grant date using the Black-Scholes option valuation model, was $2.71 and $2.68, respectively. For the three month and six month periods ended June 30, 2011, the weighted average fair value of options granted was $2.18 and $2.20, respectively. There were no options exercised in the three month period ended June 30, 2012. For the six months ended June 30, 2012 the total intrinsic value of options exercised was $74. For the three month and six month periods ended June 30, 2011 no options were exercised.   The status of the Company’s stock option plans at June 30, 2012 is summarized in the following:   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="64%"> </td> <td valign="bottom" width="5%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="5%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="5%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="5%"> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Number of Shares</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Weighted Average Exercise Price per Share</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Weighted Average Remaining Contractual Term in Years</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Aggregate Intrinsic Value</td> <td valign="bottom"> </td> </tr>   <tr bgcolor="#cceeff"> <td valign="top"> Outstanding at December 31, 2011 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,057,104</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4.35</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.6</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr> <td valign="top"> Granted </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">350,563</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.93</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Exercised </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(53,123</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr> <td valign="top"> Forfeited or expired </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(159,238</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.12</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Outstanding at June 30, 2012 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,195,306</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4.18</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7.0</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">211</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr> <td valign="top"> Vested and exercisable at June 30, 2012 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,562,681</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4.01</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.4</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">149</td> <td nowrap="nowrap" valign="bottom"> </td> </tr>  </table>   <table cellspacing="0" cellpadding="0" width="100%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="54%"> </td> <td valign="bottom" width="4%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="4%"> </td> <td> </td> <td valign="bottom" width="4%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="4%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="4%"> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" rowspan="2" align="center" style="border-bottom:1px solid #000000">Number Outstanding</td> <td valign="bottom" rowspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom" rowspan="2" align="center" style="border-bottom:1px solid #000000">Options  Outstanding Weighted- Average Remaining Contractual Life</td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" rowspan="2" align="center" style="border-bottom:1px solid #000000">Weighted Average Exercise Price</td> <td valign="bottom" rowspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000">Options Exercisable</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom" nowrap="nowrap"> Range of Exercise Prices </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Number Exercisable</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Weighted- Average Exercise Price</td> <td valign="bottom"> </td> </tr>   <tr bgcolor="#cceeff"> <td valign="top"> $.01-$1.00 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">43,329</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="center">0.6 years</td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.00</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">43,329</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.00</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> $1.01-$4.50 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,696,502</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="center">7.4 years</td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.58</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,346,152</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.63</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> $4.51-$11.11 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">455,475</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="center">6.2 years</td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6.70</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">173,200</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7.73</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr> <td valign="top"> $.01-$11.11 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,195,306</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="center">7.0 years</td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4.18</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,562,681</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4.01</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> </tr>  </table> As of June 30, 2012, of the total 2,195,306 options outstanding, 632,625 have not vested. Of this total unvested amount, 235,425 options will vest upon the attainment of certain milestones, and the balance will vest over the requisite service period. The weighted average vesting period for the non-milestone, non-vested awards not yet recognized is 1.9 years.   As of June 30, 2012, of the $986 of total unrecognized compensation cost related to unvested options to be recognized, $433 is to be recognized over a period to be determined by performance-based milestones, and $553 is to be recognized over the requisite service period through 2016. As of June 30, 2012, there were 1,462,639 shares available for future grants under the Company’s 2005 Plan.

8. COMMITMENTS, CONTINGENCIES and LITIGATION The Company is obligated under a non-cancelable operating lease for office, lab, and manufacturing space expiring December 2016. The lease is subject to escalations for increases in operating expenses. The approximate aggregate minimum future payments due under this lease are as follows:   <table cellspacing="0" cellpadding="0" width="68%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="89%"> </td> <td valign="bottom" width="6%"> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td valign="bottom">Year ended December 31,</td> <td valign="bottom"> </td> <td colspan="2" valign="bottom"> </td> <td valign="bottom"> </td> </tr>   <tr> <td height="8"> </td> <td height="8" colspan="4"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> 2012 Remaining six months </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">216</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> 2013 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">461</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> 2014 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">478</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> 2015 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">478</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> 2016 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">478</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td valign="top"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,111</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr>  </table> Rental payments are recognized as rent expense on a straight-line basis over the term of the lease. In April 2012, the Company entered into an agreement, effective May 1, 2012, which amended the existing lease for laboratory, assembly and office space which runs through December 2016. This amendment increases the previously leased space by 1,700 square feet at an annual rental of $22. ASKION GmbH (“ASKION”), located in Gera Germany, which specializes in precision optics, is an integral member of the MelaFind® manufacturing and development team. ASKION produced the MelaFind ® hand-held devices used in our pivotal clinical trials. In January of 2012, the Company entered into an expanded manufacturing agreement with ASKION to continue developmental engineering, production and testing of our hand-held device, and to assemble and test the integrated finished MelaFind ® system to be placed within the European Union. The Company, primarily through ASKION, engages Carl Zeiss Jena GmbH (“Zeiss”) to build the lenses and assemblies, as well as provide certain technical consulting, for the MelaFind ® units that had been used in the Company’s clinical trials and the commercial units currently being manufactured. This work is expected to continue on commercial MelaFind® units beyond 2012. In addition, we are utilizing Nexcore Technology Inc., an FDA GMP compliant and ISO 9001 certified and ISO 13485 original equipment manufacturer of medical devices in New Jersey, to provide the assembled and tested MelaFind® systems for installation in the U.S. The Company has an employment agreement with its President and Chief Executive Officer, Dr. Gulfo, which provides for an annual base salary, stock options and discretionary performance bonuses. The agreement, which provides for automatic one-year renewal terms, currently runs through the end of 2012.   On November 19, 2010, a purported securities class action complaint was filed in the U.S. District Court for the Southern District of New York, naming as defendants the Company and certain of its officers and directors, entitled Randall J. Pederson, Individually and on Behalf of All Others Similarly Situated v. MELA Sciences, Inc., Joseph V. Gulfo, Richard I. Steinhart, and Breaux Castleman, No. 7:10-cv-08774-JFM. Two similar complaints were also filed, one on December 2, 2010 and the other on January 20, 2011, in the same District Court, entitled Amy Steigman, Individually and on Behalf of All Others Similarly Situated v. MELA Sciences, Inc., Joseph V. Gulfo, Richard I. Steinhart, and Breaux Castleman, No. 7:10-cv-09024-JFM; and Martin Slove and Linda Slove, Individually and on Behalf of All Others Similarly Situated v. MELA Sciences, Inc., Joseph V. Gulfo, Richard I. Steinhart, and Breaux Castleman, No. 1:11 cv-00429-JFM. These three securities class actions were consolidated into one action on February 15, 2011, entitled In re MELA Sciences, Inc. Securities Litigation, No. 10-Civ-8774-JFM (“securities class action”). The securities class action plaintiffs assert violations of the Securities Exchange Act of 1934, alleging, among other things, that defendants made misstatements and omissions regarding the Company’s product, MelaFind®, and its prospects for FDA approval, on behalf of stockholders who purchased the Company’s common stock during the period from February 13, 2009 through November 16, 2010, and seek unspecified damages. On May 2, 2011, the securities class action plaintiffs filed their amended consolidated complaint, alleging similar claims to their prior complaints. On July 29, 2011, defendants filed a motion to dismiss the consolidated amended complaint in its entirety. Plaintiff’s opposition to the motion to dismiss was filed on September 23, 2011. In light of the Company’s receipt of the Approvable Letter from the FDA for the MelaFind ® PMA Application on September 22, 2011, the parties filed a stipulation on October 19, 2011 in which plaintiff stated its intention to file a motion seeking leave to amend its complaint. Defendants withdrew the outstanding motion to dismiss the current Amended Complaint without prejudice to renew it at a later date. On November 18, 2011, plaintiffs filed their motion for leave to amend the consolidated amended complaint. On December 18, 2011, defendants filed an opposition to plaintiff’s motion for leave to amend the consolidated amended complaint. On February 8, 2012, plaintiffs filed their reply to defendants’ opposition to the motion. On March 16, 2012, plaintiffs filed a revised proposed second amended complaint. On March 30, 2012, defendants filed a surreply in further opposition to the motion. On April 16, 2012, plaintiffs filed a surreply in further support of the motion. The Company believes that it has meritorious defenses and intends to vigorously defend against the securities class action; however, as with any litigation, we cannot predict with any degree of certainty the eventual outcome of this litigation. An adverse outcome could have a material adverse effect on our business and our business could be materially harmed. From time to time, we may be a party to certain legal proceedings, incidental to the normal course of our business. These may include controversies relating to contract claims and employment related matters, some of which claims may be material in which case we will make separate disclosure as required.

9. STOCKHOLDERS’ EQUITY In May 2009, the Company entered into a committed equity financing facility (“CEFF”) with Kingsbridge Capital Limited, pursuant to which Kingsbridge committed to purchase from time to time at the Company’s sole discretion, up to the lesser of $45 million or 3,327,000 shares of the Company’s common stock, prior to May 25, 2012. In connection with this CEFF, the Company issued a 5 year warrant, exercisable as of November 7, 2009, to Kingsbridge to purchase up to 200,000 shares of the Company’s common stock at an exercise price of $11.35 per share. The CEFF terminated in May 2012 with 1,095,315 shares of common stock remaining unsold. Legal, accounting, and other costs associated with this agreement approximating $62 have been charged to operations in the quarter ended June 30, 2012 as the CEFF expired. The 200,000 warrants held by Kingsbridge remain outstanding and, if not exercised, will expire in May 2014.   In May 2010, the Company filed a Form S-3 shelf registration statement for an indeterminate number of shares of common stock, warrants to purchase shares of common stock and units consisting of a combination thereof having an aggregate initial offering price not to exceed $75 million. The registration statement was declared effective by the SEC on June 1, 2010. On June 30, 2010, the Company entered into an underwriting agreement, relating to the public offering of 2,200,000 shares of the Company’s common stock, at a price to the public of $7.50 per share less underwriting discounts and commissions. The common stock was offered and sold pursuant to the Company’s Prospectus dated June 1, 2010 and the Company’s Prospectus Supplement filed with the SEC on June 30, 2010, in connection with a takedown from the Company’s effective shelf registration statement. On December 15, 2011, the Company entered into an underwriting agreement, relating to the public offering of 5,000,000 shares of the Company’s common stock, at a price to the public of $3.25 per share less underwriting discounts and commissions. The common stock was offered and sold pursuant to the Company’s Prospectus dated June 1, 2010 and the Company’s Prospectus Supplement filed with the SEC on December 16, 2011, in connection with a takedown from the Company’s effective shelf registration statement. The gross proceeds to the Company from the sale of the common stock totaled approximately $16.3 million. After deducting the underwriters’ discounts and commissions and other offering expenses payable by the Company, net proceeds were approximately $15 million. This offering closed on December 21, 2011. Approximately $42.2 million remained available under the Company’s 2010 shelf registration at December 31, 2011. On June 15, 2012 the Company entered into a sales agreement with Cowen and Company, LLC to sell shares of its common stock with aggregate gross proceeds of up to $20 million, from time to time, through an ATM Program. The common stock was offered and will be sold pursuant to the Company’s Prospectus dated June 1, 2010 and the Company’s Prospectus Supplement filed with the SEC on June 15, 2012, in connection with a takedown from the Company’s effective shelf registration statement, leaving $22.2 million available under the shelf registration. There were no shares of Company common stock sold through this ATM Program as of June 30, 2012. During July 2012, there were 187,102 shares of Company common stock sold through the ATM for gross proceeds of approximately $0.7 million. As of June 30, 2012, the Company had 45,000,000 shares of $0.001 par value common stock authorized and 30,332,217 shares issued and outstanding; and had 10,000,000 shares of $0.10 par value preferred stock authorized with no preferred shares issued and outstanding.

10. WARRANTS   <table cellspacing="0" cellpadding="0" width="84%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="73%"> </td> <td valign="bottom" width="2%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="2%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="2%"> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Issued</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Issued</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td colspan="2" valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">2007</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">2009</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Total</td> <td valign="bottom"> </td> </tr>   <tr> <td height="8"> </td> <td height="8" colspan="4"> </td> <td height="8" colspan="4"> </td> <td height="8" colspan="4"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Outstanding at December 31, 2011 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">346,781</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">200,000</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">546,781</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td valign="top"> Outstanding at June 30, 2012 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">346,781</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">200,000</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">546,781</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr>  </table> In connection with the Company’s private placement in August 2007, the Company issued 5-year warrants to purchase up to 500,041 shares of the Company’s common stock. At June 30, 2012, 346,781 of the 2007 warrants were outstanding and exercisable at a price of $8.00 per share. At August 3, 2012, 60 months from their effective date, all 346,781 of the outstanding 2007 warrants expired. In addition, in connection with the May 7, 2009 CEFF with Kingsbridge Capital, the Company issued a 5-year warrant to Kingsbridge to purchase up to 200,000 shares of the Company’s common stock at an exercise price of $11.35 per share. These 200,000 warrants are outstanding at June 30, 2012 and, if not exercised, will expire in May of 2014. No warrants were exercised during the three and six month periods ended June 30, 2012 and June 30, 2011, respectively.

11. RELATED PARTY CONSULTING AGREEMENTS The Company has in place the following consulting agreements with related parties: Consulting Agreement with Breaux Castleman In June 2003, the Company entered into a consulting agreement with Breaux Castleman, a former member and the former Chairman of the Company’s Board of Directors, for consulting services related to the FDA approval of MelaFind® PMA application and the Company’s business and financial strategy. Under this agreement, Mr. Castleman received compensation for each month of services rendered. The Company made payments pursuant to this consulting agreement of $6 and $12 in the three and six month periods ended June 30, 2011. This consulting agreement was terminated in December 2011 at the time of Mr. Castleman’s resignation from the Company’s Board of Directors. Consulting Agreement with Gerald Wagner, Ph.D In January 2007, Dr. Wagner, Ph.D., a former member of the Company’s Board of Directors, entered into an amended and restated consulting contract with the Company for consulting services related to the Company’s operations. Under the terms of the amended contract, Dr. Wagner is paid a monthly retainer of $2.5 and will be paid $2.5 for each additional consulting day. This amended agreement may terminate at the option of Dr. Wagner or the Company at any time, by providing fifteen days’ prior written notice, or immediately upon the mutual agreement of the Company and Dr. Wagner. The Company paid consulting costs pursuant to this agreement of $7.5 and $15 in the three and six month periods ended June 30, 2012 and June 30, 2011, respectively. Dr. Wagner resigned from the Company’s Board of Directors in December 2011, with his consulting contract remaining in effect. Consulting Agreement with Anne Egger In March 2009, the Company entered into a consulting agreement with Anne Egger for certain consulting services primarily focusing on physician advocacy. The agreement was for an initial term of three months, and has subsequently been extended to run through September 2012, and may be terminated by either party with 30 days’ notice. Under the terms of the agreement, Ms. Egger is entitled to receive a consulting fee of $1.6 per day. The Company did not pay any amount to Ms. Egger for consulting in the three and six month periods ended June 30, 2012 and June 30, 2011, respectively. Ms. Egger was appointed to the Company’s Board of Directors in June 2009.

12. OTHER INCOME During April 2005, the Company discontinued all operations associated with its DIFOTI ® product in order to focus its resources and attention on the development and commercialization of MelaFind ®. During December 2006, the Company entered into a sale and exclusive licensing agreement with KaVo Dental GmbH (“KaVo”), a leading dental equipment manufacturer, which provides for KaVo to further develop and commercialize DIFOTI®. Beginning in July 2008, KaVo is required to pay to the Company a royalty stream based upon the worldwide aggregate net sales of the licensed product, as defined in the license agreement, or a set minimum. During the three and six months ended June 30, 2012 and June 30, 2011, respectively, the Company earned $5 and $10 as the pro-rated portion of the minimum royalty as KaVo has not re-launched the product as of June 30, 2012.

13. SUBSEQUENT EVENTS During July 2012, 187,102 shares of Company common stock, for gross proceeds of approximately $0.7 million, were sold through the Company’s ATM Program. Approximately $19.3 million remains available under the ATM Program as of July 31, 2012. The Company had 30,519,319 shares of common stock issued and outstanding as of July 31, 2012.   In connection with the Company’s private placement in August 2007, the Company issued 5-year warrants to purchase up to 500,041 shares of the Company’s common stock. At June 30, 2012, there were 346,781 of the 2007 warrants outstanding and exercisable at a price of $8.00 per share. On August 3, 2012, 5 years after their effective date, all 346,781 of the 2007 outstanding warrants expired.

In June, 2011, the FASB issued Accounting Standard Update No 2011-05 “Presentation of Comprehensive Income” (ASU 2011-05). Under ASU 2011-05, an entity has the option to present the total of comprehensive income either in a single continuous statement of comprehensive income or in two separate but continuous statements of income and comprehensive income. The option of presentation of the components of other comprehensive income as part of the statement of change in the stockholders’ equity has been eliminated. This update was applied retrospectively and was effective for the Company for the fiscal year beginning January 1, 2012. For the periods ended June 30, 2011 and June 30, 2012, comprehensive loss was equal to net loss as the Company had no other comprehensive income or loss to report in either period.

The status of the Company’s stock option plans at June 30, 2012 is summarized in the following:   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="64%"> </td> <td valign="bottom" width="5%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="5%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="5%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="5%"> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Number of Shares</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Weighted Average Exercise Price per Share</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Weighted Average Remaining Contractual Term in Years</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Aggregate Intrinsic Value</td> <td valign="bottom"> </td> </tr>   <tr bgcolor="#cceeff"> <td valign="top"> Outstanding at December 31, 2011 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,057,104</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4.35</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.6</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr> <td valign="top"> Granted </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">350,563</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.93</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Exercised </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(53,123</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr> <td valign="top"> Forfeited or expired </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(159,238</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.12</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Outstanding at June 30, 2012 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,195,306</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4.18</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7.0</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">211</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr> <td valign="top"> Vested and exercisable at June 30, 2012 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,562,681</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4.01</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.4</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">149</td> <td nowrap="nowrap" valign="bottom"> </td> </tr>  </table>

<table cellspacing="0" cellpadding="0" width="100%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="54%"> </td> <td valign="bottom" width="4%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="4%"> </td> <td> </td> <td valign="bottom" width="4%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="4%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="4%"> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" rowspan="2" align="center" style="border-bottom:1px solid #000000">Number Outstanding</td> <td valign="bottom" rowspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom" rowspan="2" align="center" style="border-bottom:1px solid #000000">Options  Outstanding Weighted- Average Remaining Contractual Life</td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" rowspan="2" align="center" style="border-bottom:1px solid #000000">Weighted Average Exercise Price</td> <td valign="bottom" rowspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000">Options Exercisable</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom" nowrap="nowrap"> Range of Exercise Prices </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Number Exercisable</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Weighted- Average Exercise Price</td> <td valign="bottom"> </td> </tr>   <tr bgcolor="#cceeff"> <td valign="top"> $.01-$1.00 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">43,329</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="center">0.6 years</td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.00</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">43,329</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.00</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> $1.01-$4.50 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,696,502</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="center">7.4 years</td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.58</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,346,152</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.63</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> $4.51-$11.11 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">455,475</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="center">6.2 years</td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6.70</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">173,200</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7.73</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr> <td valign="top"> $.01-$11.11 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,195,306</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="center">7.0 years</td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4.18</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,562,681</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4.01</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> </tr>  </table>

The approximate aggregate minimum future payments due under this lease are as follows:   <table cellspacing="0" cellpadding="0" width="68%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="89%"> </td> <td valign="bottom" width="6%"> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td valign="bottom">Year ended December 31,</td> <td valign="bottom"> </td> <td colspan="2" valign="bottom"> </td> <td valign="bottom"> </td> </tr>   <tr> <td height="8"> </td> <td height="8" colspan="4"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> 2012 Remaining six months </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">216</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> 2013 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">461</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> 2014 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">478</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> 2015 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">478</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> 2016 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">478</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td valign="top"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,111</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr>  </table>   <table cellspacing="0" cellpadding="0" width="84%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="73%"> </td> <td valign="bottom" width="2%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="2%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="2%"> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Issued</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Issued</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td colspan="2" valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">2007</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">2009</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Total</td> <td valign="bottom"> </td> </tr>   <tr> <td height="8"> </td> <td height="8" colspan="4"> </td> <td height="8" colspan="4"> </td> <td height="8" colspan="4"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Outstanding at December 31, 2011 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">346,781</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">200,000</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">546,781</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td valign="top"> Outstanding at June 30, 2012 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">346,781</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">200,000</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">546,781</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr>  </table> false --12-31 Q2 2012 2012-06-30 10-Q 0001051514 30519319 Accelerated Filer MELA SCIENCES, INC. /NY 2.5 42200000 22200000 12 15 6 7.5 15 7.5 P2Y 25262538 25262538 30323061 30332217 3327000 45000000 187102 1095315 Up to 10 years 16300000 20000000 700000 75000000 1700 62 2.5 15000000 0 0 0 0 7.50 3.25 2200000 5000000 522014 19300000 200000 200000 11.35 11.35 8.00 632625 553000 P60M 500041 500041 62391

670950

1328742

36027

50000

68360

745754

976775

149304424

150057460

2654210

2107429

546781

2742087

2195306

546781

31393309

21900999

29058421

18417375

30520812

20942709

27996871

17211098

-9578103

-10785773

8.00

200000

346781

0.001

45000000

30307538

30332217

187102

30519319

30307538

30332217

30519319

30308

30332

502458

372048

62391

144199

138216

140994

47334

40640

283785

330395

-0.39

-0.19

-0.37

-0.18

33000

P1Y10M24D

986000

433000

734000

28000

564000

13000

774000

345000

426000

199000

4601179

2208059

6746066

3528575

-415451

-296291

-419525

888813

68360

16956

2778

87974

383181

6751

-647

12277

410357

-306814

59208

53258

473454

34465

13934

22405

9021

1585913

2577755

31393309

21900999

1447697

2396121

138216

181634

-165632

-30811

-1390572

-9547292

-9229569

-9751726

-4809657

-11237212

-5484187

-9797861

-4828613

-11269613

-5498204

2111000

216000

478000

461000

22000

586498

71235

30993

43270

11670

5022

9996

4996

1.6

198942

30811

1390572

0.10

10000000

1061550

664463

20000000000

700000

33310

1626791

3214932

2011-12-01

5196682

2620554

4108096

1673338

-119527336

-130764548

87007

75757

734222

774493

P5Y

2014-05-01

0.00

P6Y6M

0.7632

0.7968

0.7054

0.7355

0.0334

0.0160

0.0247

0.0093

546781

200000

346781

546781

200000

346781

1462639

149

1562681

4.01

P6Y4M24D

74000

-159238

6.12

350563

2.20

2.18

2.68

2.71

211

2057104

2195306

4.35

4.18

P6Y7M6D

P7Y

235425

3.93

4.01

1.00

7.73

3.63

0.01

4.51

1.01

1.00

1562681

43329

173200

1346152

2195306

43329

455475

1696502

4.18

1.00

6.70

3.58

P7Y

P7M6D

P6Y2M12D

P7Y4M24D

11.11

1.00

11.11

4.50

11.11

29807396

19323244

-53123

EX-101.SCH 6 mela-20120630.xsd XBRL TAXONOMY EXTENSION SCHEMA 0403 - Disclosure - Inventories (Policies) link:presentationLink link:calculationLink link:definitionLink 0120 - Statement - Condensed Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0613 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink 0612 - Disclosure - Other Income (Details) link:presentationLink link:calculationLink link:definitionLink 0611 - Disclosure - Related Party Consulting Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 06101 - Disclosure - Warrants (Details Textual) link:presentationLink link:calculationLink link:definitionLink 0610 - Disclosure - Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 0609 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 06081 - Disclosure - Commitments, Contingencies and Litigation (Details Textual) link:presentationLink link:calculationLink link:definitionLink 0608 - Disclosure - Commitments, Contingencies and Litigation (Details) link:presentationLink link:calculationLink link:definitionLink 06073 - Disclosure - Stock Based Compensation (Details Textual) link:presentationLink link:calculationLink link:definitionLink 06072 - Disclosure - Stock Based Compensation (Details 2) link:presentationLink link:calculationLink link:definitionLink 06071 - Disclosure - Stock Based Compensation (Details 1) link:presentationLink link:calculationLink link:definitionLink 0607 - Disclosure - Stock Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 0606 - Disclosure - Net Loss Per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 0602 - Disclosure - Revenue Recognition (Details) link:presentationLink link:calculationLink link:definitionLink 0601 - Disclosure - Organization and Basis of Presentation (Details) link:presentationLink link:calculationLink link:definitionLink 0510 - Disclosure - Warrants (Tables) link:presentationLink link:calculationLink link:definitionLink 0508 - Disclosure - Commitments, Contingencies and Litigation (Tables) link:presentationLink link:calculationLink link:definitionLink 0507 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 0506 - Disclosure - Net Loss Per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 0405 - Disclosure - Recent Accounting Pronouncements (Policies) link:presentationLink link:calculationLink link:definitionLink 00 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 0110 - Statement - Condensed Balance Sheets link:presentationLink link:definitionLink link:calculationLink 0111 - Statement - Condensed Balance Sheets (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 0130 - Statement - Condensed Statements of Cash Flows (Unaudited) link:presentationLink link:definitionLink link:calculationLink 0201 - Disclosure - Organization and Basis of Presentation link:presentationLink link:definitionLink link:calculationLink 0202 - Disclosure - Revenue Recognition link:presentationLink link:definitionLink link:calculationLink 0203 - Disclosure - Inventories link:presentationLink link:definitionLink link:calculationLink 0204 - Disclosure - Use of Estimates link:presentationLink link:definitionLink link:calculationLink 0205 - Disclosure - Recent Accounting Pronouncements link:presentationLink link:definitionLink link:calculationLink 0206 - Disclosure - Net Loss Per Common Share link:presentationLink link:definitionLink link:calculationLink 0207 - Disclosure - Stock-Based Compensation link:presentationLink link:definitionLink link:calculationLink 0208 - Disclosure - Commitments, Contingencies and Litigation link:presentationLink link:definitionLink link:calculationLink 0209 - Disclosure - Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 0210 - Disclosure - Warrants link:presentationLink link:definitionLink link:calculationLink 0211 - Disclosure - Related Party Consulting Agreements link:presentationLink link:definitionLink link:calculationLink 0212 - Disclosure - Other Income link:presentationLink link:definitionLink link:calculationLink 0213 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 mela-20120630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 mela-20120630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 mela-20120630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document and Entity Information [Abstract] Document and entity information. ASSETS Assets [Abstract] Current Assets: Assets, Current [Abstract] Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents at end of period Cash and cash equivalents at beginning of period Total cash and cash equivalents Cash and cash equivalents Accounts receivable Accounts Receivable, Net, Current Inventory Inventory, Net Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Assets, Current, Total Total Current Assets Property and equipment, net Property, Plant and Equipment, Net Patents and trademarks, net Intangible Assets, Net (Excluding Goodwill) Deferred financing costs Deferred Finance Costs, Noncurrent, Net Other Assets, Noncurrent Other assets Assets, Total Total Assets Liabilities And Stockholders Equity [Abstract] LIABILITIES AND STOCKHOLDERS EQUITY Current Liabilities: Liabilities, Current [Abstract] Accounts payable (includes related parties of $50,000 and $36,027-as of June 30, 2012 and December 31, 2011, respectively) Accounts Payable, Current Accounts payable, related parties Accounts Payable, Related Parties, Current Accrued expenses Accrued Liabilities, Current Deferred Revenue, Current Deferred revenue (ST) Other Liabilities, Current Other current liabilities Liabilities, Current, Total Total Current Liabilities Long Term Liabilities: Liabilities, Noncurrent [Abstract] Deferred Rent Credit, Noncurrent Deferred rent Liabilities, Noncurrent, Total Total Long Term Liabilities Liabilities, Total Total Liabilities COMMITMENTS, CONTINGENCIES and LITIGATION (Note 8) Commitments and Contingencies Stockholders Equity [Abstract] Stockholders Equity Preferred stock - $0.10 par value; authorized 10,000,000 shares: issued and outstanding: none Preferred Stock, Value, Issued Preferred stock, par value Preferred Stock, Par or Stated Value Per Share Preferred stock, shares authorized Preferred Stock, Shares Authorized Preferred stock, shares issued Preferred Stock, Shares Issued Preferred stock, shares outstanding Preferred Stock, Shares Outstanding Common Stock, Value, Issued Common stock $.001 par value; authorized 45,000,000 shares; issued and outstanding 30,332,217 shares at June 30, 2012 and 30,307,538 at December 31, 2011 Common stock, par value Common Stock, Par or Stated Value Per Share Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common stock, shares outstanding Common Stock, Shares, Outstanding Additional paid-in capital Additional Paid in Capital, Common Stock Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity Attributable to Parent Stockholders' Equity Liabilities and Equity, Total Total Liabilities and Stockholders' Equity Operating expenses: Operating Expenses [Abstract] Research and development Research and Development Expense General and Administrative Expense General and administrative Operating Income (Loss) Operating loss Interest income Investment Income, Interest Other Nonoperating Income (Expense) Other income Net Income (Loss) Attributable to Parent Net loss Basic and diluted net loss per common share Earnings Per Share, Basic and Diluted Basic and Diluted Weighted Average Number of Shares Outstanding Basic and diluted weighted average number of common shares outstanding Basic and diluted weighted average number of common shares outstanding Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Noncash compensation Share-based Compensation Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Increase (Decrease) in Accounts Receivable Increase in accounts receivable Increase (Decrease) in Inventories Increase in inventory Increase (Decrease) in Prepaid Expense and Other Assets Decrease (Increase) in prepaid expenses and other current assets Increase (decrease) in accounts payable and accrued expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities Increase in deferred rent Increase (Decrease) in Deferred Liabilities Increase (Decrease) in Other Operating Liabilities Increase (decrease) in other current liabilities Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Net Cash Provided by (Used in) Investing Activities Net cash used in investing activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Proceeds from exercise of stock options Proceeds from Stock Options Exercised Payments of Stock Issuance Costs Expenses related to Public Offerings Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Cash and Cash Equivalents, Period Increase (Decrease) Net decrease in cash and cash equivalents Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Non-cash investing activity: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Reclassification from Other Assets to Property and Equipment Reclassification of MelaFind components from other assets to property and equipment Reclassification of MelaFind components from other assets to property and equipment ORGANIZATION AND BASIS OF PRESENTATION Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Organization and Basis of Presentation [Abstract] Revenue Recognition Disclosure [Text Block] REVENUE RECOGNITION REVENUE RECOGNITION Revenue Recognition [Abstract] Revenue recognition. INVENTORIES Inventory Disclosure [Text Block] Inventories [Abstract] Use of Estimates [Text Block] USE OF ESTIMATES USE OF ESTIMATES Use of Estimates [Abstract] Use of estimates. RECENT ACCOUNTING PRONOUNCEMENTS Accounting Changes and Error Corrections [Text Block] Recent Accounting Pronouncements [Abstract] NET LOSS PER COMMON SHARE Earnings Per Share [Text Block] Net Loss Per Common Share [Abstract] STOCK-BASED COMPENSATION Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock-Based Compensation [Abstract] COMMITMENTS, CONTINGENCIES AND LITIGATION Commitments and Contingencies Disclosure [Text Block] Commitments, Contingencies and Litigation [Abstract] STOCKHOLDERS' EQUITY Stockholders' Equity Note Disclosure [Text Block] Stockholders' Equity [Abstract] Schedule of Stockholders Equity Note Warrants [Text Block] WARRANTS WARRANTS Warrants [Abstract] RELATED PARTY CONSULTING AGREEMENTS Related Party Transactions Disclosure [Text Block] Related Party Consulting Agreements [Abstract] OTHER INCOME Other Income and Other Expense Disclosure [Text Block] Other Income [Abstract] SUBSEQUENT EVENTS Subsequent Events [Text Block] Subsequent Events [Abstract] Amendment Flag Current Fiscal Year End Date Document Period End Date Document Type Entity Central Index Key Entity Common Stock, Shares Outstanding Entity Filer Category Entity Registrant Name Document Fiscal Period Focus Document Fiscal Year Focus Condensed Balance Sheets [Abstract] Condensed Statements of Operations [Abstract] Condensed Statements of Cash Flows [Abstract] New Accounting Pronouncements, Policy [Policy Text Block] RECENT ACCOUNTING PRONOUNCEMENTS Schedule Of Stock Options And Warrants [Table Text Block] Schedule of stock options and warrants Schedule of stock options and warrants. Schedule Of Approximate Aggregate Minimum Future Payments [Table Text Block] Schedule of approximate aggregate minimum future payments Schedule of approximate aggregate minimum future payments. Schedule Of Warrants Issued [Table Text Block] Schedule of warrants issued Schedule of warrants issued. Organization and Basis of Presentation (Textual) [Abstract] Organization and Basis of Presentation (Textual) [Abstract] Organization and basis of presentation. Revenue Recognition (Textual) [Abstract] Revenue recognition. Revenue Recognition (Textual) [Abstract] Associated Revenue Over Related Service Period Associated revenue over the related service period Associated revenue over the related service period. Stock Options [Member] Common stock options [Member] Warrant [Member] Warrants [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Potential common stock equivalents Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected life Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Expected volatility - Minimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Expected volatility - Maximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Risk-free interest rate - Minimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Risk-free interest rate - Maximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Dividend yield Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block] Schedule of fair value of each option award granted Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule of stock option plans Schedule of stock option plans quantitative information Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Award Type [Domain] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract] Schedule of stock options and warrants Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract] Schedule of fair value of each option award granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Schedule of stock option plans Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Number of Shares Outstanding at June 30, 2012 Number of Shares Outstanding at December 31, 2011 Total options outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Number of Shares Granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Number of Shares Exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Number of Shares Vested and exercisable at June 30, 2012 Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Weighted Average Exercise Price per Share Outstanding at June 30, 2012 Weighted Average Exercise Price per Share Outstanding at December 31, 2011 Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted Average Exercise Price per Share Granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighted Average Exercise Price per Share Vested and exercisable at June 30, 2012 Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted Average Remaining Contractual Term in Years Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Aggregate Intrinsic Value Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Weighted Average Remaining Contractual Term in Years Vested and exercisable at June 30, 2012 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Aggregate Intrinsic Value Outstanding Vested and exercisable at June 30, 2012 Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table] Exercise Price Range [Axis] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] Range of Exercise Prices, Lower Range Limit Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit Range of Exercise Prices, Upper Range Limit Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options Number Outstanding Options Outstanding Weighted Average Exercise Price Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price Options Exercisable Number Exercisable Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options Number of stock options to purchase Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term Options Outstanding Weighted-Average Remaining Contractual Life Options Exercisable Weighted-Average Exercise Price Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price Range One [Member] Range one. Range One [Member] Range Two [Member] Range two. Range Two [Member] Range Three [Member] Range three. Range Three [Member] Shared Based Compensation (Textual) [Abstract] Shared Based Compensation (Textual) [Abstract] Shared based compensation. Employee Stock Ownership Plan (ESOP), Compensation Expense Compensation expense Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted average fair value of options granted Commitments, Contingencies And Litigation (Textual) [Abstract] Commitments, contingencies and litigation. Commitments, Contingencies and Litigation (Textual)[Abstract] Operating Leases, Future Minimum Payments Due, Next Twelve Months 2012 Remaining six months Operating Leases, Future Minimum Payments, Due in Two Years 2013 Operating Leases, Future Minimum Payments, Due in Three Years 2014 Operating Leases, Future Minimum Payments, Due in Four Years 2015 Operating Leases, Future Minimum Payments, Due in Five Years 2016 Operating Leases, Future Minimum Payments Due Total Leased Space Increase in leased space Leased space. Stockholders' Equity (Textual) [Abstract] Stockholders' equity. Stockholders' Equity (Textual) [Abstract] Class of Warrant or Right, Outstanding Warrants Outstanding Issued During 2007 Warrants Outstanding Legal, Accounting, And Other Costs Legal, accounting, and other costs associated with CEFF agreement Legal, accounting, and other costs. Public Offering of Common Stock Shares Public Offering Of Common Stock Shares under underwriting agreement Public offering of common stock shares. Price Of Public Offering Of Common Stock Shares Initial Public offering price Per Share Price of public offering of common stock shares. Initial Offering Price Aggregate Initial Offering Price on Self Registration Statement Initial offering price. Schedule of Warrants Issued [Abstract] Schedule Of Warrants Issued Schedule of warrants issued. Class of Warrant or Right [Table] Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Warrants (Textual) [Abstract] Warrants. Warrants (Textual) [Abstract] Warrants Issued To Purchase Common Stock Warrants Issued to purchase common stock Warrants issued to purchase common stock. Class of Warrant or Right [Line Items] Monthly Retainer Monthly retaining fee Monthly retainer. Additional Monthly Retainer Additional retaining fee Additional monthly retainer. Schedule of Related Party Transactions, by Related Party [Table] Related Party [Axis] EX-101.PRE 10 mela-20120630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R39.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details) (USD $)	1 Months Ended		6 Months Ended
Subsequent Events (Details) (USD $)	Jul. 31, 2012	Aug. 31, 2007	Jun. 30, 2012	Dec. 31, 2011
Subsequent Events (Textual) [Abstract]
Proceeds from issue of common stock through ATM program			$ 20,000,000,000
Remaining Available Common Stock under the ATM Program	19,300,000
Subsequent Events (Additional Textual) [Abstract]
Common stock, shares issued	30,519,319		30,332,217	30,307,538
Common stock, shares outstanding	30,519,319		30,332,217	30,307,538
Warrants Issued to purchase common stock		500,041
Exercise Price of warrants outstanding			8.00
Contractual Term of Warrant			5 years
Issued On 2007 [Member]
Subsequent Events (Textual) [Abstract]
Warrants Outstanding Issued During 2007			346,781
Subsequent Events (Additional Textual) [Abstract]
Warrants Issued to purchase common stock		500,041
Atm Program [Member]
Subsequent Events (Textual) [Abstract]
Number of common stock issued through company ATM program	187,102
Proceeds from issue of common stock through ATM program	$ 700,000
Subsequent Events (Additional Textual) [Abstract]
Common stock, shares issued			187,102

XML 12 R33.htm IDEA: XBRL DOCUMENT

Commitments, Contingencies and Litigation (Details Textual) (USD $) In Thousands, unless otherwise specified	6 Months Ended
	Jun. 30, 2012	Apr. 30, 2012 sqft
Commitments, Contingencies and Litigation (Textual)[Abstract]
Increase in leased space		1,700
Annual rental of lease	$ 22

ZIP 13 0001193125-12-340701-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-12-340701-xbrl.zip M4$L#!!0````(`.U[!T&_WX3:RUT``%\_!``1`!P`;65L82TR,#$R,#8S,"YX M;6Q55`D``PUM(5`-;2%0=7@+``$$)0X```0Y`0``[%U;4QO)DG[?B/T/==@3 M$YX(7<'8,X#GA`RR#W/,91'LS.X+4>HN277X7><\-W*MBN]IVH^W.W?9UQ(">V+S;&J5ILM=L3B:3!AYN M*#UL;K=:.TT9FY3'@=BR5^Y%,O[\P.5XN@_/\Y??WKM^LD-7MW_^^>;[??/D2YO<+?`,(=#9L+BA?/&;ICV97VKD+*G`E>WF[R>?>L%( MC'G][@-"<6=U(X+&4-TTX<0,^K-4SZ7^YR:B&M!_G6HQ@F3_MW@H=2"/.M0P$<=ZYE6;K%Y3O'GT&0=AG'S1GDE0P MT:QR<="L".P@$5JJL,1SRG5Z!#'E%V\UK3:LD1_-+Q1Q6+KL37VGA4N'I8L. MFJ7%#YI.S5^O<[`ML=$Z:1U%\5?1^UF\T3I]!D&LO\Y/1>KT_E?7.4B"#JV- MSM_S"*%*QYP--@E]Z0G=(L6THD=_;(%ZW"3I)23IY>ARDWB?.O$^M1XWR70Y MR71Q>KRDT`Z;J,HZX1*+T0K77T\1A.'^XQ*[E]G$Z_IHGHY!. M^?C.@TF:96'B9)7QOS^@N8 MU^.Z$$^P<;&QK;6SK:?NQ[YLPU@C]3Q046UT]-*JEP?@Y4:9:P/E-JI<#]@$ M[(YEFH)NNW]D0/#U!QG#93(>OA!5]D20:9E*87+*+S4'!=(T:ZDSF7-J&:$/`]=!?B)_-J4,<$VO3')NK+9OP[(B# M>=DZ*PUK/+)L?+F*:V_<;!7!R!=PY<;-5E5Q,U'D*F7KIQB6627^OG,\`8.7:&JVWI^H&WW'>M*.>O!W5^KF.&/#M8O1VPJ>DM\UP MXY-KK;7['5J[FPA_S:*5`.YW$\;;QR6,MPM*&.U=/U;=&XEH<'TAAM*DVNYG M]%)8'+7U0JSWT:&'>"VSFG.ZG.'J]NXB>^&MC>Z6H[O6DVWR7P!GF///P>VG M+T1CCF8BN:0J\WY:/E-^=[%T>&TV^^=_6<1&I2^TD?[`_,9&J6LWQ[%1Z4OM MQ,\-O9L:>FUB<17O=A*]$D5;M0GT>D%-H/:N-^!..KX^UVJH^7C=+!98M_W-V&5^J_'9L?-*O9"S6M)XWD[(RLEB"2V$!UKR'Y0>"WU] M)+4(4J5?2&3[ZLZ09=-SN?YM^8U:7W(U\$!K?J/8E]R>?T"Q[Q77X34`4,^T M\;H^''&)WP"PKKHFSL\&.=^6;<_UVNA^[M;,QJ77<'MFX]#/Z]#/]J+UIO.S MH,;`XK\*=Z.:1:CFJ;XW=1,OGRU>/L<>QZI,)E>#SMOOL.Q?>8QR)&,&HP9) MU5>"PR6I^F_U^E4L\]^7\S\OE^$Q%,]YID4NB['@!C[_0K_DMY?`GP=-?\RN MC??=6>&J=]0]O\K7".4-R*(@'Z\[S<;XDXRJ\DUH?F'WPX-[L$[U:9:UV??3 MLD__^@V:)_/G<]E:06ZLS0]]&MTB&>W]DL"0$?97> MLY,LU7OFCT'Z""NQ7Y,WQ])F43U/^O>6F"O1\@KX4XO=B.8'[OW4(OWHIQC* MF+V/5/"97?+A4(3L5*4BO\9GD3,]Y+'\D[:Z#R%[J$B&]*$3A^?``ZQ/'\\& M#AKP*!]<,$?2!)%"^B[!/^W#G+->X"]%S@U5/T3I/E!Y='9X^;_G739*QQ$[ MOWK_Z?B0;=6;S=]V#IO-H\LC]OL_+T\^L7:CQ2C#2:2$1\UF]W2+S?CYS,N+ MYBVNU<:;W9_UM'1G(TS#+9#!#\-TGZ3N")DKKC:KLZ<2U0PRT'IJL9E%H3UU M>_?4`,3-3#J-(*SCW_4!'\MHNI<"8#`L%A.F%63W+6;DGW#)]A;>C3?V_1_- MXB]<8-57S^]>`@/Y,@\](O'KC[D&(ZJG*MEK;R>W^^YS7Z6I&N^UDMM\\>^C MJMU@9QY/#X[99W3(_:^TSONL;,/[/RBV^N>7MHSY6. M!/N!CY/]__II>[NUCX,Z/)[F1]K[/]:8-'#[6(0RX!$+Q8T,-A4K(DO1E.DC?,4!!&=]P(V]$C25*PO/4H!Z@!;V2I&T6 M*JQ[O+&TW^X;$-T`S.-'AE!<9R3-5#$N0^;O$:G+KB!E!&``./@"^/P&>0\$ M3R%_(+(ITR,96I81+\*C@1G42J32+`)!W,1\1`*8F0P MX`DN!67E4*;H)3SE;`!DLB"2,3I.-"4*>3I-R(\2264?N([Y#**)!!:CIL$N M449X-PH:!(;6R:/IGW!AEDIP*8@5S*AD)$T*"^$"`;X6"Y5%8+V-1T.E93H: M@_/GNGFS#VE;QB(L:0N=%NT-W#'14D!A,:5'X^^-E[5CR#+[(D9?<836D&NX M$:$AJ):^ZYB>CMH&:DSJ%0Z:XD/A_;Q<=JU+:+N42/%H$` MA[-1"A!U2*(_TMF0=4(`YOFP:T5PKTH1_,-1IQR]&4]02V!P5O@,@%4=?^U> MI*SC3Y7O/S^Y=W_D+0MT08XZ6'9`B@$\WMC:R2"APL">2M'0T+819"!*` M)9J0!.S9S<#0A8AC4>'XL%MA&(532,VSO.389..`9P;TGDIR=4[E@%91!!\B MGL7!:"'9ZMN48B`$!DC65:/7(*5\%-CZ`I]'`S-X#8@3:,0JI0&V)Q5YJ3T( MA./QBMY&/(34D[*AB+'$199)FS3C(G`F!#$O$`Q`I)'8KF!+&'SYJG"H$O MA^S\L+#A\D#HE&.059F]1>BX9C]-!'TB$9S(,(Q$O9,"5@!``KR"UYK5]I=R M;"6J04A`M$5\$F431;F#8+P".0).BB%G1LH8C$,8Q["04-BG$+P?85%!$-!) M>F85A">^.X%^@Q';HJWF"(NQ^$)R.#M7IH0#>FD63JMHH-.K)$,I@:$R:AQVFF*,YX!/@S4;2R M8)@%&!]@(,MHH647C:6"T?)TOU)<%"!Z9)%8BN,5'%@4COEEXC;AL`RS7+!964>TWK?WV;FU&/L9: M$"4#=3944,02N,10"ULZW6W4].A\QY^O."F%]D,U$39"NR?4V*=/AU7@BY=4 M[DP5B0=P7<1LR[TPFY)H;>X8PL.':$A##4$1B\%`B)#NR!+4ZM^W6[56R_ZS MR`T%A6?P_UJN0@",):IX6@=>ZQ9"EJAC@EYRP`Z#(*23V(WS"DN=RQ/F-M0K MC&7X(]A0)\K`2X9B/(@!RC(#=:06Z:O2]LF*`RXBHO.`Z=?F MYS25VN9%P,V(I$-_8#``+$(ZGB"F0`QS*\>@=D@.?V^_;6PSH"NB#M!)T8+J M@V@A?SNL!\(U=KV^'7)@/%(@6AO@9E\K@&=WT6P%43Q#W5CN#A9M_`HBXP`[ M<23'Q740$"H61%P!0_-C.=2EX&3$6]7C(-;P`*+05S@;"0&9W6L7KO:EL)V[ MQR/=N+6\L@EK()_I;4.[9)XVQ]_->%03030.L=>`6(_1CA%VS?,2JVIB3]/8 M>EQ/RSMW7N,C;;9S"#CE*J8T@3Y7-%`PV6%#JZ0W^JNU\]-^Q39QH.R&Q@)I M95S%]KFB$BQ/,OC+X,Y=8>@3I3\[`\1DYT%*`!3U$:9@RSW3&,#RP';'S>$R M*E*+_%FJ_0=^2+$L`)M?&ZQ3NHY"PYA/J45'H!V6O>$RHK5Q[R'`TL$^26C< M@7`BG$VM)9;*\.I3;(%YAY%0(0JSU,\.I&,ATKF.'1,Z=>4YA7DD,>_=8(1/ M\X>2"/+^JP&DX\6GN83R]`Z]YGZIA)\]:O$HQ%(),#]#\.,@52A-`'``%]-3 MC%'@*I(VIE8*$#K`Q\$B:=-)@4/'Z,@#/YQA>S\TG>%L%\ZBZH')$8=LU!>0 M3@`;`IHI1XN^4A93(DA2.KP+M=$E3,:M\/"XSB+A;\A!F+^IF+VE*[JW%K\Q M>EG:4/0O5PR][F&E4D"G!`J5)J@&%^-4)VNWZO]-7D=2*.]*X3-BG&P)\X$4 MD"*>MFTW)P9LJ`$WD8`K9PHL%XLD+P(QD(,0$G%!`M:S_H5=<;@DBU-;!U&; M#T7BC!M'VN`:&I:I[@Y]['3.*^P6>BD4"A)0]KWRBN1-!C&91.\"?T7\=L<" MC5S+\6P6S4AE$6XDPGWIK+(YT#:'^1RK_/#?F4DM80&*(Z1.2PQJ-@9C+D%H*'2E M]I5K&=2;+YAUX4)>BKE_(/8A0&H#@H]QF28X&7.;8>?:U$'SJ4;E2C./0-+\ MJ<;'3#ZZK_"C`ND"`O@PILRX_K.,VZS.'L_\G85G!HJ?GG#*;;O!+KK_TSV] MZL+_AV8:"B2$T(/`,J`"^V MDS5CD>Y1VR6C"2=`?SB?CW6BK1JM"^/WS+MH*FZE20WB^0BNUQ;CJ0!]V:9, M(S3VM,KQ0&,^@=/[1`GD:5A?8A/]UMZ"LU`:QZTA/MO.?J"H4>5Q(X5P;A1> M,;6P&4/IO)"1C$0EYI.P_LBDML4E]=V(QH5P^TV,SM*" MRUZ0:\0MI`NRO@RGGM0$4![-1Y9V"I])0UJ,H30Q!2AS0GX!;<;*5GS9/OQ( M21$XP".!*EBVJ$7\5A+N-$:B#HIA-.2B52P#/[7FZA3L\H86^!IA/]@2'\OX M11O=UPT"U(J)1)HEC&G+S4X4NN%$,$/!`=%[GFXD),)RN1]-J_)SDXL@+:BH M])#J*[_Y5QD?8`,ABO6?T8KMAD2`?7N(-=HVW&MY"*]!28/3;=AK07.'^MSV M@%W7AW8(,)2@%3S+T-'Q_5J0*J2B^!MFTIXL@KN?4:V[R%I.8W?Z%"'NQQ;^ M`#K+`R;NF)&8L#WLXJ]?$`=$0Y8E=N@;MRLL>,<>;%]?JY4JX;P:L-D_G2BJ!U:H9^*CD1L2LI+W MX[^^RSPS1:"7&5^5$%B@/C[&*6'-DZ-$!=98_@ZZ#C&+IW2T_6O+G9*;TH]Q/9SUQ4[$*9. MH:ZX/+LX[O:^I9XH]DC>5/=(9NYK?-L6R:Y-A7*;:N!$UPN)=N'@J01;_A(8-;>._@RHBS0=>DM'MK MUM6?7_MNP1QVG]N/7S?85:^+K[QU>Y?')YW+;W/FI_6Y2ZJCL5.>=^CF]#/1 M>NS@_]15DS,[YC-:ZS.;Z*ZR-,7FOWU'1G@]VK0,%?K8_J(TZT_+S5B[T348 MX+:TW5[`4#%&BFCG`NX4KKT=25O^^QV,\L:"':A#)@C8S;DI]3`_[Z?.[:5; ML'6?GLK``^U)&=<4"8LY\V*?Q.(SVYD88\##]^KHE21LG>0RLK".-A-P5*IN M@610^G;P"EBU,@T"C;NLG@@H4>PDC^\1![2K$$J<"\L+.:S;_&,7LEW_@.O- MS$4.*'9U>GE\>G']GYQ=DI_'W8/8$3?RU$1>-A=J_-UDL?.KWW M4*G@[WJR0K$8E:'2U"&[2BC,G2IFOQALMSQ*6MX9L5AJ0#A)BQ$.KD/%>ASC M#$-YRO15IW?EU_H14B(-CI:.82G+[!>WY-O\*O&O/OK!1RKU\LFURB,E/9() M2:-+N-OKFDU^HD1EIHC2<^]7="^6O<:F0\'Z63IS#>,GM=RMMM%\?TT;OATS M.$-Y?R^L>#V6LH0B'F;2!Z+!H45_7Y4ANR/O$BVE@I&*L*=??CO5S?NBD*F; M+B))7TUB.^`XDV%U[\;_(DF-A%0K@YT!("6R@Q=PGK@7E'V11+^!F(^XYENC M!FMSV@KN8Z2A`4V(CAG7T](`MQ_7_>#NL]G/N.WCF1..]IW%><./50GB.R;$ M%4@`R`&S\F^>W`7[]FVYA]0`%-*-;K+;9FR4_/^S]Z3-C=O(_A64UZE*JBA: MMRS/9JL\MF?BR?AX(R5Y>5]>420D<4.1"D'*UO[Z[6Z`EZZQ91V4S*VMC"61 M`/INH`\H_HL,]POV!*_2J]LP<#>&CP01C]RG9C'':LR:*6.V%.9];Q>:.KN_ MZ;*O#YT.>[SYQJX>[NX>[EGGE\MO-_G;-WPTA&TF8C26XD(Y^XA5&8JQ.-:@ M.V%P*0$-Z894W9PJ;5&E"&%`9ZTX41SRE(MQ3_&L0EEG"+]K0P>&!C90>IQ#F`J\$CGGBO&L6186I!Y MDT\I3"H3I)"9E$C`1A%C3WCTBG55%*46%VOM5*H;\?$DDYK<<01F.;N#GT_* M)_19Q>GH\Y-M!<.?3UK-'TY8S_.!>^EKM2CY30FCV,98\(OHCP\,U7/)<&!7 M>,$3)X%.D)_ELI=>V`-K`FGMAHM8@ MT10#5WOA^SM^Z`"6F_1WFB///+EFP,GJ]W00-#M31CB^CZ4M#8N9&B`G\$5S MEI5GA$')8&7\S"AMB_VC3/];UZ!5LG9XSJ5<97NWBJ[W2/SJ?HF/CNW>Z/W. M$5_)C:!E["9NMY9;S5G+^M&SIO.6E?4&@&@/3/L_3).#EWBR%!IP.+*V>]:A M1V-_`9NI,A\I+\#&///@HB2_?)M??Y7VRY3']3T7*B]2\=J=U]LD1WVDG):W M+:2J5=H-K59NOF@=KO?D&^.?3^2_)SE"24'DU40NM[1ZM7T`1%[+\=BSXOI# M[0@+9;5=/F[4FUKKO'(`7%R0^.A)O$I1+8Q`+_>[T@M^[<'!VB_-ZTKE;=-I M\V)7>]614WZF+?"X93RN9/V#V6YT,:1;F.QMNYZM>E4KG[<.0*,71%Z;R,U& M7:M6R@=`Y*,VVS70^Y87XF'03NW-AN8M,+EU3+[PN''14>(9!1753$DFR=*D MAFUDC209[`_]JU2FJ;K4[0H3[6D5'S$9]=&84LK4L>:6M%*Y)6_$S+XS4%HZ MZW0?KGXM?;SLW%QC`LKCS7UG:Q>UO-%SG.D.1#5RRW*@QXZA>J]2[],.G6[? MNACIP/2%1_@YT]6%GL)OTZU=M$S32QR,[BN,<@'C6PNIO0:5L5-?U0$>2U$+ M6)J,.L'QT=CQIIQ3MT07LZX-*B6THC$T=>^'+^(J=J-'=\S@9174GHD*VU3& M'^;E4V/1&*3,`;Z&EX]@+@C>EF>Q^70*GXO`MZGZ3_Z(%]NH2MRDL;,CO!C5 M7MR]=R72,_UN).)F9L>&'JET%TRY=#TB^D!F>*AF)2/#6M798Y7,;*$4L9/" MDF*+F1Y7F3X":9@)+^FF!@2GK'.2Q9VII!9`A<,%M6V)+O](RIN25%`:W9TK M4J"1=?:@`JJ;=U$4KG:_[D&[VK!I_+[IA@/!,R:Z8834C.51;(NMU M3^O5)ON1+FY!SCFMM-NJ-(3438J`V,,3Z`8B+'ZBT4\;S7KFU=H+WM2H$5*4 M%)SD[0K[677(E*F[!#TF5&2AT18C[CLPMEJ9A=;JC1?#V*IE7JV>KP'CO2<; MFV(><7P9"C'IHL0T@IP_8_]%$8N<$76!5K(UEAY`MD0GRIT.ACY7_49?D@^= MQFYZX5K<&3%#H-<-*2&/H484G-9J$K?E642]6$`S6[RWMO*40W_73]]1/4J7 MVN[;?J*H97JDM`!D-VA)D4K&9$U5TV3-:G+I0,A6_>1U.`88W(XY]+#>3@VI MKA&`OT:>Q9VYXCDC:@<3>PQ1%Q_:411YDAO(DVQ6WY@G6:EL,O-P>[.\H\2T M?>9$??)2'1-!:),/'?LY^2!OD5^Q0>OY[&PS*Z*KZI.98_.>S9>,/^0VFZX@ MZQO)^H)!W-0;_W"D#-LJZXUZJ=74:]4?EL)X'$D%WVSQ5ZF/ MNV=J,PP;*[KS['VP=V"C"$!U]VD+UL%1G5TDS275!73]TG)**&-!U M+WU.5W*H=DCRG%3&F_B\%R*#"ZGC++I-+NKVC(7BV0::>)>[YU-?R&2057<4 M608VK<7@+078HLL43;4D?[%%F0,[U2Q$-L95%[I;44$Z78+3Q1;4H1^UT:); M4[*UVK.XCJ,($M\S>+(RN@,7]1_N>_.M+9"\$^IR:2R84LM=4)N1)?3)(?H\KC\=:?D MFHQD5/66["8#?S7/E\6VTO&8#*@OZE:S#L31ZBKGT>JJL\$6@K^;OF`S'B0) M/BF9G0\HK:31\JC>LFA1TJ,)M"3P"/:;F(,M619!UZIO`,.$!8I3I>`G?,2S MK1>6VDR`8Y=6&MM"A2NO5EV0BV`L4)813JMH3U*]-6;C1P<3.6I76Y[02Z1U_=B;$[F2E$IA"9#8O,-[IC"MS>G8!WYY8ZW<\%=D;:Q69 M.?&1R4/Z2#98<5'Q/"[S$I%[$_R;B9EMI'RYW&AIE7+]1>LH:M1?`]'IGFE; MUVN-@JS'*[M-O>AHR/ZPE)O6YB&H MZG50:.K\0%08Z1R0/K]&>F$CJN7;[;T`->\G''UK^_P@OWCIO;UT'"=S,VDM MB^NU"K=_VRDMQ;5NQYO24MG_=N[XR)H;V6WIAW"/QJ&1=]]26UV4QYD[JA[U MCN58[_3(#_J+E][;2X<8A_B="^J#,=\&I=BL[,,T5K1&LZHU#^+6ST,C\K[= MGKI>+LAZQ++;U(NJF>.3VDK]$*^*CS^_L:%A:H.SAUY!E7(YO\V"&F]M%O32 M]W?\T$Z66^#DG2]WK\I%T7^LD\1?53%]:FH%0'6BT%\ M+;PI&'?B6FR.4GFACKJ\+X&&%CU#H8AP45N5T@JR'51?E7BN3$N5:-@==3Z) MV83&_QI=';*V5+PGY9+31C\Q&M\VX>Y[8[U;?1PS=S,7^IC=)(>E>],&;W&A M9K>KF?%F`S?+Q:VXD6HS8?F7[IWP>0+_387/3 MNVK>KJ-PH+:>`=9L-[5&N:ABWKH/U=+KN;L<^Z`U M<$UO%.4X1ZV;:O6F5FD4NND89?<@>I"N\IX.Z#P*/"D\D,+;20N':LO[O49# MJ[>*SN=;=Z>:>K5PIS:;4-XZA`WMH9$U-YJITJIIU8,XLS@T$N];*G@PX(/W[*=C#^_L2-'J@5'NB6'*MZ(>W"LJ^DO M!99?+6[^I>%/P9"SP`L,A\4[(N:IJC@OJ4O66+,&+DFUP8;&A(-Q"MB$>HWI M[`$'L84:)70GJ@?9R`O=`&:J-;1ZM4&01P,_V8Y#[[-P[+FT!B,(#-L=P78# M5V5R'S\R`!">\EPN-&IJAD_V#,=P39X:Q)MPGW[R^=^A+>R`,\']B0T/C;EO M>[#(+OSZI"I6F"&K5.AE[.4L'V)]3X[B>FXIGEBCCQ%,3X9O"8)^R@.8SO0& M+F#;8@!_16_+;8[.OK=Y7]2/)=N.914OK!+317RUHK7+5MGJM'W>E&3OQ\R1 M0IGIC<;<%0:R!'P0B$_'0#0'7L)&$PKC&3NNU&K/G?Y'L8$14E3]; M'+:Q(]N%GWM3_`F(/4(V*O4,`5_.,MIIH[%B\%6\!C_Z7C@8$N2`C^8KV&&O MR@"`\E%(X#\5K8X;D%J;B:'APX#&Q+`=4G`H)/TP".&I`5XH+(!4ED+)%5#4 M<*=R\/-JI?5!P-CE!GL$B5V!AG^>A:(T,(SQQ;4M3,<3,/I#_RK%']\D9UP! MEX@.+NDC4NW1F*+"$%W^''QT//.O?R%*_QEI9/H*]/)@`'2[]X!2I5+RA*R' M6OY,M"18QL@.:)Y+U\(F!:`RN&O:7"2KC5<`C.SBL>`WWO_YY(OAELJ5$J+W M_P'KI5J9_C[YE[(;UP]7W3\?;]@P&#GL\;>/7V^OV$GI[.R/VM79V77WFOWO M+]V[KZ!8RJP+N`9F`U08SMG9S?T).QD&P?CB[.SIZ4E_JNF>/SCK?CM[QK$J M^++ZLQ2DWM2MP#I97APVCXQS5F+K(6)FDH4L?KYY%L<7>_C'N?+[NW#_>2,WLQ6[Y25)N;!Z.;2!-J M(:\'3@JI1BEL!ADE$_67E$H/=(]!MLSA(!DDI5Z_#UI)8_"$U&DP2]C'!AL^ M/HC]NKB\JPP_7G.38XFM4EFP`()9#@=+$&'OW]P,4"%R88()EFH9)[)=T\?' M!/R56@D,#>++P1S22`B2,1[[WK,]`E`8<)G/$2C0O:X]"D>16ADKJ696R&/E M`BN02P'99P;.ZSC>D[A8R]3NH?59\SR_G<_.VV_L?-8\HCY4KY?8F2+A/\$% M9!S8UHIE*F5M*]HJ7;.[([5T%7GNZ^%?N/=:O_)Y;NU#VBJ`:+Q0,)+G$\S6 MUXM-'D[6*_HR+&[E!#\]LQ&\.UP0YSF*V.6^CXZKE4,(5AYBW!TX>4%^UU$P M;6Z"6O7FP<<]#DDS+^A=7?#S1OFY=0@Q^`/5Q@O*.PKN+;CW8+7Q`L>MX.>" MGX\JJ^(X4Z/?9$#7HTS.9'SOVUZM4EPPN&_A/M94E0--Z_@&SHGA)*$2C(JD M@M2&@$\PK`K!,,]E!LSA&RB-)<=V,8M"8&`IBF9C=#R*VU.@16>W+KL<^[:3 MA(?CD!2%(+A%8-MNX#$#)ACXG.-J-`;.&#<#>\+9G3%-T%Z)(LU/0]L<,F,D M3\EQ8/YLBYGPE6,`&QB!YT\U@$?P4<^94AA+QK54_$H.Y8>8(2#C[O.1+("3 MYJ+DDB18A?..?3ZQO5#`T#2SI8;M35E%:Y7+3/P=(F[[G`=XBQ["Z;HAH-XG M"D3I#:?5ZB;#_!]4!"G]U1M#_YU?,=#Y>=3[A?T8!>BK9?5]_$7EPT\:9DSYEZ]U",LK#;E#:\16V2P4DA1>Z+.Q/:$\&A-$V#;A MC\`'2@B2U2\`I>%/$<=+!3865E`,!@J?)$X6/Y$G'H"(RB??0@#*$H=$+04V3::4A($-%@UU MU3U_-CWXIHM,Z#G>8`K:U=115[%/UY?L\]TCI2XZMN$&1-3;S@-KE\L5XE^[ M;ZL+>/'K2JU^WF`>[()L%W7EWZ%->G.6QF0:1]PB?HDT/_#6/4#PA?N"@Z0" MN2-!H819I3.M6&EN6#V^6#-2%I#R!068!)D;%(G&;WHG/QF0Z;RJH4%^"@=2 M>N1&SYH^9.I'GPO;XHK25T.;TV469DCN[0.YHK[&KGT]\7,_AT[?4]X20:C( M)K.E$A<2,T^9,!P#75P18.Y=E.U*3HHMP%6EQ#T_D[+*>IX;4F(5Y50E?K?T MS[*SA8`WH(<)&H*7,#T9/5?^A&H)W#K0PXGVR7C1Y)63M_U:B<[L<0\HI_D! MQ`WV0]F$G4J;-BUE#1.*0W_L^8'RF@0P@0]*A*.F!V%DAJDRF8&AP(H!$V&> MFNTD5H)$X1IV.KYM!L"'H1_$5JWCA9B`ZR:_`^91_/\$M:\Q%P!`YTR`=N@# M72CS-NWA(<=$]A/>1-Z5&R4_XB;PTV$W)="P!W:`RT)4V;2=A"=`;MD7G3UR MV'H+U(RWKF4#(P&G1ALOEWWD0\,!9ZY/*+B$5QYPU8)U;$`P.`I3^"L(R6>; MZ.SNYNLEZY@V!ZX5FM*C7SS!QT/VN\Z4H'P#KC5\4)@ZZP1@`>%#(%W#C[!5 M"Y_!`Q&P7B"8)KF0UGSOI42N=5$IE\Q)J7S>:M5+7S[=@6P\>4!>6E5"$R'S MF\$<>Y(T&LH%0C:?JU65E(_MMH>0XJ/*TTX]6=8('_`X['$5L07L.6>(O0CU MEZ,I03T@\%;B?/?X3K"ML<7X;I>KA.\/^'XLL?3*'0P+N.@X(%0RX18,DR$_ MYP[2I9Q5N:B`80=(R_5J6W'6D`NTP:!WEVD!0:@@7D,7%H^GU98:K#ARG%(6 M\/]/O.=GV:G2T!0KS;,+^"XPY@+H62=9R5?X9T!&>"D!@7Q7]J04B4O&GU\" M4]K#S[>#AV9QF7J6>L#N]P5Y4*"!)[8793.K\XD4*F^>@8/P$JM+J9$K[5H= M.,AQ,*<0-B7&R,/]+:D&W!$.A$;;!,)#2E6/#`L3G07X1P%79W;(]/@538VY MT#ZB8>E^0NVMM1T[>5)>T)[``O#L)Y#,C88+_6'*Z9X8#FI2V`-$$DS^S-!S MT)J`8^*A]014"G6VLG##!!L8&$-Z0I8\C:!#.E6>!9`LDI8:2DNY'7LN"XQX M,S;B`(K@_"_8LM`Q%CGKEC'"C:[.P`/('%A6(SD,EC.4=/`2II(&'UZP_?B$ M,Z,"8EN4L%%BI^"'$14=R0%@<^ZEK1=G3+P@ M^+[#Q\&LF:U)`.@0R\$#ZD@,%_$(.#'<'L>/7$KFPZ.CKSP`CU9R"?Z$O+FQ M(X,U3HT>[RYQ>0YLZ2)5OPCZ#(^-T63RA'XBL,>A$[__``[<(N^T@C13SG]$ M*T::1@HN'J2Y$5UP[(0U4!BB,P>'8VDG'L`WYJP%^Z.+!\P16Y1 M4B2ZC-_D#H-=*E:[2CQD&`C>QS/D?X<6GNK#J[0_@=GIO)UAW9?/D%=3UFNQ MJWX>H7*).*K547`A"VJ@JEU62T9V`?,.8[*`>5%TL_*2+#'#W2M7^*K5S>O) M\RCZL@0[/A_C(:`W8[E2ZYL!(1%WI3E!O\_IW$7S&0RC+F@)0'AA1(RZGB`M4GD.D0(A"-/OC>Y+LO6W]F%@IZ90")G/O%P"R:"30";A4C M-16A*8_'(#WNV'S"U>FF'="YR`A,+FP6,30FD1N=X)(JL43$)Q-[X/DR?B9I MP(R!@:=`JTSF!S;TGF!*7QX"XU$++L2)O58ZE3,-%^NL0358N(&*'[,X'GBD MBL2#J3RLF(".P6,54"C`/USB'NO&XG%U=HE'?Q,\4(L?,[W0L615.VA%U#9X M@AH])4.9J'PQ@-$+A>UR(1T@\M]27ZJ1>CP>Q<%#)G^$)[AYH?PG,H_P!$D` M_$NX'AG(!WC$`09H2@?+ZB@!'!2,,_N>R;DEW5O;->E$#(^0/%4P[X]4H`]P M0,CM9U`3[9EP'GC="2W29H&/\6>!_$&EW^3PR4-MO`@\-(^N_HIJ:K=JMDC6\4YK=G2K%ESG>D]A>VYFI M/+D8B;)9*XE>4K+C\^L/&@!)D.(%)$&)E)B'))9%HKO1:#3Z\H&>#1CC!RYF MUDD#N5HV$X,?#K:O@;U;VA`YP'4?F@[0$4OLH'L#N(K.'$I0-T)P$W).,NQI M=TA/>NC]\0,HB00I^&R$ENW:)D$,+"+8W+`H0(+Q*4&>]Q;[)CI&)$%G,`^P M&H8#.[HT&4P6-[=DWL+R$I#PB(2%`=0]:#K)#YD(<2X.?(.B./&-]>V"JY!4<>;2R? M87=%7M!L!E@Y)*`$7@7V(0$2!0>IW)F#1PQG// MF-(0GF.'1/0/SE`L*%D%H@H8$PJ!@D&*%[(535P7H;%%^E*^8PFD)VC6=H,2@HK5M` MJN2$!3[8\G^'$1T"Z>39Z%.DB63.&;P'M`8VX)*YR+?&03YB`4`?`%WB![B: MF-V?33V:'VIFB>YEL/^.\V/(`X3]**I"_$Y."`^7YSA]$]-S4I0HT(Y))#(,&- M="DRI'C#BE,*&QO8'.)=X^V2!**)?&,S_HYWB@5F&P=0D>V*[;]95O^.!HSA M$(DM6*KHPP1;_BO(`D#GZB55=;PXJ$W,F-QH"IW=_=,:;)#W/W??UU'0,(V$ M2(_REEY[-BL\8'J`2F>#C0UHM`[:7,G_R=5F=:1@MX#DW8]&HXNU.64*C6&8 M9@Y"EHUJ-'(B3A($)`YBU(E`U M62+SAIF/S1U:2:FX,Y2.MEBIG>V6&B;E!N'L_GY\SEH MJ6\OEY'-\(.ZF+@IP(LF]$T2JHZ>($>=GQ4IF*[A[CER&"8?D?VG!;N]WNRD31`Z(-[[\'2#R`-UVY" M$P(5B\T.GH6H!`XM'APZG?U M,F&?I)$9&:BV+/)"P$FF&',^T-+*)W-',D6&DE?(P_OU8?:"]N"E?;M(I^%/>E8\UG@RFO6S035)'#JJ#,?8 M/Z?W]].;QXW&P"4;4!>S!4^BR$9 M7WF)M4M-1@920YV:+&S?KO$VFV?O6@*\T(N^@Z+O-%)J;WT:7P**))E'O0!: M+/A)+_@#"/X1PKD'DSPG8DMWP*`/]6S>7M$=<+U;MK(@+_2]JT\]`I](F"Y5 M,X9F?V7E,4\Q+5?HI_AXIUCOS"K.W;ZZ#K=WG%B:O1Q[.;9)CI6B)>WR=]-S MJ[VOV_NZ_13WOFX_Q;VOVWI?]UBAI7M)]I)LFR0Y@^=M@SM/[7[,0DERWJ"0 M%^/T4L3OP73[O/4WT+%FIC9*ZF=LFZ2?TNJH@SN@R9CS`=GU#0!%8MC=+Q@NR?1N(1Q9N1@8$.B=S6&9;J.QQ3E M0F4QQB=*4(CY9TF*4QSV!Q8=0/:H.!'4:TJY,@8'8CMN:?,K:7?,ZD1.;[;% MS,4UJ04MM`1X8:=7TTJJ5I:.EFC7I*B0);LV&]:`&S>QH$(>6(@Q`N:'6X&" M6TPI[)A?T!V[SOB5#`U3N,(>K:?EQRBRHSQ"B3ES?^>L'TW=)/[Q2[5:UB8@ M*NX)7EU\N*]8:-PM6D<1Y=M;$(<"+G=P=CUNW M0GCYJ*F((A(%*#,4DJW$1?/[JO8^CXB?QCNBDN"F3H)L!.AOMB?0:DJ`]DWYZ_F(Y@*R=M_M^<@%'%GWA(L)17F!LQI`, MW_8(;GN@.@PL(@N4"6_9,TX[8!%:#!9A7G]J"&<%7Z+8+8AHW%1E/W^,!E]I MRQ5%'V$ZA+^P*.B1]F',QC<*ZV8C"W-G6[(7NMH!.$`D0A@AP)@(%P!"J MX8U'\58YQT]7"'")#,S)SVBSIK`7%3=[F39^1@/%^<>M?7&`$/8J(CD`F\&- M@Z`#J=**S06`SS]31(7<=KI=]:SH@1W&8,$U0\OYX$_K>0VH<'"@"[W>D:RQ(DH5>S$XMGS MLN9NQ]H.R2I([`SA$HFPF-"#).[1*8LY72,GZ1(=,+SV&"03_=F37[2%R90L"I`\PD M@DH4W80("X`$R0@L%QPD_.UWW_[O-KBNR88@S(;>8^C"#2K4Y2,=W"'@,XVZ MP5LH,"7C*"!S8CL8KX+`;V+F56G'HA`;DFV"&4?,9U86D:#C1[<)8)!E[)/% MY;^P:1!I9.`0$C6KT=3-G3F.`R$O#)M#:P4H'!BV;F=$+(C$QK,_VY(B`9AK MY`2[`&$[S]ONTJU+<"R9S&N9WB7@1WQ4IZW-QCK!YR2]T<9Q08 M',(DN"&@LUQ<7]T^7E<^&(<2X3\=TXLU\"6;'C:M+ME&,#W(KKA;;Q;<8+@) MH/2IX\9>)1H`3Y%;^)S_H\#]`H[[Y;D*\4@8KT@RHT9'@ZFA>*K4ZGO2)PDJ&JJ4$DY8SL4N)(4_44:#PG-3H0CC;,_UD<2/LM" M)'Q82[3O^QO/ME;X6KAY>#+`#+V[WG+^#C?_14A%@%A%\)"":YOQ7!%4?7)1 M#+DM#"-+T9V7?H?U%<#[08X4F@3D`:VVJU!Q,G9J05MT0A,M#ZC\6:>Q&HG" MCF+N$3]GY!I8P-2G2PH?F@C%H0#1,UCHX*B!F^+99TMKNX;4!X&4HPL]'\>' M8W7?[0S M*;(+4,6'2C4LC4`U)*G6))H59CC-XXY!IB60\N1)A!)(C^U^*@!8&E(7>U,2 M;014XD<:`(!":U^7)T-5GF2!WJ8C.14,(R#;VWK@8LZR'&K'FRS-$5F6PP"W MY5;HE"S.(5*(:C-NU]D%.@2Y'6DZAL7DK<\A]+%DE:C-8=#'LBQMS;UL&@*= M#^YR#-67&[)\YXN+801L)%!*"X`(8*$BB*0T:HU^Z[R0O`&'LP5\7 MCN=#*PW:C?#_D)+_#9Q71--_D/>*4?K@G@3*(PE^DWJU]3*Z=B:\$":P(GZ( M(!]!\*G7U]ACT*[ M`G[F3-('3'``;E6'&$!X@2;U/#W[!<(-:(,CARLF@##XZ_3A:_"NOP5!<.:S M(:Z(A!`W*?EATGP;C,T)(Y)#+>"74!>/&=+!0P:A>#3EZ%B,6%J2JZJ<]18N M0XON&LAZWL7/;N#VZ>!>J>_;3>H[_"`!21^ET8R==Q*/--,`5C_`@+1+R;'Q? M("0C:2H(D\ZUU92U(77WG^(=(N](CSL,TEYK)%Z25K=ZB]<`7+$6%JS",T>X MQ?#)*@.JMDA,M7:1\+'J531(N7`8'5=Q,,=LL"S(D;/)>04[;//@FIGP4FEJ M"'UJ0X+:;APTQE[D=@6Y8(P)[=-BSS+UF\QI_``HN*;18A1U3/X\(X#%$T#C'?)RYXN34++:,] MMCJV9'=P%<]9OXQZ7$4N5%M615(2@87'3WJ2%?/+U>O2_;!MS.(=K>&[6UKK/ZSE%E?$ M3'U_NR*\GV9Q@+E;9M:@5`\#404%40O+"6YG=A<$'H+62%G`$R;I&10?^I_\ M@>UO<%/!/&S=@R(E]"3^SH!TC25;X$@!BMW;B]),V`D MDP%I.8HZK2*0J0V9IR+GMJ\_**P_,'CO>Y M)PPMVNB'!^='],,7%]H>,4/I2Z?F9.1L;X+T>JL*8TTK4STQBIRE\R>3R.8/V]X__G;`'( M$`Y&$/$W`^AS.0U5ED83%4G1D(Y5D9619IZI(U6KI,5MU=D+!]!DD%?TX=C+ M^8FHZK&J:#9CXD*J>PB=58[`)H.G=<*$"D\$]IQ!;HX%EZ%O#WDQ)QUH50H" MK>6$QP-FT\`]&8^T%W2;BZ#!E@,#C@<$/E-@-##U&`[*\=E^K&1LM#-1T8G2 MXJBH5C,JJK>GS:DGMR?W%*/@;>F^N=E2H'I,>--A4;Q%YD5@VU(+='P3_:<- ME4;V?"_S/'VS/>O9;G*L4.8DWD[O^-H+=W<8X^O5]O:W9OHETR\9P4OF/K@0 M82_LG;OD'H8M+?IM>KQ'`/5WUOL3Y[NRL?6>V M/]6"N-+A=H`^ZQR&3&[C]Z<&0.M,)(0`4J4T4+4EVER+_Q:5O$LZ`!EK7'3T M?0UE./KYP'.KC52]G];C7;O&J$<[R'[MWOHOQ`7@#KPI_TX*OOLMM]EEJ^K2 M4#?4?ND>\12/)OW\'O'\AHE=A:6I''6G.?7MW96[E/=3WT_]T>SB;=VSKUQO83NX@]H+[I/JM^^&MV]9GPP5 M=7SPA=SOWTT&06D?;V^IV\-1OTFW8.K;NTEW'I_J..$0VR/\_J%3>^@X(G.) MLI;TJ]%ZM[_IDI;^*H#C+6F1#W^<.[YI;>M4J:76N,>J[9HYOUC;-($!X[GLKT"`(H!7^D:(P,.E- MS-CWD,6R_#(\[L4'%3=3;9D=ZHE%W&"B$S,43%R`OW.6,VV=`N`)QXIA[P2O MW1-$3J@F^/V?@_L3*J^*4S(N+46$"L58;\#]@ZB=K#T.E=MHA3T>7$91]8-9 M@SHN5#*N$7M?,L.7)=._8[?RU['V6CD8D[3S<*X$>.5@:0VPVN?BA+4S4W&B MKVT-R-FN6]N&)7O*,Q+S3H-)V:<366*[%N0@"-BS!>X/&<'C4P"B^WDDR6<_ MPYNZLG]T-5NFJ4-5Z4)JY1"F>#<679E!:61$Q+3MFKMZ:_7`&IQN)7K][2U4 MB^31QAGN%VXEMZP+]83@.B$'2AOIO0/5>*F@,3&&NM2WNS?N0YDCK74W!'?: M`JLCO>_;.FK;I&K&4-9[VW2,:[<38+5YWE.'XE'(DX*`E#SJ[SYH_+RGZT/- M["'R&W>GC)'2NU-B.P_,+AQHNS:MK;%,LJD.E4[$++HVQ8=>N>;([+PSU?5> M^!Z]JW^HU\)>"X^YSY_6-?3'R.:W]!YO;(]Q>:D_2/9X:JV?UM;8IAY>Y)C7 M;B?@18[Z*-G#JO4/]7K8ZV&=XV3X`E\@P&G MF;Z^>NX/9V5M[.GSLV<_H_]\<=;.:KNZVFZ0""A+?AR;YE1@6P+I#''^PM)&B#Y#"#RQ_L'"72_?=_W6PZZV\IO/)N"9*Q">P M+66RG6O^2N'<&./VPMR,)S5A;HPC`ATIK^.)CK!OMN4-;*2V\\&%/;-QCV)( MJ2H/,7'?0VT]T/F);1EL??,CYT9;OH=1:#ZT'$"1>Y"9+J+21:DR2G)_*-0VM9$,#6C M\T&N+EGF%$3;7I^%ZK/9A81+1ZUQ2BUOK[V]]G;6&JQYB7%Y?#$9&DJI^R2V;9*22=9RL_9_6E! M^G'C7_O^UIZ?9F(NE-%N9BY//'4N21AK[4T>F6K-Y)'2GN113VXW4G-MR$GE M"K\M@)S$$&&J#YYQ[$7?%AF)>FVG<\B]]6E\"2B29![U`FBQX">]X`\@^$=W MDWM325\F4ZI,YE#/'D?:@;E""*Z%3BU&@ZNA^[[2A@.8@*AF]IU;QSS%:,<= M2CW.RS%/L=Z957S4B8CCS#+V?XM[7;9FO>ZQ%-[TD>TFV39*>!Q\Z_LQ:0F\SHO0"NO:YWG]V M)BMGJDQ&R'I5--B%.]NNPJ_>+G>.)N/<_2Y M9RVOT4GMQ__:'WRO1LM3EG19ES4R0.JK=D9R5RMW_;!!JP`#F_CLB8X=]I.U MM-8S>^K?+IY4^5_;)1YTL%T[Y/?DZ9\&#A_/KRYOSR83BXOCD?#7ZY^<:.&7\M4^0YG<]IJ>07--3+$GUS M8SEKVXL-_>#\P+_V+P'@X$F5T/B8CD^NY_W3E>BO;>SI_ ML1P/>79/7W#ZB9FFKP\7.W.DC'1J03,)8HE>N=OU9OIF.4NPAE\!+.3AQ5XN M`C;A!0\;)&+0[AP=NK!GD`E[FFY63W>>^^Q9JT)ZS_2??M,4!>]%`_8N#QEJ)0M3*[#7Y>AKCB?* M0,`1)P/ZWAEX?$&?-CLM1IN8JC0OYFC_$Y-IA#NO6159J#D)ON_.'/C>O?UF MK[?V[9OMT2+;A.^4;P$QO"]FB/ED^95F>7`])0GN`KAB*KHXI^15)$\N MY[?K1]M;(0F!,WN["(5'9!>*[LJ:.4OT0<[Q0:`&R=)$5\,]60SEC"@N?[PZ MW@?9=FX7MZ_P@CO$"I^#@0EY8O%(G^#A@+G?OKX.-NY`IMC^E(>L(1FJ?O=< MWT9PI<);=(3/IX\L>>3I_"`PG4$D@V5U?YBF@0Q MH%OK;G;-@1F.SKP^-NBSM9S.9N#W(IK0 M+GJ[>;&]<]??^'R+NL:F00YQ2DA@-BD,Q2V)+V5'E6[LS4%MD0&'LICB%5'$ M$,_X1\CP(C.-7*;%E6US*8/\1(\G3_C(Q"?2@,C,D4M3EW-(;P5]F5K:"NIR M3M<-TX<-XNWB;OM]Z*7H.;O4]*AH,;#S3OAX6J,Y'!0MPXEV'AWIXM+=]W%LX,#P[6'&^24]^W M-_ZCB\S\JXT6)]H\83=^W8F=%0<0TE:QK@`D)"6X$A$Q)BCD;Y@?8%C&839\ M`J.>(<\9L,`QG\0<\W+#LS@F13NVV7>15-/EEQ M,QYG)7%';F^.BC]`9H93Z.-1DZ:#DUT1,B<4^%_7;[:_241IJ\;^"DVOH4(Z MIJ[\$J072N/>1G+VG8T=2[A]LS>/[B<;.4+N\]KY/WN^&V"O+X>D)Z,B-TQ7 MB[:?,@0SW-,J0QQKQ>])25DFG:_I]KG4\OCMSI"^4.(SQMNE**A[=(,40E8@ M)94ZR>3SQC4Y3E?>J.)IK&!@&N#%0TJ#3B&WBZ]K:^5Z&U"3<%_9C0=6.T@8 MBCH)Z2L>D=`77&]&8X,^S<_3>M#BLJPBFDQI`@?]_&'JD9*2V4PMIE"5L:DI MM6AABA8X*$;>R.*.F.,I+A+ M7=I8.U1Y:`E_=JSOD)`3.*VFIINZ%J,I?:3:!''*:&(:IJF7)RBL]KRSG/GU M^MQZ=3;6DBL?Q2DJ69NHDJ8IK+0*1Q5'):\%04M`-[68GI6E*)=B=10U:\H(@=N0]<4 MF65&!'&'XII](&7(+P$,I"$53;>D(^,D,P<4KG&%DIKB/*1.G#31%)/5S/V3RJMCYF1B MC$VY!5(MU$E3D65I,FZ`5!(!NE[//"A40I+#_Y;U(].(/IOHR)Q*:A'1Z10( MHKU:O.0,N7YCW33%T`YIV["C^-:[AS!Q+#HUL_SG M3QMTA/^IO)G\1?Q0668N9:B@=-WR;CUHQWYOV\0W/UY:6R;BJ2QC?ZA;VP MT2F6IOMLG.R[<=ETY.FR6SX(G64=$+N M$97GZ%]G$U%=/Z6ACA79V*4G;3`19'&+29I,M'ID89T3%8G13%5-I8<=)9<2 M@=+1)$.3,HG)ELRK9T,W.=3)K.=3DF_'/XHX8BMC%9U36:HRAZM&5S5[J")K M/*E"5C*$FF@QKB"RW7JP,VFD,L:@8,CJ]'&UP&=1*.^#0J[)31>@>4@!\E`H MCZM2N'I=NA]V4,B57NX%42!2/T#R`$$DY7:!70Z:=RF3G*Q6F<88)(%T[T<@ M.>UBIRJ21JH753463>B<4'(:XXY"3Y#K0*IB<:6LCR^CB@V,O-,;=_/-WD1U MI`$XHD<_@N_)8L``[N1OLO1%T2Y*RD<8&WL28::^I4=_ZJC:9&R47X)U>6JG M&-&,+USH^Y[93R1`02582\!:%1O7D(#Q-][7MN>_.*_`P>7#[1W[7MJ'V[QS M8*I:NE1X2=P+A\UHA#)N#^L-.3JZT:+IS>&QF0F6,U9\BW2[WJ9AFBV:WDP. MFYE<%2?!6L)[0_ZGIF0X!2WCL:'E.YF(Y/YW&SUA+2&V-%\Y:XH2\&:7V8F* MXG\&^H[)A&4*QJQ.(&_@*`VC82SI^R"Q8A<2%,@;QB%%6!BYU)6QSM;^E2.1 M@F,M'!'H#V>:K&LZDTQA7L\W;F4QG"D30YGP#)TL?;I>)[I_0'([S21"RLLT M>:(KS%15(T4X.]4F>XS^R.J^F(EZGT0LZWA_%<^H170&V17!*B,;$]W(HS1E MW+JD5I.I8IKCA@@5E_8>FQ-3XZ$R-1>]^_5K="!?;UQ/C`C5L2JS!7:YXQ61 MAH%V;E_A3@B`L-DMK*^Z(^JY%*8-6XY4T4;7T$Q^@DMH)Q_5U:0L*V@Y-4+U MG6>_6LX\T'/J%`00BBEJ4M7YE"55SV6!AQ+AW%3T:U3)&,NYAJ,*-QMK_>S` MQHA_>V-O2*,.FM#?77?^[BR7M0LW](DBQ3MQE85O2:5Q"Y^Y!8$ M\1=Q:'ILLJ.7[P[KXT)CI!#N"JG!QD;'S=(]K:F;@:89>IR(M*$J$%3YM`8M M7%HC)%5T.11-VK.("KO2)44N2U'6UE&I4$L?ZQ/6*\_<&KA&Y>VWTTW3U/5R MHR+;B&,G+^YR;GL^:;!HH,^P:$A1!%;N3:Q,H*C615G33&-BIE*46K/6`)R# MHDX,F5T[)6AHL-`Q=91:A'#W=,H&:VPY"`%0$,M_N?/<-P?9K$\?7WU[?KT. M6Y:FLXWS)LI#/9,-W6#KE_E'YZ*:F,YLJJN>!E1I+,N%5*>,+H3JJK)6)Y)N M%@N[*MG1>4VLL">Z9BJ38KI3QA="=T5Q3Q1EHAL3(623C?^SZPN2*#I^FXH1 M(RT:@G?TRA[@F3:6)@9[KJLT?M5E("NJJ\W$?*H=P#9B8 M8X,Q82D#E:.DCC8HB!15("W5-<.8B*6DCI9,QHJD5:$%7[WA7VTW6\_^XJR= MU79%02G]BWH-3[C$1);E6`Z3<]Q*Q`IP3@G-1A624UU&SF?!:7FSX8[E6NHHM0CAW!E,Y+_HY>EHX,2O M2I.)FJ"DZ,!=FA;><"M<95B%%B0T-[ZS"BR>D65CAZK,`2L35]GUTB5%:9RZ M:L[89#(Q#B>X0FVK3%U@6*]S@HAAB[A?X>/2LM6_-0+P7Z$,^ MMY+_EMK?0,)GLG+&(LCEC)\DU+*J]R<8BJ2SM4"-D%=MR6JR!,F80XFNT,,U3&14QA7)PWV`MGYM2W*F3-'.-5UB-3-_7B(=T/:[GY2"L4KQK_87;#^-NY1ZX>W*D]=,5#:8,\%Y:` M\@V=WA@O8L)-55/8F%KZ2*6IJ383IJEI;("V.C$<5]WMWA`(SO[CBT5O$,RY M,3"\(O<PA+V)K+1]M;\5G:WZ[T[\5\7@@^KLBVDP/L1BYNI=^<]+GO.OV M!*8@O+>1_W##*SST9>U,TF,G&T&$"N+^"IW%<.1JBEA:!4?H5W1B0ZZ:`[5D MZ_D]IUS8_>MNZ]F[L;P8?'[C-!]21,6;:DLE]+UXN.]EAH.ERH6B)<.EJM^, M+PGV&Z'G('QG^Q@'9%NT=OWAHE,>Y,4_0+^^6#^@X$.0\3!CU=S[([\58JML M4,R),3X-J9'J(E'*)K%!M?V1WPJQ55VQ.@JIW3O^?ZX\.^R,$V_7I!@B M][Z(;X'(JCM)LM&4F]0BB0FU9Y+"@@SLB_@6B*R&)UXK+>/7E' M)^V;+1Q32R4J,JHTDK=\[H/N-DJ*-S)0*-#DG6R]0$7?#7=J$N4ON3KUQ5PV MS-U](4+X+" M;/'*+A@`^4V>L_:=&7:LY-HU#+*6E$8C=`K2H-UQQ-E^64>Z(61E95'9F!`2 M>:/81;SUJ\NUD9`D3CFR&UM`G#DV_@"V%K_=X@"D-J)7MG^])A=JX*L,XNNY M^=L&1/@,)1@ZL`B;O[SH!(38#&Z^)L9_[8X8F[\@J7M"1&[=PG:@D1M0P*)R MA)""DG&W#!?D3-8GBBHB9\5+]Y[%Q.VH5+Q+T!C)(O*D(M@1*UE\J`C'Q?#I M8E1.U27=$!'LS2:T24DD9@#_$FJ$PM"S>$]E5^N4D2+0NI5DL#W2%>3$I,E7 M%F@3.RM?(?Y-FG2%5$ET7;J"W)XT^9H"C\\'E2\3&,QQ(*L!KPJ442:9C4E# M7#I1D713ED041611>3`A\(?B%'FBJY)QS$*H'P?3PI6JB$*L M+* MCH2;R6Z9@XNIABK_0:[RQ:=^4D7NPD=5#+V`&P^SM@!5UQ2!MHZ7Z9*B]NNX MM,)#1.JH5&V;..)YUC'-)H<@2%^10?(8C`]0#S_VUGL@E,D94;+R".%(&C_= MV)LG_&K.0TY*CO!`S'5*S$3$MVD%-:EBEG>;I'HQ\XH9G_`Y!6V.S*25Z`7- M+>AWEU/,ZF@G]MP>,>]L"Q4I^>R^VQ[YG[-RN%`52QK@L#>@:&,3PT';9%7* MBO:R*F,*"9C12#]M:?'9,PH0>ZJ:52-*'DBN,(O6>LD%9:&[NT\]ISOC!,A9 MLRB9Z:A[WSTF$![UA])&".ZIM>Q&5%'+/H M4.2D?)&57L[BY1P9;+`57)W";9"RJ$/"U]?7?60^97E47#XNAH6V":M\ZK/! M-$LG9%4N]7GRJE4F]ZF-]!-5K=JYSX.I&3S^XB[1FWR"`U3[\AYE,I9,E;W[ M:'>0ZD3PPMI,5$55-*TD$02EZ6+KH7V25'02H8NXV2TC3'>FJ[*B)N@L10?B MXQ^__/CN+=%__A]02P,$%`````@`[7L'00MX9-GO"P``890``!4`'`!M96QA M+3(P,3(P-C,P7V-A;"YX;6Q55`D``PUM(5`-;2%0=7@+``$$)0X```0Y`0`` MW5W?;]LX$GX_X/X'GO?A4N`>%HI$VT1ET4M* M2;Q__0UER;8HBJ(D*Z+]%,?FC+Z9;_B;')W_\C+WT1-FG-#@HC<\/NDA'+C4 M(\'THA?QOL-=0GJ__.?O?SO_1[^/?O_X<(<^XP`S)\0>>B;A+/[NB\-^H"NZ M6#(RG87HZ.H->ERBAP=T38,`^SY>HGX_5?+1X2!+@Y6VT?$P^C_NGP^(5[/?`!0N>,^O@!3U`,X$.X7."+'B?SA2^`Q]_-&)Y<].;8 M=T##<'3R[O1$R/]T3=UHCH/P,O!N@I"$R]M@0MD\1MU#0N_WA]LU?"$/Y`+; MF!^[=#X0!09Z'8.F$!^P*Y2[+HU`>S`=,QK`1Q>+9_(Q]0D@XJ9@3;4UAOTK M#N\HYV/,KNA\3H.O,X?A;\ZC;XY5JZ(QP*\A=7_$]0JT+W#`8\*J(=3K:`Q1 MF$W"F)DK&M,%SP=Z(-+N2$BF-1!74MG8@-\$6.)DG9!#G>".2+L+F<,KP:ZE;N1`W5-1^LA#/,;F%".:_:D:HDFU>"Z)'C/R.P\>:I MAM\*Q7=0.X&0V/?WD_N%F%U#&U"A:JJE&\.Z#82=E$'K5'5NIA1-`+F.[T9^ MC/(.'I\!!G4&!Q[V4FA"6:,Y:Z*S5?M19]`0*3R$T;G2ML-N2$N6W[A8C`/TCSZ&.;`FS+3%[:1( MCSEAYJUUS*1=\!+0*IC(_FRGY[,8$T^_L\[38X87#O%N7L2<&D-MCD>O92VN MD92=O!A!3^AZ;QU=*YR%?6#G3L^U/TJ_VM<5C!F%V4>X',,(*!Z-0W^V$`,D M=0.D+VX9!WJP%O']X8IW[[XCS2'P2$JP95*D*=3DM&CM+,6$HGQ#)!3N+EF(WR_,A&;*U M`Q,`S"+L&060IJS=E!2AMG9LDG8%R9Y^,25%!2WFHPBRM:./N#G+-59V)0'BA*OM0&3'%+5$9`O8K'W\V"M;4\O/8^LH(P=XMT&5\Z" MA(Z_98%J`?9N'!:08,IARAW-H_@D'0Q1B$M4`R\3 M(8L),X%?;0IE>T>O*F%M&R*M,AA.`7)E;2#'9/R?`UZA7ST?2$?!&IX/TQ]% M2\^)G1:?$]LH0'2"A`H4ZT!'WP,G@G82>V_L.3TF#KP`Q#&C3P0@?%Q^!QMN M@^2T:3"]=$/R5+1:446XBVH$^%8GC<75'37^[=\[JR[524CKD&2!Q0W:@F&7 MI'?1+N>4A,AWJ*L]5&I%JIN@@V#8S-0T#S5C'GC"0#E:(,4!N7[]2*ZU7=!!A8&9J M&@;V#9_R%J41795TI=Q!<*RT+*5T'P9;TAI&)3K7,@=%Y=JJ]1K.'M`8]RQK MLZO63XWT05"KL2\EV<(=,.7UNS%FA'JRB:K=L4KBG=%RD.\MX(?D;O72!788++ZNH-M@K"-O63&GH6^_'5S"O/'K[ M76YEM5")E0ZT=G6XP(C559*:E5@IW-'E.1=CCW\"ON--R/O8[?SF!3.7\$U& MC.P-NC(9VZJLAJRMJW9E5ED;HFES1.:U#Y'L:A M-;!*E[6PE9//E2*^^>,W!I;>3R;WD^^!L]I.2J_>`2955)J+V1:=)7,6<\., M!K$+"`I0MK1V=JI<-*XJO&<<5S4O74(ZTS=("JX+CI,TR)16FH5U=_E',D>3(20"M].P:$!!U+`^L2073I6??39+W]BJ>_JFR/W_.5T*A`&TTH`+@ M]?VKS#7=*%%U6]XL>)CLQ'>R$T$."4$$DF@EBK)`ZWM/G0NY62;EMOQ7]#39 M@?^6'1@+]E\_HS3&.\V)W)9W#1\N._N][.PM/?]"&4WQ.$9A2,/H ME8ZI5XA)"A3K0!LE2(&^P6QND[VZ1L+KUN9G MVX^0/96;1L2ED82H08LE)<^NFW2[M=8J]QS90[GIQ$8$M8O-("/S.C/QT#`S M,3K**'K3S4AZDQL\:\?;ZB-J,"A1UIHMVI!E4%O2[NBMYZ"C1V&(+5/C. M*-D&D[6T]@'K7R(E8Z[2SK2-O.354C)T=4N#5"U-I\B'"NBY<"_%CH;=H!\I MT.<"O1S]J!OTZ[?HY&S(C\=*;4B4==MA%5:')CW6NGYTD3MN?>93;+;Q3U$( M\+^0@,RC>7H@X%IYZME8LI.4>&;@Q";_$_X?=ICJA$<=)9WMNE8D-1JQY#&R4'&X,;&PTNBV[/R'P#9[:O!W8UG*P0;!MI-%IJ#V* M@F?:/`;6.@XW`M8F&IWEW!?^-6ES*RHX4.:K98,U/WG5X4"^<(;R/C='K#Z@ M;WW*HGFOJVR/T69=^U/UW&M?)9RZY;-7QE84&L/\:ED.8^O,&[\&5@9?9U.M M?=>KWA@K(]=N M<[@AXO)7&M"T5UT!2I)C_&AJM;="+05_!O@Q`S M^$9!4W%1.PDJQKMGTS9MA5>6LI,0)=3]6$CYC`/`[HL,+=X<)@8\%)8\:1JU M4HGN)TG%3)6"+V_<"BZ?O';>8PX3=5?[B)5[MC=^4!(/SHP=!%LD(D'<0``"%2`$`%0`<`&UE;&$M,C`Q,C`V,S!?9&5F+GAM M;%54"0`##6TA4`UM(5!U>`L``00E#@``!#D!``#M'=ERXS;R?:OV'[C.PTX> M9/G83':\F4W)5]95'LME:Y+L4PHB(8D5'AZ`M*W]^@5X2)1X@21(@!1JJJ9F M*!S=C>Y&H]'=^.GG=]O27B'"INM\/CH]/CG2H*.[ANDL/Q_Y>`2P;II'/__[ MKW_YZ6^CT>^73_>:X>J^#1U/TQ$$'C2T^5I[>M*N7<>!E@77V@PLEQ#%HVJG M)\?TS^FG3__2KMR7-3*7*T_[CE>>]7(S';V]OQ^]S9!V[:#D^.SDY'\>MCZ+F[ZGV;^=! M:P+:IW'PZZ8I&GX]R_WS_H*VF!D.M@#CA[# MP@8U-B]PT/W>U8$7K%!I-RVW!?W?*&XVHI]&IV>C\]/C=VP<$1)K6DADY%KP M"2ZT@"`7WOH%?C["IOUB49"";RL$%Y^/;&@!,LSIVTP;C(O'&'.!\]ES M]3\#/B-SO$`'!\2-)CECA;1LE`Y@G<%WSP<6%X@W8W&$>^5:!M$"-]]\TUM7 M9(2"`?A`^!M`"#@>K@A7JELKT%1?&![(E^(HG\$R%M?N0[V+8_L#Y,E M@I!N!%4IR#P<)T[TYQA^\\G(-Z\UH,WMGH0.()T5P!S]'&\K5#'_$,"](D,@ MW9_#D6$2NM"]]$B+)DJ"O1G%=+PQ:3J.VHPS!V@;ZLU4(\.U@5D1Y'3O#N&% M"T!8L3;`H(K2[7=N&%%A6-?B"#A%4Q!34_A-SL'8-%Z9C MTNU*^W!O.E"[\Z"--<_=MOD^,!1C?(Q-!]+\SQV7A^$N@%$+`**4>3"A.\LRU,R7ZVV;1["FWR9O`!DS,-\RB07FT`H.#[S''XNB40@$ MF67R;N(Z.S3!PFUHC.)C6TA7,%-E1C_QX9:M5PM/Y!95&:'P^\I`/MQ]=QR/J MX,8*QB3'?KBD_V!417?."B(SN-_0%B[2M@?T"TV+<+IH3BFEUP8NLQU2Y08@ MQW26=,5C($V=[-K7IN5[T)AZA*.W2XPG<^PAH'LYI*@]FCB/AN.9!H7.?(7/ M4/>)^)H0W[SKED\DYY;H.+JHOA>LZ72QC^#$=GTGCQJ!T??JBM2+W4RN&B'"X]<[BTY@Z([VTD]@?4.@K>=W]-4A82L2_[/Y[M"W\P M@A;&`"7'V,B^=B;O$3'XBB>^MW*1^3]H?"7D0PE7!UUFP@\W[V0E3`P?D:G# M)\HH353#_51J=`([/AP9+G":TA+:>^.AJ[0AB2"_:!;&I<: MEE7#F6K0+1U61;_\$0P[=6#F+4]F"\YSS][L=FN]^Z'FDTETS\N+/89B?'CFFBZGOT41QFG\?A<=V0=2BV<72=\X)PS1FOT%:AP`:DU>( MP!(^07HD)#]?$JI$X3-]S=P1-V8K#]&9W M1]`B.W'?67XHM)7!!HQH_X.BO2#3+EJ`CX>V`%V8=1%M?SPTV@JSWB*"_U/* MY`+EA%<1>4./R!.2ZC"D\*Q!Y$MLBOBE5-IY=946#29O((=*KW_Y(TX#*M#: MNTUZD8/0J,C4+K[]S!,8EB`W9%(!D!9NYW)5>4JN.86LO-Q37@_Q\=Y9C)(E MVM+%6#.6+\JCO#)&I-=ARAA1-2\YUKQD+L.@[!$)^52XEZ*W)1FZM.4@6KC( MIN[VT%=0:!GEMA9O%4E244(R)SK_XHJY+,#%/!.9U#,L]:U,L4&5<%-E%W>R M;,XES;*1I.SB(>FY_LAPD\($P51&"IR(_#EI+)5Z\H/UYOW%1.LPQV6ZV%XT M94&7WU9<"4O[Q7+7$(;79&\..5*NS!<*U,WS]#%)0P(\^6?>#EEC'/$X0_1J M1I9=BF6N`%X]01V:KV%%Q?C>D*CU1-GQ,FKPF$$RBT%%?$M)7Y6/IO+11%H8 MD3C]0A\CP'=.N,GMQ8@%/UX##]X"$_T*+#_WO-4U%+VE=\Q+&V1GK@>L.\=# MIH--O4TBLTW=6\HFPGG#W:,E,F;,P]F2;@#<5^<58F]['$O9VES&[BV/_!H@ M,'$,:M3JY)\SEW[JBG78IY?;UGYP(U8(D,.!'MFQE%WL/;C>?Z%'[&5WZ="= M-50YMRZ*/M%V>7EL70,Q/&KS.O,TG[MMW?@$O_DF-KT8CW")"4`S]Q)N@^G*GF62WQ'DB=X-O6GU_`L M29ZAR8TB/+Q+DF=<-KZ-Z3C!3-;L2:GHF)>C+FOFHU3$R\M'ES6UL1WBM>@+ MVL]<5/2LX?:)B/A)$9'5Z1.'%)T,C&27J&8I)(,E8AT8(E(!_@V+&O.H5SIQ2O7(M#C&V(T>>O<)Z$_94I_U/?O6MA; M@M>@MP]XWYH.<'1R0IN1Q<5`IT0KS$IAZ2E..Q1"5U13BJ&C'$G"["NW(]$, M^,E=H^20!)`KHTJ#%=T6BC=;G@>-D#4V$^>_3UG6@V>P"+06 M3W!IT@R2X/;&`UZP_^9#5]Z''WP3SWY$[A(!.Q^>=!OQFN0I/<*4_* MTVP_5W$XY7"OA=B\Z4;L: M;A5V"ME>,V1#5$F\])+1R-9,K0%+YG-Y)[Z6.MVFR92//M)7`,/)$L%`,,+; MESQKO:Q7-S#F1F\S=)(@.>?!=<+KTG"A[QRRPG[@"TQ$)K('I_.;L2^T*:I= MWSW=BJ&1U[V?AW0*UZE']K[9"CCIZ"?&YTFXUZUH!\96M%>H&K\ZF"CWJ4-G M(AL1A7&ZR#L;W@+=M,B'$A77:&1^N-[#)=FF=-WU'8],,7&,8#%HJ$CF/E+< M7IB\7!%["D\7OP'*?=X4/5&N2;!1#@N7=^-'Z3MJ*`)KNE@06]19YNJ[[';\ MX'CTYY:IQ\.'W+;#DUE`,73B""%%>;JH!RAS7W[P_H)C+@& M[D.YSA?RY,DU5TJ-#A_RY+S5)$3Q&4:>%+3ZHE-^KI$G1ZSF(F8?DR1*Y*J) M%\/)1:(TK+I(,I_2)$J4JHDKRSE/HO2EFEB6GQ4ERBVJB6/5$Z9$R4(-MI*\ M\VBIR?[(AKWD$`L,VWMHEBF MH@YR7:`4Z)2"]E+D!Y2O2NEY2?)L@.$)#0]V$XU#X695V(/C36-@H4V=V9L[ M6[D^)F?^B6,\PU>8_1PI:Z>V(7P@.T]5`)-]Q$?4E[)UJ=*1+G:>@* M9]V\"A?3+%3HA2'=I7WZ%QN:?Z_<>M'\2E/+:!D4JK9NR%+UK>I._:W#TU_J M-"K86]K>8:JG?M&\:DNG)Z>EPB6^NM*`+7CE)^V/GW2`0J1V*N4W57Y3Y3?M M"5X]]YL.<`,9AA7&U^&D_*A#\*,.4%CYLGD3:R2F&$.%C-RF_*$)-YV9&R=> ME20Y,G53OMYN?+V25:W(SQ,24;6"&1KN,A6\?Q@@$+Z.4"!'Z:;]DQU50T-* M:53U=51]'?&Z8:/?Z,MUW*5Z;W09S_J9AQ-V4TJ:W'[)KWG%IX)57'V1%H\T MM0+J24S::)(F?[]#*1EXVKYX<8D(I648GK6^6'`*:$+AI)"X;2MF-I MV\$DB`[A3JT+5F9WRDH4YX>-B/D7G"L&RLV.WZK>BLF32!<&5?D?P1K*E$S-PE`4/EPL_99X%;H+)MR+;C7+^S!C_)? MB%I:642M$8%RLHW\5!..ZVX8@0H"%@,T&-[%N8>B4DMQ4_"B;N M*6_>Z5T+Q--%!BAEC26RH2O41V42>BD/"JPV2:$:D"9\H_+RI218FJB*ZIR8 MKY:DB:RHPWDII25-=$/E)2K0>_NA"5)=,2NK6GG$"SWB0FZEVW>O]N5V^MF? M8_C-)])S\UHHC^>ILM^;GEK850+I.\P7T[G6,A=UC\R^R73]'(.QP4I7GM^?( M%%?U'Z=RSN12E$.9?LKT.X@*:C4-O?)2:LR%/I5])Q2W%1;HD7MREP%`YW'MU-Y,'&/KQC'F+_"E3`J?ZFJ1U+D MCBR]=HB^T[_F`$/RY?]02P,$%`````@`[7L'07A)P_IM/P``,:L#`!4`'`!M M96QA+3(P,3(P-C,P7VQA8BYX;6Q55`D``PUM(5`-;2%0=7@+``$$)0X```0Y M`0``Y7UK<^,XDN#WB[C_@.N=B*F.D+NJNG9FMGMG=D.VY1KON"ROK>K>N8Z+ M"5J"9.Y0I)JD7.7Y]8<'28$B\>(#"7F_=+ML9"(SB4PD$HG,/_[[UVV$GG&: MA4G\IV_>?_?N&X3C9;(*X\V?OMEG9T&V#,-O_OW?_O?_^N/_.3M#_W5^?X,^ MXABG08Y7Z$N8/['??0K2OZ.+9/>2AING'+VY^!8]OJ#[>W29Q#&.(OR"SLY* M).=!1F"3F&/[_KOWQ=^B,/[[(_D;(C3%V9^^>[Q&C(`?\Y<=_M,W6;C=191P]KNG%*_;J8C2]"V%?QOC#?U` M=(8?Z`SO?T]G^*?BUS?!(XZ^073DY_MK*4,_U'`50&^=4;E(\B#J1*H(V8U> MAGL=9(]L`J('FR#8D8G>?_\61WE&?T,Q9F?T5V?OWA>?\)^"KV%VB=?!/LJ; M1#?P,9HC2N?;&N!(,OZ7,[+<"D*+7S>)9!CV61N-%4Q!'_OM#:&C1B'^FN-X M18?QWU($"IWA^*FN,:04;;*L(8RHXB5IB8_-^J=OMC@*_G:9+/=;'.?3>#6+ M\S!_N8[72;IE>CI]S/(T6.9U65$P]M'>_?[#.R8)"T1O*Q(I#=.T3F>0+LNY MR(\:MHL1;Y<)L4B[_"SBJY6#K]-DVX'#/+$`^EOT&!US5&,GQ5FR3Y>XJ]SY M!,34$DBZF>#X[/.#U:)@(OFWN_3;,,Y]GQ`BO8E@URJQYJ4JDN MM(^P7O@FJX1X4(])AF]$,I72DJR(ZM/&!BGTS?7RO-BG*54\ MDU7:&`NY6"6$-]?LT4#8I=M*3&.5%*,0A_D1:"F;T`>+S&AYC'"MS@O-B39%J<$`7)L#-BH^3>*\6!NCI:FI@=1@*"T@G'O M\?0@^P`S002JSK#L<9)GO//'_":>V@(6'2"!)F`5LP):YK`S#G MKK@Q38T55D"B`I2Y!@P8'1T-H9R=_JQA#IHQWA+&V[(X[@8,C2=1')/CO!=1 M&VVTQOGZ-UD.1^MY@IAW/\ZA1+A]ZTPO/WS4@TF0.T!"3G'YRQVAD07ZROA MX$X#IK0U5V"0\\@667EY&JSP-DC_GL$H4`\V#J"5>T>@T9L*'I4(OH73J$N\ MQF336UV%,4U6ND@RPB-9L7PGE.\W!G`PNF3,D*A(6B`H+3(DK'G57\"A-0.D MBVU)89WK3V\&"D#$((D&5;#`6Y%P,CK0)!&"9"R,@B@)%Y6B=:#STX:"BL:B MJ9^E#\.ACM/VM/MQ1E8>I&!/Q?+C,-`Y6',`!C_W*@^\T`?=FS!X#*,P#W%& M#B;+\^U,2K7":T1-'_J+)M3$'AUFRMNR)B]H4UOFRMR.LL?`$<$3@D8@` M<0QCYU@:6.Z^3%Y/SZ]OKA?7LP_-4+ MI3-+:5,!@"N607*;?#246Z^C2)KF)@"ZSW6SIEH`\"OKK;R0O@M>Z&6T6?[# M\6#8S(=VTMMR'NHCH;,=VJB1)PSL^&CT)HQIT`33S(>(O07;!2G;0Y(U^LWO MWDW>O7O'XD6_^?#[R;OO_W`6L+_\QS[&Z,.[":+K@/W]$B_Q]I%XVA_>L]^2 M_Q*&=WB9A\\X>FE$8IRE4]C)I1CM00+%$?WW_//<\:]CI5@24"_43,F60NE: MX3Q1005M6H6<'.LAM-YT8J;2H@(:%>!^J%6ZQZOFEBL7AVP\F`*I&3C2FO;! M@*JB(JAM2='Q5?H#A#IT(KC-18._C;C'SSC>:_PRV6#8>X=VTMLN&^HCG9_C M563(P_'%:/!,I6[4IWPT>O.P`+QS8Z%>8\LN'0UX?6!FU25#8:X0C"TC#\2; MV$6GUPB6])=)=]$!S*>(DW&$P9\(DUED"3(!!/%5&5%,?DGB#%CC=>A-4-2==5.4#E!>AU8-C M%N<7Y/]AKDV/4(-`N_-R-MJ=^N9X0-=>1HS*P2<+B0/YD$+1AQ78LVRK8ML8 M`:^V!..M`-(!TBX-B>'TQ0W2TL\]H=:=RXN%KF?1@T6M69%LMV%.'RW0%(Z+),[#>(/CI7R9*B&`JICHF:C5+I$/AW+-M20U75N=1(IUU5IF?J7)#L`'ZV)Z?%AA5JFI7K2/! M'M/+B#YZ/'\\#.X9I824MH?DQ?$MHT/1&?K-N^_>OZ-Y!NB9POTK"O;Y4Y*& M_R!CWK/,'Y;]DST%A/@?49AE]&*3O3_?Y[0&,WUK]2.*D]A]L90N?+.A$UZ. M:X*N&3N^*,A=D,[3AYPF2S#Z[G#Z0.5NQ+X7N9P3MR'A)-:>])O#X(*_;>0>1WS%,>X+4[<2T!K_3&*CLZW+ MR+0YY3P:\9OOWKU[+XE%_//OCF(1_RJ)1=`721\^?#_Y_OT?*B\Q;WFK1(>] M^\/D=Q_^A?Z]\7+)"SVR#`@808)KFTTHP``,\NK%B#3EFH>,`/3FP.^SO\"> MX<%?"0&N-R9'?L5PR+W+\'1<7U;:HS&`IMLQ8AJK`-0)Y0%?.MH379`?[25# MX75`>1IN6_\>^7'F')@$(P`7O?XDKP;Q9/EKSO"J\1XX3:9GWM8E!7ET[\[# MD6)[<6J?KE8A[4\81'=!N+J.+X)=F`>1P*1$#":`0(^CC5FJO9+60H$]ES:D MK/D,N0)$M'S\61BC)8=U_X)Z`!XH)"(\%+`3)*H5G`;=XSP(8[R:!2GM$I5- ME\O]=L]*'ESB=;@,9=E>)H`P&F3.DJA!>BCG_IC,E\C$BH_T*3]2PF[;0%_R(=LTH3G*@_Q'@X3!WY:)C],\3\/'?<[* M0^4)#?&,]4Q)FQ??BQ,O'FZT%CF4<*L'`W_BH63'ILJF=]4U#:IJE@T;:`L' M/QZ+V'#2>$'"^/%+<>8[G`8T?;]HE*3K7*X8#U3$0\=`K8R';##4:4-#4+,B M1CF^*L_D_IEW=YI+`"]>=]_C#)-U1CNB7N)G'"6L*TQ!HM035,)`G1\,&*D? M'10`4)I@0%3+N8'#,+NZ.D`Y5XG>Q`M0I9;`:<9''!.-C0@ST]4VC$.JJK2F MJ%HWM%`PVF'(C*@?&A#GCI01/8WU54"QY56'DZTP5ZK>GY^@!N>!]W0=+Y,M MODDRV8/R(S((MG=T MQM[TMI:L;$_HY"-!ND^;45N M.;Q0S`DJ(8"K5MXF<5+74[5_HP,"K&&I9:51RE(*`5/14D..I#"D"%69_0(0 M[+*@!S_M&NU.+6YQKO5CCL;`+/I60L4U7AO@?$FWS-[XXK1]9LU3\>H6P)0# M6*>EO(\K\V?/@RQWIN M"FA"UJE*PJGS>A%D3W=I\ARN\.K\Y7.&5]=Q%6"9TK98_`I7?W,A.5_^]Y[&B;)'<8ZH!881K9Y%%,HR2CS,55`;V>&*K MYVP//P]_J/-O3."@&HFH&6BWDM`.AQ*];4DM53A/T#P MZV'61;&G<7*4DLL%` M*>M*TFMIZZTCH;1"14W3P21RH`9X*0QUK@=6%+/!9X]T-+I04.WRQGV98D+/ M)>;_%_;,XLF5QH6U00!U*V_+8OV>WA0:[N;>CL+F.?2)_(N^V:[Y>UF&B\KJ M$60WI][T$>`=L;$GCG"45!RE$HY@E0JF@X4 MD]GDG4LT,+ZH40LC:OT1`#Q0G`8UIAHC`/JC*1;<$!;"8C3@JZLF"W>4 M<6S^J&H/WDLDZ$V)EO&^*W@O'\3Q$I6USM%!JQ!\<"[O@A>Z1=,XSG*9[HDT MM1WHNB+S1=UM6#=S2568_#D;FE.KT/J5J/65K[?C*'ELDB.MU,&#<^,@G+?[ M[7<"YP52/UKV-:50FKPN&MX*ZXM"*QA3ZV\+H#_J*B5.Z5NN5`U[`52O`Q=U M3:LZ$'NN5?>8./72,N@&<+YITQ%#9II4`!UK$6A4FWIB5`>'%8TM!E'?9E#?HC]*LP)8/B^,Z\UOZQ^^(A\,)SFN66]D]/\SX;L MEP4)\9S(BK0A\@'!GAWUYU2;1N6=%O(WL@/D*"L1>:65!BP;:*<"BV_8T-JE"Z%L2WUWP4J1#3I>_[L,4$_J)CT8)N MK(Z/1((V"(`ZF%FS6&MF9@SM?".U):W9$:Q`0#-0"Q2HQ#%!#,NDJEDX0B4J M\\![?U8)44\!#:'&_]F7`T`'UXA^"'0:("%%6P\&?"^9J11GMV$77' M%TDFS=E2@\">^U1LM)WTVL:#G>WDQ,A/<[2X!5M3)11B8-!G-PM6JL+:*>;= M1FC]J/UC%"[1?+W&*2U#,5_1\-`#T'$34T=\1`)*OCZU")F.Q0`#5O[,!FK9FC!;S[ M+J?6Q+6?QF@LC_T@8)D@C@>UW.+#:.4`W%*]+._G$>O*5W#/?L`'K(`/GO>[ M7819M:>(LGI%3LK7\3I)M_R9MSI^8@P-]"3:CKG:&VDS4+!'TS;D-=\D"]!H M%6;+*,GV*3NF+)1^R$\&Z]:]O[+ MZCMIE+(_6KB]A.ZV\@EG3,,;\?P7]SH^$H^5OK.B(HS; MP\T,W7Q;8Z(']#U-@Z1$ZCU>1D&6A>MPR0P0#40)#X\627E-JKC([X,(H#QJ M+Y:KXJB=L+@MC=J#Q);>3'5R9O6#S\-4(^-D<15Z\HQ\!Q@#2U' MX:/9,./^X_3V^O].%]?S6S2]O43GTX?K!S2_0G?WLX?9[8+]Q7UK3$?<"]-, M4&TB9F+$J:BAJB9#A]EJOA:=$+$9`0]BO82G:UL[#.X3M#_*=KA#(';?,6@X MJI6:Q52)ED5G-X0UG1KI<,(>[]'*IYLXI//HMUH;0)##AP5+PF'#`,KUX<*8 MI!;7D<$B`=C4^#HZ._3@;?;3[/;S#-W/+N8?;Z]'VW0-?/U1F1A)K26[E@6< M9TK=MML8`_FCTII=HDVCY5L"O`(8LI,>8+^#;47*RG.9'S35('`M275L'++Z>97FX)<>93'DFD`X%'AOWI+^AQD-FLT>%M>?IHN1;+;6=QF6YL$43.6=RT:"JY?4`V\? M!JE<&G/:U"U@%[L+];@<#NA1%]7R:.%V7G">WG>E:9)>)"GQ^=D["IV+;8D# MJ!-6%T9K+:YL$(#UKK(GLB7D<4'<=#2]N)A_OEUP3^8-[ MWWT(I@XX4-E9@=W,4S1(P..)@V_"LJZ-G14*?Y52V7;.`M[Y(<&>N+;,`EHF M3%B\=VD2DY^7Q46=#TF2QQVP==N%8KP?[=65VX!TL"\MU766\':V0#?SAP=T M-[M'%_-/G^:WZ.'/T_L9>.MT'>7-INF>6.MC1C2663[M$,D6SL7O$5UL80\,*&',-)\+;8@N^=/-MGSSD-/LZJ`C\;0]L8*U$9R M&&'46DWV0PG6CG((LIMO+Q;SB[^JY.5"*HI,U:,7H?*<;@MRF$:#E M`\Z88M5UQ(?MD.[/(>_W3-]W)NSH@^-E[9&);O>S10+TI*H3J[4'5%88P)Y+ M=:"R^7"(G%:N%RP(-2%;%PM.S6XOKFV^3TET0JG M&7WU=LR6'M8;PH,]K3>CL#V`]"?YS>7L_N'WZ+9?WZ^ M7OS5_?OYODP(\+]%'`.B*/S;*#AQNJ#8T2"@4%@KJ;4`6&V$^[!7R_1F:V.4 MK*.'Y1->[2-?@S0-%*&JKD@`4BDZLUIE65AC<)N`T9&\YNHK\%2U M\PI,-2-5(H-/BAJ*[9^G]_?3L:['M?DG8W/A;K\7?Z61IH?/-RP3:OKQ?@:4!34`5\7U M!T.!1!S^G1EDW&K,OQ[,+Z53&7P=C'-+;T:09MG15]G[B#?AV*38HSPF5O[E M.EXFVZKG?%$[V:*LB1T.H)H!71BMU0:P00!6;<2>R.:3_\6?9_?H^O9B_LE] M>M0@#+!J0QP)B\3R7Q1X_#/[C+S;)*YZ,W+2"WIUA3P,@0&USIBUAKII(=W7 MVK`@2[TP?;#^#_O'#/^Z)[O1[-DDN4HQ'JJ4KH:!>O%S5):/;QSHWG6I"3)9. M1XM9T+'"X=^FQ/->4>_[*@HV\H65X>5WF^3Y+0'A:XK\<+R46M"Y70Q2?NC7 M;_S1^G/+I-;^N:S7R+]52!'%VOF+7O"N\E?$J0NBO^(@G<6K2W+TZO]QY9C= M?V<=E^4GEXWK\_75./LOA`(_XA,@.@,B4R`Z1^=E<5G<'?#&"(.M"0E:]PM" MR5^Y&EH']5D*"H3]UT&)O&RY,=@:6)!QPWUZC@WNBXO<'']H^K$?Q]UP![Q\0N?%D">#;?YUD>Q"MR&!]L02CG`%L=!IP?+14%Q`#K M1HM]N$54/%ZCOC^G_Z=OP#?;M M#\@1Q=[;+^0'#NYM7I'?9?U7@`(UG,,+8D^0.?M-8 M<:>MEBH9#54I54E\O4IJZU"`"JD*.A1+1VA"DJS1G%\ML[I<'BPB03G*UGC: MZS(E"+C!DK(A,52-\9`&2D*,\>JJ^A#ZL;IN\9=#H:]ZG:^[)`J7+_R_NL0$ M>S0PJ[`KNW1E$K2]^1QEE78CK*5:T1=YT;<)X@C0+\7_`5_0#,2O;52]D@L=(W5/'&@7\:S53-F5OU73PH"_5S(B3OU.;%^_44($($4SB M`S6*#%+)QN"9;'\9XSDI>*;)H5\*5%X\81N5PTX5E[469;K;I$-^^!3&X7:_O=KG^Q17-:PL;$QGI*!6IZ1JEU*!R0`=J`SJY5)L,;@UCIT)*]KF]PW!;9O MQV[=HK,:KY5OK8$9C?''DO&=@&M(L]/L9VE@9@R`O&B8JC,C6@CH5JEFJZ:M M3ZH_NM&7*U6[5"=6S?5GZ:'-TRQ+EB$M$5!,/B?,%44#'G#Z'"XQSV=IX]," M&$"[K5FKM-P8TJVV6Y+5;,-4P:-RI5$,567V`D>1P`2B.0.RF!8L)I3%_(F: M!&$1H*6Y=^-=]^!Q$;9=<#AVNJB&-V%UF2DW9AN4& MG;\T>M9,OP3IZBH(TY^":(^)?[G?\EV8EA1:$G]R@=/M>YGC-N*$0`[@Z"*L M'$EGLAO/(1U36`W'5F@<5FN>),R''E_:&HPA-ND$T6D1FQ<)$T]0.36BVXQLZ5,"&,WX$61(F9E-E-8`812MB51)X/$CF32>-U&1]F?[]*,;Z.%.RNWD*_$F[22ML).ORI\L?>;+ M\#E.G9*A'[=![12><#2=L-XG:1;-JVS-GUN MI"`T4%586?%4FBF/I09FUQ\OQ4AXE)V.SHH%?C]]%FL!F;HNG24#YL'8B**+ M(V.M8I#/:!BS9);IUS"3Z,;1&*!G+6V$5L]35!2.MLZ.26H\%V&?F`Y`O]`A MD.:SLR(XC-./@^@+S@XNW=!*32)#[( M9UV2L7P3QO@ZQUN9G1T"L:=Z8BR2WE=24EGX=^UW8-3"3T">=/R2J)DLV+KGF)BYE/ M;/>T%^HH&1]FTO1O_[42G[.L#Z;I`@W`M@U(NB=U@]I51,5ED=`P]SZ)HJLD MI7\4_+BEF+T-/[ MW`$%<+M7U:P;?IZ3MTQU@8U@E-HE=0KVJ!*-(U,T07S&46P0KRPYBU<.K)!4 M

LAIVZ,-[)HSW)[XO M206Q2/(@JN((R0'B='>CC[P'14^I3U#^>;%R!,3 M.F=?<;H,"?,R.],!$6`MYTXLUVH]]^)U/"/0A;DQ=;R<1U!SL*+3?>724-]J M\.EZ$@4+-`MKU'-MRSRGZ45(!3:4#Z&5E+<>1)MH'-@6.M]IGVM-!-

XML 16 R37.htm IDEA: XBRL DOCUMENT v2.4.0.6

Related Party Consulting Agreements (Details) (USD $)
3 Months Ended 6 Months Ended

Jun. 30, 2012

Jun. 30, 2011

Jun. 30, 2012

Jun. 30, 2011

Consulting Agreement with Breaux Castleman [Member]

Related Party Transaction (Textual) [Abstract]

Amount payable under consulting agreement $ 6 $ 12

Termination of consulting agreement Dec. 01, 2011

Monthly retaining fee 2.5

Additional retaining fee 2.5

Consulting Agreement with Gerald Wagner, Ph.D [Member]

Related Party Transaction (Textual) [Abstract]

Amount payable under consulting agreement 7.5 7.5 15 15

Consulting Agreement with Anne Egger [Member]

Related Party Transaction (Textual) [Abstract]

Consulting fee payable 1.6

Consulting fees outstanding $ 0 $ 0 $ 0 $ 0

X

- Definition

Additional monthly retainer.

+ References

No definition available.

+ Details

Name: mela_AdditionalMonthlyRetainer

Namespace Prefix: mela_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount payable to related party under an agreement of service.

+ References

No definition available.

+ Details

Name: mela_AmountPayableToRelatedPartyUnderAgreement

Namespace Prefix: mela_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Monthly retainer.

+ References

No definition available.

+ Details

Name: mela_MonthlyRetainer

Namespace Prefix: mela_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Outstanding expenses of fees.

+ References

No definition available.

+ Details

Name: mela_OutstandingExpensesOfFees

Namespace Prefix: mela_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: mela_RelatedPartyTransactionTextualAbstract

Namespace Prefix: mela_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of cash paid during the current period for fees which are not defined elsewhere in the taxonomy.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (g)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3536-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 27

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_PaymentsForFees

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Date of maturity or expiration of arrangements with a related party (for example, but not limited to, leasing and debt arrangements between related parties), in CCYY-MM-DD format.

+ References

No definition available.

+ Details

Name: us-gaap_RelatedPartyTransactionDate

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

XML 17 R9.htm IDEA: XBRL DOCUMENT v2.4.0.6

Use of Estimates
6 Months Ended

Jun. 30, 2012

Use of Estimates [Abstract]

USE OF ESTIMATES
4. USE OF ESTIMATES

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires the use of estimates and assumptions by management that affect reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to stock-based compensation arrangements and accrued expenses. Actual results could differ from these estimates.

X

- Details

Name: mela_UseOfEstimatesAbstract

Namespace Prefix: mela_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

USE OF ESTIMATES

+ References

No definition available.

+ Details

Name: mela_UseOfEstimatesTextBlock

Namespace Prefix: mela_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

EXCEL 18 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\P9#,V-#-E-E\T-F0Y7S1D,C9?8CEB.5\W,&,X M,3@V,3!A86(B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I% M>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=OF%T:6]N M7V%N9%]"87-I#I%>&-E;%=O#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/DEN=F5N=&]R:65S/"]X.DYA;64^ M#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DYE=%],;W-S7U!E#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;6UI=&UE;G1S7T-O;G1I;F=E;F-I97-?86YD7SPO>#I. M86UE/@T*("`@(#QX.E=O#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/E)E;&%T961?4&%R='E?0V]N#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/D]T:&5R7TEN8V]M93PO>#I. M86UE/@T*("`@(#QX.E=O#I%>&-E;%=O M#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O M#I.86UE/E=A#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D]R9V%N:7IA=&EO;E]A M;F1?0F%S:7-?;V9?4')E#I7;W)K#I7;W)K#I7;W)K#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O M#I%>&-E M;%=O#I.86UE/E-T;V-K:&]L9&5R#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/E=A#I7;W)K'1U86P\+W@Z3F%M93X- M"B`@("`\>#I7;W)K#I%>&-E;%=O#I7;W)K#I%>&-E;%=O#I!8W1I M=F53:&5E=#XP/"]X.D%C=&EV95-H965T/@T*("`\>#I0#I%>&-E;%=O M7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^,C`Q,CQS<&%N/CPO'0^43(\2!&:6QE3PO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^06-C96QE2!#;VUM;VX@4W1O8VLL(%-H87)E'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'!E;G-E'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$6%B;&4@*&EN8VQU9&5S M(')E;&%T960@<&%R=&EE'0^)FYB'0^ M)FYBF5D(#$P+#`P M,"PP,#`@'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6%B;&4L(')E;&%T960@<&%R=&EE'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$F5D/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PP,#`L,#`P/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\P9#,V-#-E-E\T-F0Y7S1D,C9?8CEB.5\W M,&,X,3@V,3!A86(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,&0S M-C0S939?-#9D.5\T9#(V7V(Y8CE?-S!C.#$X-C$P86%B+U=O'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\P9#,V-#-E-E\T-F0Y7S1D,C9?8CEB.5\W,&,X,3@V,3!A86(-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,&0S-C0S939?-#9D.5\T9#(V M7V(Y8CE?-S!C.#$X-C$P86%B+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'!E;G-E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$2!A;F0@97%U M:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4R,BPP M,30\'1087)T7S!D M,S8T,V4V7S0V9#E?-&0R-E]B.6(Y7S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQAF%T:6]N(&%N9"!" M87-IF%T:6]N0V]N&)R;"QN&)R;"QN>"`M+3X-"B`@(#QF;VYT('-T M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ M3IT:6UEF4],T0R/CQB/C$N($]21T%.25I!5$E/ M3B!!3D0@0D%325,@3T8@4%)%4T5.5$%424].(#PO8CX\+V9O;G0^/"]P/@T* M("`@/'`@#MM87)G:6XM8F]T=&]M.C!P M>#MP861D:6YG+6)O='1O;3HP<'@[/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@2!F;V-U M3IT:6UE MF4],T0Q/@T*("`@/'-U<#XF6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0Q/@T*("`@/'-U<#XF7IE9"!U M=&EL:7II;F<@6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@2!R96-E:79E9"!#;VYF;W)M:71E($5U2!I;FET:6%T960@82!C;VYT6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@2!R979E;G5E3IT:6UE MF4],T0R/@T*("`@1'5R:6YG('1H92!S96-O;F0@ M<75A2!C;VYT:6YU960@=&AE#0H@ M("!-96QA1FEN9#QF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@3IT:6UEF4],T0Q/@T*("`@/'-U<#XF3IT M:6UEF4],T0Q/CQS=7`^#0H@("`F2!I;B!T M:&4@3F]R=&AE87-T('=I=&@@861D:71I;VYA;"!I;G-T86QL871I;VYS(&EN M(&-E#MM87)G:6XM8F]T=&]M.C!P>#MP861D:6YG+6)O M='1O;3HP<'@[/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@7-I8VEA;G,@:6X-"B`@(&1I86=N;W-I;F<@;65L M86YO;6%S(&%N9"!H:6=H+6=R861E(&QE3IT:6UEF4] M,T0R/D]N($IU;F4F(S$V,#LQ-2P@,C`Q,BP@=&AE($-O;7!A;GD@96YT97)E M9"!I;G1O(&$@28C.#(Q-SMS(&-O M;6UO;B!S=&]C:R!S;VQD('1H6QE M/3-$;6%R9VEN+71O<#HQ,G!X.VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@2!E;65R9VEN9R!M M961I8V%L(&1E=FEC92!C;VUP86YI97,@2!P97)S;VYN96PL(&%N9"!R96QI86YC92!O;B!T:&ER9"!P87)T M>2!M86YU9F%C='5R:6YG(&]R9V%N:7IA=&EO;G,N(#PO9F]N=#X\+W`^#0H@ M("`\<"!S='EL93TS1&UA#MM87)G:6XM8F]T=&]M.C!P M>#MP861D:6YG+6)O='1O;3HP<'@[/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@2`D M,328C.#(Q-SMS M($%432!0'0@='=E;'9E(&UO;G1H6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@'!A;G-I;VX@;V8@=&AE($-O;7!A;GDF(S@R,3<[2X@/"]F;VYT/CPO<#X-"B`@ M(#QP('-T>6QE/3-$9F]N="US:7IE.C%P>#MM87)G:6XM=&]P.C$R<'@[;6%R M9VEN+6)O='1O;3HP<'@^)B,Q-C`[/"]P/@T*("`@/'`@#MM87)G:6XM8F]T=&]M.C!P>#MP861D:6YG+6)O='1O;3HP M<'@[/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@2!A;F0@:6YT96YT M('1O(')E9'5C92!C97)T86EN(&1I2!P=7)S=6%N="!T;R!T:&4@&-H86YG92!#;VUM M:7-S:6]N("@F(S@R,C`[4T5#)B,X,C(Q.RD@9F]R(')E<&]R=&EN9R!O;B!& M;W)M(#$P+5$N(%1H90T*("`@:6YF;W)M871I;VX@86YD(&YO=&4@9&ES8VQO M2!A8V-E<'1E9"!A8V-O=6YT:6YG('!R:6YC:7!L97,@:6X@=&AE(%5N M:71E9"!3=&%T97,@*"8C.#(R,#M'04%0)B,X,C(Q.RD@:&%V92!B965N(&-O M;F1E;G-E9"!O28C.#(Q-SMS($%N;G5A;"!297!O M65A28C.#(Q-SMS(&EN=&5R:6T@9FEN86YC:6%L('-T M871E;65N=',@87)E#0H@("!U;F%U9&ET960N($EN=&5R:6T@2!B96QI979E'10 M87)T7S!D,S8T,V4V7S0V9#E?-&0R-E]B.6(Y7S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'1";&]C:RTM/@T*("`@/'`@#MM87)G:6XM8F]T=&]M.C!P>#MP861D M:6YG+6)O='1O;3HP<'@[/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@&ES=',[(&1E;&EV97)Y(&AA2!I3IT:6UEF4],T0Q/@T*("`@/'-U<#XF6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UE MF4],T0Q/@T*("`@/'-U<#XF2X@/"]F;VYT M/CPO<#X-"B`@(#QP('-T>6QE/3-$;6%R9VEN+71O<#HQ,G!X.VUA#L^/&9O;G0@2!G96YE7-T96TL(&-A<'1U2!T>7!I8V%L;'D@8VAA3IT:6UEF4],T0Q/@T*("`@/'-U<#XF6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@F5S('1H M92!A6QE/3-$;6%R9VEN+71O<#HQ,G!X.VUA M6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'1";&]C:RTM/@T*("`@/'`@6QE/3-$9F]N="US:7IE.C9P>#MM87)G:6XM=&]P.C!P>#MM87)G:6XM8F]T M=&]M.C!P>#XF(S$V,#L\+W`^#0H@("`\<"!S='EL93TS1&UA6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P M9#,V-#-E-E\T-F0Y7S1D,C9?8CEB.5\W,&,X,3@V,3!A86(-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,&0S-C0S939?-#9D.5\T9#(V7V(Y8CE? M-S!C.#$X-C$P86%B+U=O'0O:'1M;#L@8VAA'0^/"$M+41/0U194$4@:'1M M;"!054),24,@(BTO+U&AT;6PQ+T141"]X:'1M;#$M M=')A;G-I=&EO;F%L+F1T9"(@+2T^#0H@("`\(2TM($)E9VEN($)L;V-K(%1A M9V=E9"!.;W1E(#0@+2!M96QA.E5S94]F17-T:6UA=&5S5&5X=$)L;V-K+2T^ M#0H@("`\<"!S='EL93TS1&UA#MM87)G:6XM8F]T=&]M M.C!P>#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/CQB/C0N(%5312!/1B!%4U1)34%415,@/"]B/CPO9F]N M=#X\+W`^#0H@("`\<"!S='EL93TS1&UA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@'!E;G-E6QE/3-$9F]N="US:7IE.C%P>#MM87)G M:6XM=&]P.C$X<'@[;6%R9VEN+6)O='1O;3HP<'@^)B,Q-C`[/"]P/@T*/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@ M(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P9#,V-#-E M-E\T-F0Y7S1D,C9?8CEB.5\W,&,X,3@V,3!A86(-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO,&0S-C0S939?-#9D.5\T9#(V7V(Y8CE?-S!C.#$X M-C$P86%B+U=O'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/"$M+41/0U194$4@:'1M;"!0 M54),24,@(BTO+U&AT;6PQ+T141"]X:'1M;#$M=')A M;G-I=&EO;F%L+F1T9"(@+2T^#0H@("`\(2TM($)E9VEN($)L;V-K(%1A9V=E M9"!.;W1E(#4@+2!U'1";&]C:RTM/@T*("`@/'`@#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS1"=F;VYT M+69A;6EL>3IT:6UEF4],T0R/CQB/C4N(%)%0T5. M5"!!0T-/54Y424Y'(%!23TY/54Y#14U%3E13(#PO8CX\+V9O;G0^/"]P/@T* M("`@/'`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`\(2TM($)E9VEN($)L;V-K(%1A9V=E M9"!.;W1E(#8@+2!U6QE/3-$;6%R9VEN+71O<#HQ.'!X.VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@6QE/3-$;6%R9VEN+71O<#HV M<'@[;6%R9VEN+6)O='1O;3HP<'@^/&9O;G0@2!D:6QU=&EV92!S96-U2!D M:79I9&EN9R!L;W-S(&%T=')I8G5T86)L92!T;PT*("`@8V]M;6]N('-T;V-K M:&]L9&5R2!T:&4@=V5I9VAT960@879EF4Z,3)P>#MM87)G:6XM=&]P.C!P M>#MM87)G:6XM8F]T=&]M.C!P>#XF(S$V,#L\+W`^#0H@("`\=&%B;&4@8V5L M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#6QE/3-$)V)OF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT M:6UEF4],T0Q/CQB/DIU;F4F(S$V,#LS,"P\+V(^ M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$ M)V)O6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0Q/CQB/C(P,3$\+V(^/"]F;VYT/CPO=&0^(`T*("`@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O M;G0^/"]T9#X-"B`@(#PO='(^#0H@("`\(2TM($5N9"!486)L92!(96%D("TM M/@T*("`@/"$M+2!"96=I;B!486)L92!";V1Y("TM/@T*("`@/'1R(&)G8V]L M;W(],T0C8V-E969F/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S M='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P M96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@F4] M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C(L,3`W+#0R.3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/E=A6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V)O6QE/3-$)V)O3IT:6UEF4],T0R/E1O=&%L/"]F;VYT/CPO<#X- M"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO M9F]N=#X\+W1D/@T*("`@/"]TF4Z,7!X/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@ M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O6QE/3-$)V)O'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6UE;G1S5&5X=$)L;V-K+2T^#0H@("`\<"!S='EL93TS1&UA#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS1"=F M;VYT+69A;6EL>3IT:6UEF4],T0R/CQB/C6QE/3-$;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP<'@^/&9O M;G0@2!H87,@;VYE('-T;V-K+6)A#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL M>3IT:6UEF4],T0R/E-T;V-K(&%W87)D&EM=6T@;V8@=&5N('EE87)S(&9R;VT@=&AE(&1A=&4@;V8@9W)A;G0N(#PO M9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1&UA#MM87)G M:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE MF4],T0R/E1H92!C;VUP96YS871I;VX@97AP96YS M92!R96-O9VYI>F5D(&EN#0H@("!T:&4@4W1A=&5M96YT(&]F($]P97)A=&EO M;G,@:6X@=&AE('-E8V]N9"!Q=6%R=&5R(&]F(#(P,3(@86YD(#(P,3$@9F]R M('-T;V-K(&]P=&EO;G,@86UO=6YT960@=&\@)#0R-B`H;V8@=VAI8V@@)#$Y M.2!R96QA=&5S('1O('!E"!M;VYT:',@96YD960- M"B`@($IU;F4@,C`Q,B!A;F0@,C`Q,2P@8V]M<&5N&5R8VES960@=6YD97(@ M86QL('-H87)E+6)A6UE;G0@87)R86YG96UE;G1S(&9O2P@86YD(&9O2X@/"]F M;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$9F]N="US:7IE.C%P>#MM87)G:6XM M=&]P.C$R<'@[;6%R9VEN+6)O='1O;3HP<'@^)B,Q-C`[/"]P/@T*("`@(#QP M/B8C,38P.SPO<#X-"B`@(#QP('-T>6QE/3-$;6%R9VEN+71O<#HP<'@[;6%R M9VEN+6)O='1O;3HP<'@^/&9O;G0@6QE M/3-$9F]N="US:7IE.C$R<'@[;6%R9VEN+71O<#HP<'@[;6%R9VEN+6)O='1O M;3HP<'@^)B,Q-C`[/"]P/@T*("`@/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C M96QL<&%D9&EN9STS1#`@=VED=&@],T0W-B4@8F]R9&5R/3-$,"!S='EL93TS M1"=B;W)D97(M8V]L;&%P'0M86QI9VXZ(&QE9G0G M(&%L:6=N/3-$8V5N=&5R/@T*("`@/"$M+2!"96=I;B!486)L92!(96%D("TM M/@T*("`@/'1R/B`-"B`@(#QT9"!W:61T:#TS1#8R)3XF(S$V,#L\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,24^)B,Q-C`[/"]T M9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T M=&]M('=I9'1H/3-$,3$E/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO M=&0^#0H@("`\+W1R/B`-"B`@(#QTF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0Q/CQB/D9O"8C,38P.TUO;G1H6QE/3-$)V)O6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UE MF4],T0Q/CQB/D5N9&5D)B,Q-C`[#0H@("!*=6YE M)B,Q-C`[,S`L)B,Q-C`[,C`Q,3PO8CX\+V9O;G0^/"]T9#X-"B`@(#PO='(^ M#0H@("`\(2TM($5N9"!486)L92!(96%D("TM/@T*("`@/"$M+2!"96=I;B!4 M86)L92!";V1Y("TM/@T*("`@/'1R(&)G8V]L;W(],T0C8V-E969F/B`-"B`@ M(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F M=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R M/C8N-2!Y96%R3IT:6UEF4],T0R/C8N-2!Y M96%R6QE/3-$)VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)VUA3IT:6UEF4],T0R/C`N.3,M,2XV,"4\ M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I M>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1C96YT97(^/&9O;G0@3IT M:6UEF4],T0R/D1I=FED96YD('EI96QD/"]F;VYT M/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1C96YT97(^/&9O;G0@6QE/3-$;6%R9VEN+71O<#HQ,G!X.VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ M&5R8VES92X@5&AE(&5X<&5C=&5D('9O;&%T:6QI M='D-"B`@(&%S'!E8W1E9"!D:79I9&5N9"!Y:65L9"!I2!I;B!T:&4@9F]R97-E M96%B;&4@9G5T=7)E+B`\+V9O;G0^/"]P/@T*("`@/'`@&5R8VES M92!P3IT:6UEF4] M,T0R/D1U2X-"B`@(%1H97)E('=E M&5R8VES960@:6X@=&AE('1H&5R8VES M960N(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1&9O;G0M6QE/3-$;6%R9VEN+71O<#HQ,G!X.VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@28C.#(Q-SMS M('-T;V-K(&]P=&EO;B!P;&%N6QE/3-$9F]N="US:7IE.C$R<'@[;6%R9VEN+71O<#HP<'@[ M;6%R9VEN+6)O='1O;3HP<'@^)B,Q-C`[/"]P/@T*("`@/'1A8FQE(&-E;&QS M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Y,B4@8F]R9&5R M/3-$,"!S='EL93TS1"=B;W)D97(M8V]L;&%P'0M M86QI9VXZ(&QE9G0G(&%L:6=N/3-$8V5N=&5R/@T*("`@/"$M+2!"96=I;B!4 M86)L92!(96%D("TM/@T*("`@/'1R/B`-"B`@(#QT9"!W:61T:#TS1#8T)3XF M(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U M)3XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF M(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT@=VED=&@],T0U)3XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF M(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V M,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U)3XF M(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V M,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0U)3XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V M,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\ M+W1D/@T*("`@/"]TF4],T0Q/B8C,38P.SPO9F]N M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@6QE/3-$)V)O6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0Q/CQB/E!R:6-E('!EF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UE MF4],T0Q/CQB/E=E:6=H=&5D/"]B/CPO9F]N=#X\ M8G(@+SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0Q/CQB/D%V97)A9V4\+V(^/"]F;VYT/CQB6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V)O6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ MF4],T0Q M/CQB/DEN=')I;G-I8SPO8CX\+V9O;G0^/&)R("\^/&9O;G0@2`M+3X-"B`@(#QT3IT:6UEF4],T0R/D]U='-T M86YD:6YG(&%T($1E8V5M8F5R)B,Q-C`[,S$L(#(P,3$\+V9O;G0^/"]P/@T* M("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B0\+V9O;G0^/"]T M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$F4],T0Q/B8C,38P M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M3IT:6UEF4],T0R/B8C M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@3IT M:6UEF4],T0R/D=R86YT960\+V9O;G0^/"]P/@T* M("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@F4],T0Q/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@ M("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A M;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T*("`@/"]T6QE/3-$)VUAF4],T0Q/B8C M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@'0M:6YD96YT.BTQ+C`P96TG M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ MF4],T0Q M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ M3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C8N,3(\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4] M,T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT M:6UEF4],T0R/B8C.#(Q,CLF(S$V,#LF(S$V,#L\ M+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@'0M:6YD96YT M.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ M6QE/3-$9F]N="US:7IE.C%P>#X@ M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D M('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B M;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*("`@/'`@3IT M:6UEF4],T0R/E9E6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@F4] M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V)O MF4],T0Q/B8C,38P.SPO9F]N M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@"!S;VQI9"`C,#`P,#`P)SX\9F]N="!S M='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0Q M/CQB/DYU;6)E6QE/3-$)V)O6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V)O6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ M6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0Q/CQB/D5X M97)C:7-E/"]B/CPO9F]N=#X\8G(@+SX\9F]N="!S='EL93TS1"=F;VYT+69A M;6EL>3IT:6UEF4],T0Q/CQB/E!R:6-E/"]B/CPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)V)O6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@&5R8VES86)L93PO8CX\ M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I M>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T"!S;VQI9"`C,#`P,#`P M.W=I9'1H.C@T<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@"!S;VQI9"`C,#`P,#`P)SX\ M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0Q/CQB/DYU;6)E6QE M/3-$)V)O6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0Q M/CQB/E!R:6-E/"]B/CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@2`M+3X-"B`@(#QT3IT:6UEF4],T0R/B0N M,#$M)#$N,#`\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UE MF4],T0R/C`N-B8C,38P.WEE87)S/"]F;VYT/CPO M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UE MF4],T0R/C$N,#`\+V9O;G0^/"]T9#X@#0H@("`\ M=&0@;F]W3IT:6UEF4],T0R/B8C M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C0S+#,R M.3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/C$N,#`\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\ M+W1D/@T*("`@/"]T6QE/3-$)VUA3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT M+69A;6EL>3IT:6UEF4],T0R/C$L-CDV+#4P,CPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0R M/C,N-3@\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT:6UE MF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C$L,S0V+#$U,CPO9F]N=#X\+W1D/B`-"B`@ M(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/C,N-C,\+V9O M;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T6QE/3-$)VUAF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1C96YT97(^/&9O M;G0@65AF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@3IT:6UEF4],T0R/C3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T6QE/3-$)V)O6QE/3-$)V)O"!S;VQI9"`C M,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI M9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V M,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@ M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D M('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B,Q-C`[/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R/B`-"B`@ M(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F M=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UE MF4],T0R/CF4],T0R M/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B0\+V9O;G0^ M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$9F]N="US:7IE.C%P>#X@ M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D M('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B M;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*("`@/'`@"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@ M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@6QE/3-$;6%R9VEN+71O<#HQ,G!X.VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@65A6QE/3-$;6%R9VEN M+71O<#HP<'@[;6%R9VEN+6)O='1O;3HP<'@^/&9O;G0@6QE/3-$ M;6%R9VEN+71O<#HQ,G!X.VUA6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P9#,V-#-E-E\T M-F0Y7S1D,C9?8CEB.5\W,&,X,3@V,3!A86(-"D-O;G1E;G0M3&]C871I;VXZ M(&9I;&4Z+R\O0SHO,&0S-C0S939?-#9D.5\T9#(V7V(Y8CE?-S!C.#$X-C$P M86%B+U=O'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^#0H@ M("`\(2TM($)E9VEN($)L;V-K(%1A9V=E9"!.;W1E(#@@+2!U6QE/3-$;6%R9VEN+71O<#HQ.'!X.VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D M/@T*("`@/"]T3IT:6UEF4],T0R/C(P,3(@4F5M86EN M:6YG('-I>"!M;VYT:',\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ M'0M:6YD M96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@3IT:6UEF4] M,T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT M:6UEF4],T0R/C0V,3PO9F]N=#X\+W1D/B`-"B`@ M(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/C(P,30\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N M=#X\+W1D/@T*("`@/"]T6QE/3-$)VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ M6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@'0M:6YD96YT.BTQ M+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@3IT:6UEF4],T0R/B8C M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C0W.#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT M:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T* M("`@/"]TF4Z,7!X/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O3IT:6UEF4],T0R/E)E;G1A;"!P87EM96YT2!E;G1E2!A;F0@;V9F:6-E('-P86-E('=H:6-H(')U;G,@=&AR;W5G:"!$96-E;6)E M6QE/3-$;6%R9VEN+71O<#HQ,G!X.VUA#L^/&9O;G0@2P@=VAI8V@@ M3IT:6UEF4],T0Q/CQS=7`^)G)E M9SL\+W-U<#X\+V9O;G0^(&UA;G5F86-T=7)I;F<@86YD(&1E=F5L;W!M96YT M('1E86TN($%32TE/3B!P3IT:6UEF4],T0Q/@T* M("`@/'-U<#XF3IT:6UEF4],T0Q/CQS=7`^#0H@("`F3IT:6UEF4],T0R M/@T*("`@5&AE($-O;7!A;GDL('!R:6UA2!T:')O=6=H($%32TE/3BP@ M96YG86=E3IT M:6UEF4],T0Q/@T*("`@/'-U<#XF3IT:6UEF4],T0Q/CQS=7`^)G)E9SL\+W-U<#X\+V9O;G0^('5N:71S M(&)E>6]N9"`R,#$R+B`\+V9O;G0^/"]P/@T*("`@/'`@3IT:6UEF4],T0R/DEN(&%D9&ET:6]N+"!W92!A&-O2!);F,N+"!A;B!&1$$@1TU0(&-O;7!L:6%N="!A M;F0@25-/(#DP,#$@8V5R=&EF:65D(&%N9"!)4T\@,3,T.#4@;W)I9VEN86P@ M97%U:7!M96YT#0H@("!M86YU9F%C='5R97(@;V8@;65D:6-A;"!D979I8V5S M(&EN($YE=R!*97)S97DL('1O('!R;W9I9&4@=&AE(&%S7-T96US(&9O<@T*("`@:6YS=&%L;&%T:6]N(&EN('1H92!5+E,N(#PO M9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1&UA#MM87)G M:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE MF4],T0R/E1H92!#;VUP86YY(&AA6QE/3-$ M9F]N="US:7IE.C%P>#MM87)G:6XM=&]P.C$R<'@[;6%R9VEN+6)O='1O;3HP M<'@^)B,Q-C`[/"]P/@T*("`@/'`@#MM M87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT M:6UEF4],T0R/D]N($YO=F5M8F5R)B,Q-C`[,3DL M(#(P,3`L(&$@<'5R<&]R=&5D#0H@("!S96-U2!3:71U871E9"!V+B!-14Q!(%-C:65N8V5S+"!);F,N+"!* M;W-E<&@@5BX@1W5L9F\L(%)I8VAA2!A;F0@;VX@0F5H86QF(&]F($%L;"!/=&AE6QE/3-$;6%R9VEN+71O<#HQ,G!X M.VUA#L^/&9O;G0@ M&-H86YG92!!8W0@ M;V8@,3DS-"P@86QL96=I;F6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@28C,38P.S$S+"`R,#`Y('1HF4],T0Q/CQS=7`^#0H@("`F2!I;B!F M=7)T:&5R('-U<'!O6QE/3-$;6%R9VEN+71O<#HQ,G!X.VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ M2!L:71I9V%T:6]N+"!W92!C86YN;W0@ M<')E9&EC="!W:71H(&%N>2!D96=R964@;V8@8V5R=&%I;G1Y('1H92!E=F5N M='5A;"!O=71C;VUE(&]F('1H:7,@;&ET:6=A=&EO;BX@06X@861V97)S92!O M=71C;VUE(&-O=6QD(&AA=F4@82!M871E2!H87)M960N(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS M1&UA#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL M93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/D9R M;VT@=&EM92!T;R!T:6UE+"!W92!M87D@8F4@82!P87)T>2!T;R!C97)T86EN M(&QE9V%L('!R;V-E961I;F=S+"!I;F-I9&5N=&%L('1O('1H92!N;W)M86P- M"B`@(&-O=7)S92!O9B!O=7(@8G5S:6YE2!I;F-L=61E M(&-O;G1R;W9E'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!;06)S=')A8W1=/"]S=')O M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\6QE/3-$;6%R9VEN+71O<#HQ.'!X.VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@28C,38P.S(U+"`R,#$R+B!);B!C;VYN96-T:6]N('=I=&@@=&AI6QE/3-$;6%R9VEN+71O<#HQ,G!X.VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@'!I&5R8VES M960L('=I;&P@97AP:7)E(&EN($UA>2`R,#$T+B`\+V9O;G0^/"]P/@T*("`@ M/'`@F4Z,7!X.VUA#MM87)G M:6XM8F]T=&]M.C!P>#XF(S$V,#L\+W`^#0H@("`\<"!S='EL93TS1&UA6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@28C.#(Q-SMS#0H@("!C;VUM;VX@#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S M='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R M/@T*("`@3VX@1&5C96UB97(F(S$V,#LQ-2P@,C`Q,2P@=&AE($-O;7!A;GD@ M96YT97)E9"!I;G1O(&%N('5N9&5R=W)I=&EN9R!A9W)E96UE;G0L(')E;&%T M:6YG('1O('1H92!P=6)L:6,@;V9F97)I;F<@;V8@-2PP,#`L,#`P('-H87)E M28C.#(Q-SMS(&-O;6UO;B!S=&]C:RP@870@82!P M28C.#(Q-SMS(%!R;W-P96-T=7,@9&%T960@2G5N928C M,38P.S$L(#(P,3`@86YD('1H92!#;VUP86YY)B,X,C$W.W,@4')O28C.#(Q-SMS(&5F9F5C=&EV92!S:&5L9B!R M96=I2`D,38N,R!M:6QL:6]N+B!!9G1E6%B;&4@8GD@=&AE($-O;7!A;GDL(&YE="!P&EM871E;'D@)#$U(&UI;&QI;VXN(%1H:7,@;V9F97)I;F<@8VQO&EM871E;'D@)#0R M+C(@;6EL;&EO;B!R96UA:6YE9"!A=F%I;&%B;&4@=6YD97(@=&AE($-O;7!A M;GDF(S@R,3<[6QE M/3-$;6%R9VEN+71O<#HQ,G!X.VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@28C.#(Q-SMS(&5F9F5C=&EV M92!S:&5L9B!R96=I2!C;VUM;VX@&EM871E;'D@)#`N-R!M:6QL:6]N+B`\+V9O;G0^/"]P/@T*("`@/'`@F5D(&%N9"`S,"PS,S(L,C$W('-H87)E'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE/3-$;6%R9VEN+71O M<#HQ.'!X.VUA6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4Z M,3)P>#MM87)G:6XM=&]P.C!P>#MM87)G:6XM8F]T=&]M.C!P>#XF(S$V,#L\ M+W`^#0H@("`\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$ M,"!W:61T:#TS1#@T)2!B;W)D97(],T0P('-T>6QE/3-$)V)OF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0Q/CQB/DESF4],T0Q/B8C,38P M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M"!S;VQI9"`C,#`P,#`P)SX\9F]N="!S='EL93TS M1"=F;VYT+69A;6EL>3IT:6UEF4],T0Q/CQB/DES MF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/@T* M("`@/"]TF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)V)O6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@"!S;VQI9"`C,#`P,#`P)SX\ M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0Q/CQB/E1O=&%L/"]B/CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@2`M+3X-"B`@(#QT'0M:6YD96YT.BTQ+C`P96TG M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ M3IT M:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R M/C,T-BPW.#$\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT M:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE MF4],T0R/C(P,"PP,#`\+V9O;G0^/"]T9#X@#0H@ M("`\=&0@;F]W3IT:6UEF4],T0R M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@3IT:6UE MF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C4T M-BPW.#$\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT:6UE MF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@ M/"]TF4Z,7!X/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`@(#QP('-T>6QE/3-$)V)O6QE/3-$)V)O"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D M/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@ M/'`@'0M:6YD96YT.BTQ M+C`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`@(#PO M9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1&9O;G0M7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA'1";&]C:RTM/@T*("`@/'`@#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS M1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/CQB/C$Q M+B!214Q!5$5$(%!!4E19($-/3E-53%1)3D<@04=2145-14Y44R`\+V(^/"]F M;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$;6%R9VEN+71O<#HV<'@[;6%R9VEN M+6)O='1O;3HP<'@^/&9O;G0@2!H87,@:6X@<&QA8V4@ M=&AE(&9O;&QO=VEN9R!C;VYS=6QT:6YG(&%G#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS1"=F M;VYT+69A;6EL>3IT:6UEF4],T0R/CQB/D-O;G-U M;'1I;F<@06=R965M96YT('=I=&@@0G)E875X($-A6QE/3-$;6%R9VEN+71O<#HV<'@[;6%R9VEN M+6)O='1O;3HP<'@[<&%D9&EN9RUB;W1T;VTZ,'!X.SX\9F]N="!S='EL93TS M1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/@T*("`@ M26X@2G5N92`R,#`S+"!T:&4@0V]M<&%N>2!E;G1E"!#87-T;&5M86XL(&$@9F]R M;65R(&UE;6)E28C.#(Q-SMS($)O87)D(&]F($1I6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@28C.#(Q-SMS(&)U28C.#(Q M-SMS($)O87)D(&]F($1I6QE/3-$;6%R9VEN+71O<#HQ.'!X.VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS1"=F;VYT M+69A;6EL>3IT:6UEF4],T0R/@T*("`@26X@2F%N M=6%R>2`R,#`W+"!$2!T97)M:6YA=&4@870@=&AE(&]P=&EO;B!O9@T*("`@1'(N M)B,Q-C`[5V%G;F5R(&]R('1H92!#;VUP86YY(&%T(&%N>2!T:6UE+"!B>2!P M"!M;VYT:"!P97)I;V1S(&5N9&5D($IU;F4F(S$V,#LS,"P@,C`Q,B!A M;F0@2G5N928C,38P.S,P+"`R,#$Q+"!R97-P96-T:79E;'DN($1R+B8C,38P M.U=A9VYE6QE/3-$;6%R9VEN+71O<#HQ.'!X.VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS M1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/DEN#0H@ M("!-87)C:"`R,#`Y+"!T:&4@0V]M<&%N>2!E;G1E'1E;F1E9"!T;R!R=6X-"B`@('1H2!E:71H97(@<&%R='D@ M=VET:"`S,"!D87ES)B,X,C$W.R!N;W1I8V4N(%5N9&5R('1H92!T97)M2!D:60@;F]T('!A>2!A;GD@86UO=6YT('1O($US+B8C,38P M.T5G9V5R#0H@("!F;W(@8V]N"!M;VYT:"!P97)I;V1S(&5N9&5D($IU;F4F(S$V,#LS,"P@,C`Q,B!A;F0@ M2G5N928C,38P.S,P+"`R,#$Q+"!R97-P96-T:79E;'DN($US+B8C,38P.T5G M9V5R('=A3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P9#,V-#-E M-E\T-F0Y7S1D,C9?8CEB.5\W,&,X,3@V,3!A86(-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO,&0S-C0S939?-#9D.5\T9#(V7V(Y8CE?-S!C.#$X M-C$P86%B+U=O'0O:'1M;#L@8VAA'0^/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@ M+2T^#0H@("`\(2TM($)E9VEN($)L;V-K(%1A9V=E9"!.;W1E(#$R("T@=7,M M9V%A<#I/=&AE6QE/3-$;6%R9VEN+71O<#HQ.'!X.VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@6QE/3-$;6%R9VEN+71O<#HV<'@[;6%R M9VEN+6)O='1O;3HP<'@[<&%D9&EN9RUB;W1T;VTZ,'!X.SX\9F]N="!S='EL M93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/D1U M2!D:7-C;VYT:6YU960@86QL M(&]P97)A=&EO;G,@87-S;V-I871E9"!W:71H(&ET3IT:6UEF4],T0Q M/@T*("`@/'-U<#XF6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ M3IT M:6UEF4],T0Q/CQS=7`^)G)E9SL\+W-U<#X\+V9O M;G0^+B!"96=I;FYI;F<@:6X@2G5L>2`R,#`X+"!+859O(&ES(')E<75I2!T;R!T:&4@0V]M<&%N>2!A(')O>6%L='D@"!M;VYT:',@96YD960@2G5N928C,38P.S,P+"`R,#$R M(&%N9"!*=6YE)B,Q-C`[,S`L(#(P,3$L(')E2P@=&AE($-O M;7!A;GD@96%R;F5D("0U(&%N9"`D,3`@87,@=&AE#0H@("!P'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE/3-$;6%R M9VEN+71O<#HQ.'!X.VUA6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S M='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R M/D1U2`D,"XW(&UI;&QI;VXL('=E28C.#(Q-SMS($%432!06QE/3-$9F]N="US:7IE.C%P>#MM87)G:6XM M=&]P.C$R<'@[;6%R9VEN+6)O='1O;3HP<'@^)B,Q-C`[/"]P/@T*("`@/'`@ M#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4] M,T0R/DEN(&-O;FYE8W1I;VX@=VET:"!T:&4@0V]M<&%N>28C.#(Q-SMS#0H@ M("!P65A28C.#(Q-SMS(&-O;6UO;B!S M=&]C:RX@070@2G5N928C,38P.S,P+"`R,#$R+"!T:&5R92!W97)E(#,T-BPW M.#$@;V8@=&AE(#(P,#<@=V%R7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@ M+2T^#0H@("`\(2TM($)E9VEN($)L;V-K(%1A9V=E9"!!8V-O=6YT:6YG(%!O M;&EC>3H@;65L82TR,#$R,#8S,%]N;W1E,U]A8V-O=6YT:6YG7W!O;&EC>5]T M86)L93$@+2!U5)A=TUA=&5R:6%L2TM M/@T*("`@/'`@#MM87)G:6XM8F]T=&]M M.C!P>#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/DEN=F5N=&]R:65S(&%R92!S=&%T960@870@=&AE(&QO M=V5R(&]F(&-O7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/"$M+41/0U194$4@:'1M;"!0 M54),24,@(BTO+U&AT;6PQ+T141"]X:'1M;#$M=')A M;G-I=&EO;F%L+F1T9"(@+2T^#0H@("`\(2TM($)E9VEN($)L;V-K(%1A9V=E M9"!!8V-O=6YT:6YG(%!O;&EC>3H@;65L82TR,#$R,#8S,%]N;W1E-5]A8V-O M=6YT:6YG7W!O;&EC>5]T86)L93$@+2!U5!O;&EC>51E>'1";&]C:RTM/@T*("`@/'`@ M#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4] M,T0R/DEN($IU;F4L(#(P,3$L('1H92!&05-"(&ES65A28C,38P.S$L(#(P,3(N M($9O2!H860@;F\@;W1H97(@ M8V]M<')E:&5N'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T M9"(@+2T^#0H@("`\(2TM($)E9VEN($)L;V-K(%1A9V=E9"!.;W1E(%1A8FQE M.B!M96QA+3(P,3(P-C,P7VYO=&4V7W1A8FQE,2`M(&UE;&$Z4V-H961U;&5/ M9E-T;V-K3W!T:6]N6QE/3-$;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP<'@^ M#0H@("`\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/@T*("`@(%!O=&5N=&EA;"!C;VUM;VX@F4Z,3)P>#MM87)G M:6XM=&]P.C!P>#MM87)G:6XM8F]T=&]M.C!P>#XF(S$V,#L\+W`^#0H@("`\ M=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS M1#6QE/3-$)V)OF4],T0Q/B8C,38P.SPO9F]N M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0Q/CQB/DIU;F4F(S$V M,#LS,"P\+V(^/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^ M(`T*("`@/'1R/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V)O6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT M:6UEF4],T0Q/CQB/C(P,3$\+V(^/"]F;VYT/CPO M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^#0H@("`\(2TM($5N9"!486)L M92!(96%D("TM/@T*("`@/"$M+2!"96=I;B!486)L92!";V1Y("TM/@T*("`@ M/'1R(&)G8V]L;W(],T0C8V-E969F/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^ M#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD M96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@3IT:6UE MF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C(L,3`W+#0R.3PO9F]N=#X\+W1D/B`-"B`@ M(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/E=A6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V)O6QE/3-$)V)O3IT:6UEF4],T0R/E1O=&%L/"]F M;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R M/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]TF4Z,7!X/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q M-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^ M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O M6QE/3-$)V)O'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6UE;G1!=V%R9$5M<&QO>65E4W1O8VM0=7)C:&%S95!L M86Y686QU871I;VY!6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1C96YT97(@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@"!S;VQI9"`C,#`P,#`P)SX\9F]N="!S='EL93TS1"=F;VYT M+69A;6EL>3IT:6UEF4],T0Q/CQB/D9O"8C,38P.TUO;G1H2`M+3X-"B`@ M(#QT3IT:6UE MF4],T0R/D5X<&5C=&5D(&QI9F4\+V9O;G0^/"]P M/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I M>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1C96YT97(^/&9O;G0@65AF4],T0Q M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1C96YT97(^/&9O;G0@65A'0M:6YD96YT M.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@3PO9F]N=#X\ M+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M3IT:6UEF4],T0R/C3IT:6UEF4],T0R/C'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1C96YT97(^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@6QE M/3-$)VUA3IT:6UEF4],T0R/C`E/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@ M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$8V5N=&5R/CQF;VYT M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@'0^ M/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U&AT M;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^#0H@("`\(2TM M($)E9VEN($)L;V-K(%1A9V=E9"!.;W1E(%1A8FQE.B!M96QA+3(P,3(P-C,P M7VYO=&4W7W1A8FQE,B`M('5S+6=A87`Z4V-H961U;&5/9E-H87)E0F%S961# M;VUP96YS871I;VY3=&]C:T]P=&EO;G-!8W1I=FET>51A8FQE5&5X=$)L;V-K M+2T^#0H@("`\<"!S='EL93TS1&UA#MM87)G:6XM8F]T M=&]M.C!P>#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/E1H92!S=&%T=7,@;V8@=&AE($-O;7!A;GDF(S@R M,3<[F5D(&EN('1H92!F;VQL;W=I;F6QE/3-$)V)O6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0Q/CQB/E-H87)EF4],T0Q/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@"!S;VQI9"`C,#`P,#`P)SX\9F]N="!S='EL93TS1"=F M;VYT+69A;6EL>3IT:6UEF4],T0Q/CQB/E=E:6=H M=&5D/"]B/CPO9F]N=#X\8G(@+SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL M>3IT:6UEF4],T0Q/CQB/D%V97)A9V4\+V(^/"]F M;VYT/CQB6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@&5R8VES93PO8CX\+V9O;G0^ M/&)R("\^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L3IT:6UEF4],T0Q/@T*("`@/&(^4F5M86EN:6YG/"]B/CPO9F]N=#X\8G(@+SX\9F]N M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4] M,T0Q/CQB/D-O;G1R86-T=6%L/"]B/CPO9F]N=#X\8G(@+SX\9F]N="!S='EL M93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0Q/CQB M/E1E6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@"!S;VQI9"`C,#`P M,#`P)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0Q/CQB/D%G9W)E9V%T93PO8CX\+V9O;G0^/&)R("\^/&9O M;G0@6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@ M/"]T6QE/3-$)VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ M6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF M(S$V,#L\+W1D/@T*("`@/"]T6QE/3-$)VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ M6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@'0M:6YD M96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ M6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ M3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/B8C.#(Q,CLF(S$V,#LF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\ M=&0@;F]W3IT:6UEF4],T0R/B8C M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/B8C.#(Q M,CLF(S$V,#LF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/D9O'!I6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/BDF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@ M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D M('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T*("`@/"]T6QE/3-$)V)O6QE/3-$)V)O3IT:6UE MF4],T0R/D]U='-T86YD:6YG(&%T($IU;F4F(S$V M,#LS,"P@,C`Q,CPO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C(L,3DU+#,P-CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@3IT:6UEF4],T0R/C0N,3@\+V9O;G0^/"]T9#X@ M#0H@("`\=&0@;F]W3IT:6UEF4] M,T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@3IT M:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R M/C6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/C(Q,3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`] M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V)O6QE/3-$)VUA3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL M>3IT:6UEF4],T0R/C$L-38R+#8X,3PO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ M6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0R M/C0N,#$\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT:6UE MF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C8N-#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@3IT:6UEF4],T0R/C$T.3PO9F]N=#X\+W1D M/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@2`M+3X-"B`@(#PO=&%B;&4^(`T*/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0M86QI9VXZ(&QE9G0G(&%L:6=N/3-$8V5N M=&5R/@T*("`@/"$M+2!"96=I;B!486)L92!(96%D("TM/@T*("`@/'1R/B`- M"B`@(#QT9"!W:61T:#TS1#4T)3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT@=VED=&@],T0T)3XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF M(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V M,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T)3XF M(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT@=VED=&@],T0T)3XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF M(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V M,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T)3XF M(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V M,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0T)3XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V M,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\ M+W1D/@T*("`@/"]TF4],T0Q/B8C,38P M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]LF4],T0Q/B8C M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@"!S;VQI9"`C,#`P,#`P)SX\9F]N="!S='EL M93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0Q/CQB M/D]P=&EO;G,F(S$V,#L-"B`@($]U='-T86YD:6YG/&)R("\^5V5I9VAT960M M/"]B/CPO9F]N=#X\8G(@+SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT M:6UEF4],T0Q/CQB/D%V97)A9V4\+V(^/"]F;VYT M/CQB6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@"!S;VQI9"`C,#`P,#`P)SX\9F]N="!S M='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0Q M/CQB/E=E:6=H=&5D/"]B/CPO9F]N=#X\8G(@+SX\9F]N="!S='EL93TS1"=F M;VYT+69A;6EL>3IT:6UEF4],T0Q/CQB/D%V97)A M9V4\+V(^/"]F;VYT/CQBF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@"!S;VQI9"`C,#`P,#`P M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0Q/CQB/D]P=&EO;G,@17AE3IT:6UEF4],T0Q/CQB/E)A;F=E(&]F($5X97)C:7-E(%!R:6-EF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT@8V]LF4],T0Q/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@"!S;VQI9"`C,#`P,#`P)SX\9F]N="!S='EL93TS1"=F M;VYT+69A;6EL>3IT:6UEF4],T0Q/CQB/E=E:6=H M=&5D+3QB6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T6QE/3-$)VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1C M96YT97(^/&9O;G0@3IT:6UEF4],T0R/B0\ M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ MF4] M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B0\+V9O;G0^/"]T9#X@ M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$'0M:6YD96YT.BTQ M+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@F4],T0Q/B8C M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/C3IT:6UE MF4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$'0M:6YD96YT.BTQ M+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/C8N-S`\+V9O M;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C$W,RPR,#`\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT:6UEF4],T0R/B8C,38P.SPO9F]N M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$6QE M/3-$9F]N="US:7IE.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B M;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS M1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@ M("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@ M("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A M;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B M;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M("`@/'`@3IT:6UEF4],T0R/B0N,#$M)#$Q+C$Q/"]F M;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1C M96YT97(^/&9O;G0@65AF4],T0Q/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ M6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@6QE/3-$)V)O6QE/3-$)V)O'1087)T7S!D,S8T M,V4V7S0V9#E?-&0R-E]B.6(Y7S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&EM871E(&%G9W)E9V%T92!M:6YI;75M(&9U='5R92!P87EM M96YT'0^/"$M+41/0U19 M4$4@:'1M;"!054),24,@(BTO+U&AT;6PQ+T141"]X M:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^#0H@("`\(2TM($)E9VEN($)L M;V-K(%1A9V=E9"!.;W1E(%1A8FQE.B!M96QA+3(P,3(P-C,P7VYO=&4X7W1A M8FQE,2`M(&UE;&$Z4V-H961U;&5/9D%P<')O>&EM871E06=G6QE/3-$;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP<'@^#0H@("`\ M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/@T*("`@5&AE(&%P<')O>&EM871E(&%G9W)E9V%T92!M:6YI;75M M(&9U='5R92!P87EM96YT6QE/3-$9F]N="US:7IE M.C$R<'@[;6%R9VEN+71O<#HP<'@[;6%R9VEN+6)O='1O;3HP<'@^)B,Q-C`[ M/"]P/@T*("`@/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS M1#`@=VED=&@],T0V."4@8F]R9&5R/3-$,"!S='EL93TS1"=B;W)D97(M8V]L M;&%P'0M86QI9VXZ(&QE9G0G(&%L:6=N/3-$8V5N M=&5R/@T*("`@/"$M+2!"96=I;B!486)L92!(96%D("TM/@T*("`@/'1R/B`- M"B`@(#QT9"!W:61T:#TS1#@Y)3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT@=VED=&@],T0V)3XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF M(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V M,#L\+W1D/@T*("`@/"]T3IT:6UEF4],T0Q/CQB/EEE87(@96YD960@1&5C96UB97(F(S$V,#LS M,2P\+V(^/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@8V]L MF4],T0Q/B8C,38P M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M2`M+3X-"B`@(#QT'0M:6YD96YT.BTQ M+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@3IT:6UEF4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T6QE/3-$)VUA M6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C0W.#PO M9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@3IT:6UEF4],T0R/C(P,34\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\ M+W1D/@T*("`@/"]T6QE/3-$)VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$9F]N="US:7IE.C%P>#X@#0H@("`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS M1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P M)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P M,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D M/@T*("`@/"]T3IT:6UEF4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V)O7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6QE/3-$)V)O6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@6QE/3-$)V)O M6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@"!S;VQI9"`C,#`P M,#`P)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0Q/CQB/C(P,#<\+V(^/"]F;VYT/CPO=&0^(`T*("`@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^ M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`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`C,#`P,#`P)SXF M(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/@T*("`@ M/"]T6QE/3-$)VUAF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C,38P M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ MF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$9F]N="US:7IE.C%P>#X@#0H@("`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG M;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P M,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*("`@/'`@"!D;W5B;&4@(S`P,#`P M,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*("`@/'`@2`M+3X-"B`@ M(#PO=&%B;&4^(`T*/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\P9#,V-#-E-E\T-F0Y7S1D,C9?8CEB.5\W,&,X,3@V,3!A86(- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,&0S-C0S939?-#9D.5\T M9#(V7V(Y8CE?-S!C.#$X-C$P86%B+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%RF%T:6]N(&%N9"!"87-I'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\P9#,V-#-E-E\T-F0Y7S1D,C9?8CEB.5\W,&,X,3@V,3!A86(- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,&0S-C0S939?-#9D.5\T M9#(V7V(Y8CE?-S!C.#$X-C$P86%B+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'0^-B!Y96%R65A7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'!I&5R8VES86)L92!A="!*=6YE(#,P+"`R,#$R/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M<#XQ+#4V,BPV.#$\&5R8VES92!0&5R8VES92!0 M'0^-R!Y96%R65A'0^-B!Y96%R'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B M;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P M9#,V-#-E-E\T-F0Y7S1D,C9?8CEB.5\W,&,X,3@V,3!A86(-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,&0S-C0S939?-#9D.5\T9#(V7V(Y8CE? M-S!C.#$X-C$P86%B+U=O'0O:'1M;#L@8VAA'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$&5R8VES92!0'0^-R!M;VYT:',@-B!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES86)L92!.=6UB97(@ M17AE&5R8VES86)L92!796EG:'1E9"U!=F5R86=E($5X M97)C:7-E(%!R:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD M(#$\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$&5R8VES92!0'0^-R!Y96%R&5R8VES86)L92!.=6UB97(@17AE M&5R8VES86)L92!796EG:'1E9"U!=F5R86=E($5X M97)C:7-E(%!R:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD M(#,N-C,\'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R M8VES92!07,\&5R8VES92!0'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R M8VES92!0&5R M8VES92!0&5R8VES86)L93PO M=&0^#0H@("`@("`@(#QT9"!C;&%S7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA2!P97)I;V0@;V8@;W!T:6]N('!L M86X\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S&5R8VES960\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$&5R8VES92!0'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$&5R8VES960\+W1D M/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'!E8W1E9"!T;R!V97-T+"!O=71S=&%N9&EN9RP@3G5M8F5R/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^,2!Y96%R(#$P(&UO;G1H'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$65T(%)E8V]G;FEZ960L(%-T;V-K($]P=&EO;G,\+W1D/@T*("`@("`@ M("`\=&0@8VQAF5D(&-O;7!E;G-A=&EO;B!C;W-T('1O(&)E(')E8V]G;FEZ960@;W9E M'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P9#,V M-#-E-E\T-F0Y7S1D,C9?8CEB.5\W,&,X,3@V,3!A86(-"D-O;G1E;G0M3&]C M871I;VXZ(&9I;&4Z+R\O0SHO,&0S-C0S939?-#9D.5\T9#(V7V(Y8CE?-S!C M.#$X-C$P86%B+U=O'0O:'1M;#L@8VAA'1U86PI6T%B'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\P9#,V-#-E-E\T-F0Y7S1D,C9?8CEB.5\W,&,X,3@V,3!A86(-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,&0S-C0S939?-#9D.5\T9#(V M7V(Y8CE?-S!C.#$X-C$P86%B+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R2`S,2P@,C`Q,CQB2!;365M8F5R73QB2!& M:6YA;F-I;F<@1F%C:6QI='D@6TUE;6)E2!;365M8F5R73QB2`H5&5X='5A;"D@ M6T%B'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F5D/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XT-2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P9#,V-#-E-E\T-F0Y7S1D,C9?8CEB M.5\W,&,X,3@V,3!A86(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M,&0S-C0S939?-#9D.5\T9#(V7V(Y8CE?-S!C.#$X-C$P86%B+U=O'0O:'1M;#L@8VAA M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA'1U86PI("A5 M4T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$ M=&@@8V]L'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^-2!Y96%R'!I7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA2!4'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'1U M86PI(%M!8G-T6%B;&4@=6YD97(@8V]N'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'1U86PI(%M!8G-T M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2!%87)N960@1G)O;2!+859O($1E;G1A;"!';6)(('1O M(&1E=F5L;W`@86YD(&-O;6UEF4@1$E&3U1)/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#XD(#4\7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^-2!Y M96%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$2!!5$T@<')O9W)A;3PO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'1U86PI(%M!8G-T'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\P9#,V-#-E-E\T-F0Y7S1D,C9?8CEB.5\W,&,X,3@V M,3!A86(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,&0S-C0S939? M-#9D.5\T9#(V7V(Y8CE?-S!C.#$X-C$P86%B+U=O&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I M;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA&UL;G,Z;STS1")U'1087)T7S!D,S8T,V4V7S0V9#E?-&0R-E]B.6(Y 17S XML 19 R29.htm IDEA: XBRL DOCUMENT v2.4.0.6

Stock Based Compensation (Details 1) (USD $)
6 Months Ended 12 Months Ended

Jun. 30, 2012

Dec. 31, 2011

Schedule of stock option plans

Number of Shares Outstanding at December 31, 2011 2,057,104

Number of Shares Granted 350,563

Number of Shares Exercised (53,123)

Number of shares Forfeited or expired (159,238)

Number of Shares Outstanding at June 30, 2012 2,195,306 2,057,104

Number of Shares Vested and exercisable at June 30, 2012 1,562,681

Weighted Average Exercise Price per Share Outstanding at December 31, 2011 $ 4.35

Weighted Average Exercise Price per Share Granted $ 3.93

Weighted Average Exercise Price per Share Forfeited or expired $ 6.12

Weighted Average Exercise Price per Share Outstanding at June 30, 2012 $ 4.18 $ 4.35

Weighted Average Exercise Price per Share Vested and exercisable at June 30, 2012 $ 4.01

Weighted Average Remaining Contractual Term in Years Outstanding 7 years 6 years 7 months 6 days

Weighted Average Remaining Contractual Term in Years Vested and exercisable at June 30, 2012 6 years 4 months 24 days

Aggregate Intrinsic Value Outstanding $ 211

Aggregate Intrinsic Value Outstanding Vested and exercisable at June 30, 2012 $ 149

X

- Definition

Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(1)(c), d(2)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(1)(c)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)-(4)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average price of options that were either forfeited or expired.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)-(4)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Gross number of share options (or share units) granted during the period.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of options outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph d(1)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding as of the balance sheet date, including vested options.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(1)(b)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(1)(a)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(1)(a)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average price at which grantees can acquire the shares reserved for issuance on stock options awarded.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of share options (or share units) exercised during the current period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 20 R28.htm IDEA: XBRL DOCUMENT v2.4.0.6

Stock Based Compensation (Details)
6 Months Ended

Jun. 30, 2012

Jun. 30, 2011

Schedule of fair value of each option award granted

Expected life 6 years 6 months 6 years 6 months

Expected volatility - Minimum 73.55% 70.54%

Expected volatility - Maximum 79.68% 76.32%

Risk-free interest rate - Minimum 0.93% 2.47%

Risk-free interest rate - Maximum 1.60% 3.34%

Dividend yield 0.00% 0.00%

X

- Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph e(2)(c)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.D.2)

-URI http://asc.fasb.org/extlink&oid=6793087&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section D

-Subsection 2

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

XML 21 R30.htm IDEA: XBRL DOCUMENT v2.4.0.6

Stock Based Compensation (Details 2) (USD $)
6 Months Ended

Jun. 30, 2012

Range One [Member]

Schedule of stock option plans quantitative information

Range of Exercise Prices, Lower Range Limit $ 0.01

Range of Exercise Prices, Upper Range Limit $ 1.00

Number Outstanding 43,329

Options Outstanding Weighted-Average Remaining Contractual Life 7 months 6 days

Options Outstanding Weighted Average Exercise Price $ 1.00

Options Exercisable Number Exercisable 43,329

Options Exercisable Weighted-Average Exercise Price $ 1.00

Range Two [Member]

Schedule of stock option plans quantitative information

Range of Exercise Prices, Lower Range Limit $ 1.01

Range of Exercise Prices, Upper Range Limit $ 4.50

Number Outstanding 1,696,502

Options Outstanding Weighted-Average Remaining Contractual Life 7 years 4 months 24 days

Options Outstanding Weighted Average Exercise Price $ 3.58

Options Exercisable Number Exercisable 1,346,152

Options Exercisable Weighted-Average Exercise Price $ 3.63

Range Three [Member]

Schedule of stock option plans quantitative information

Range of Exercise Prices, Lower Range Limit $ 4.51

Range of Exercise Prices, Upper Range Limit $ 11.11

Number Outstanding 455,475

Options Outstanding Weighted-Average Remaining Contractual Life 6 years 2 months 12 days

Options Outstanding Weighted Average Exercise Price $ 6.70

Options Exercisable Number Exercisable 173,200

Options Exercisable Weighted-Average Exercise Price $ 7.73

Net Range [Member]

Schedule of stock option plans quantitative information

Range of Exercise Prices, Lower Range Limit $ 0.01

Range of Exercise Prices, Upper Range Limit $ 11.11

Number Outstanding 2,195,306

Options Outstanding Weighted-Average Remaining Contractual Life 7 years

Options Outstanding Weighted Average Exercise Price $ 4.18

Options Exercisable Number Exercisable 1,562,681

Options Exercisable Weighted-Average Exercise Price $ 4.01

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 64

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (g)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(1)(c)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(1)(a, b)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 64

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (g)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

XML 22 R31.htm IDEA: XBRL DOCUMENT v2.4.0.6

Stock Based Compensation (Details Textual) (USD $)
In Thousands, except Share data, unless otherwise specified
3 Months Ended 6 Months Ended 3 Months Ended 6 Months Ended

Jun. 30, 2012

Dec. 31, 2011

Jun. 30, 2012

2005 Stock Incentive Plan [Member]

Jun. 30, 2011

2005 Stock Incentive Plan [Member]

Jun. 30, 2012

2005 Stock Incentive Plan [Member]

Jun. 30, 2011

2005 Stock Incentive Plan [Member]

Jun. 30, 2012

2005 Stock Incentive Plan [Member]

Performance Milestones [Member]

Jun. 30, 2011

2005 Stock Incentive Plan [Member]

Performance Milestones [Member]

Jun. 30, 2012

2005 Stock Incentive Plan [Member]

Performance Milestones [Member]

Jun. 30, 2011

2005 Stock Incentive Plan [Member]

Performance Milestones [Member]

Shared Based Compensation (Textual) [Abstract]

Expiry period of option plan Up to 10 years

Compensation expense $ 426 $ 564 $ 774 $ 734 $ 199 $ 13 $ 345 $ 28

Cash received from options and warrants exercised 0 0 33 0

Number of stock options to purchase 2,195,306 2,195,306

Range of Exercise Prices, Lower Range Limit $ 1.00

Range of Exercise Prices, Upper Range Limit $ 11.11

Weighted average fair value of options granted $ 2.71 $ 2.18 $ 2.68 $ 2.20

Total intrinsic value of options exercised 0 0 74 0

Total options outstanding 2,195,306 2,057,104 2,195,306 2,195,306

Options nonvested 632,625

Share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, Number 235,425 235,425

Employee Service Share-Based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition 1 year 10 months 24 days

Employee Service Share-Based Compensation Nonvested Awards, Total Compensation Cost Not yet Recognized, Stock Options 986 986 433 433

Total unrecognized compensation cost to be recognized over the requisite service period $ 553

Shares available for future grants under ESOP 1,462,639 1,462,639

X

- Definition

Expiry period of option plan.

+ References

No definition available.

+ Details

Name: mela_ExpiryPeriodOfOptionPlan

Namespace Prefix: mela_

Data Type: us-types:durationStringItemType

Balance Type: na

Period Type: duration

X

- Definition

Options unvested.

+ References

No definition available.

+ Details

Name: mela_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvested

Namespace Prefix: mela_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Share-based compensation requisite service period yet to be recognized value.

+ References

No definition available.

+ Details

Name: mela_ShareBasedCompensationRequisiteServicePeriodYetToBeRecognizedValue

Namespace Prefix: mela_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Details

Name: mela_SharedBasedCompensationTextualAbstract

Namespace Prefix: mela_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Aggregate proceeds received by the entity during the annual period from exercises of stock or unit options and conversion of similar instruments granted under equity-based payment arrangements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (j)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph i

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Aggregate unrecognized cost of option awards made to employees under a stock option plan or plans, that have yet to vest.

+ References

No definition available.

+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The amount of plan compensation cost recognized during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 40

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Statement of Position (SOP)

-Number 93-6

-Paragraph 53

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The total accumulated difference between fair values of underlying shares on dates of exercise and exercise price on options which were exercised (or share units converted) into shares during the reporting period under the plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (d)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph c(2)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph c(1)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (d)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding as of the balance sheet date, including vested options.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(1)(b)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(1)(a)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph d(1)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 64

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (g)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(1)(c)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 64

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (g)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

XML 23 R8.htm IDEA: XBRL DOCUMENT v2.4.0.6

Inventories
6 Months Ended

Jun. 30, 2012

Inventories [Abstract]

INVENTORIES
3. INVENTORIES

Inventories are stated at the lower of cost (first-in, first-out) or market value. Inventory costs only include material purchases as the Company does not manufacture its products.

X

- Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a, b, c

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section A

-Paragraph 9

-Chapter 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_InventoryDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 24 R32.htm IDEA: XBRL DOCUMENT v2.4.0.6

Commitments, Contingencies and Litigation (Details) (USD $)
In Thousands, unless otherwise specified

Dec. 31, 2011

Schedule of approximate aggregate minimum future payments

2012 Remaining six months $ 216

2013 461

2014 478

2015 478

2016 478

Total $ 2,111

X

- Definition

Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 13

-Paragraph 16

-Subparagraph b(i)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 13

-Paragraph 122

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 10

-Section 55

-Paragraph 40

-Subparagraph (Note 3)

-URI http://asc.fasb.org/extlink&oid=6584154&loc=d3e38371-112697

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 20

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41502-112717

+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of required minimum rental payments maturing in the next fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 13

-Paragraph 16

-Subparagraph b(i)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 13

-Paragraph 122

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 10

-Section 55

-Paragraph 40

-Subparagraph (Note 3)

-URI http://asc.fasb.org/extlink&oid=6584154&loc=d3e38371-112697

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 20

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41502-112717

+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of required minimum rental payments maturing in the fifth fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 13

-Paragraph 16

-Subparagraph b(i)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 13

-Paragraph 122

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 10

-Section 55

-Paragraph 40

-Subparagraph (Note 3)

-URI http://asc.fasb.org/extlink&oid=6584154&loc=d3e38371-112697

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 20

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41502-112717

+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of required minimum rental payments maturing in the forth fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 13

-Paragraph 16

-Subparagraph b(i)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 13

-Paragraph 122

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 10

-Section 55

-Paragraph 40

-Subparagraph (Note 3)

-URI http://asc.fasb.org/extlink&oid=6584154&loc=d3e38371-112697

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 20

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41502-112717

+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of required minimum rental payments maturing in the third fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 13

-Paragraph 16

-Subparagraph b(i)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 13

-Paragraph 122

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 10

-Section 55

-Paragraph 40

-Subparagraph (Note 3)

-URI http://asc.fasb.org/extlink&oid=6584154&loc=d3e38371-112697

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 20

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41502-112717

+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of required minimum rental payments maturing in the second fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 13

-Paragraph 16

-Subparagraph b(i)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 13

-Paragraph 122

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 10

-Section 55

-Paragraph 40

-Subparagraph (Note 3)

-URI http://asc.fasb.org/extlink&oid=6584154&loc=d3e38371-112697

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 20

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41502-112717

+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 25 R2.htm IDEA: XBRL DOCUMENT v2.4.0.6

Condensed Balance Sheets (USD $)

Jun. 30, 2012

Dec. 31, 2011

Current Assets:

Cash and cash equivalents $ 17,211,098 $ 27,996,871

Accounts receivable 68,360

Inventory 473,454

Prepaid expenses and other current assets 664,463 1,061,550

Total Current Assets 18,417,375 29,058,421

Property and equipment, net 3,214,932 1,626,791

Patents and trademarks, net 53,258 59,208

Deferred financing costs 62,391

Deferred public offering cost 144,199

Other assets 71,235 586,498

Total Assets 21,900,999 31,393,309

Current Liabilities:

Accounts payable (includes related parties of $50,000 and $36,027-as of June 30, 2012 and December 31, 2011, respectively) 1,328,742 670,950

Accrued expenses 976,775 745,754

Deferred revenue (ST) 47,334

Other current liabilities 43,270 30,993

Total Current Liabilities 2,396,121 1,447,697

Long Term Liabilities:

Deferred rent 140,994 138,216

Deferred revenue (LT) 40,640

Total Long Term Liabilities 181,634 138,216

Total Liabilities 2,577,755 1,585,913

COMMITMENTS, CONTINGENCIES and LITIGATION (Note 8)

Stockholders Equity

Preferred stock - $0.10 par value; authorized 10,000,000 shares: issued and outstanding: none

Common stock $.001 par value; authorized 45,000,000 shares; issued and outstanding 30,332,217 shares at June 30, 2012 and 30,307,538 at December 31, 2011 30,332 30,308

Additional paid-in capital 150,057,460 149,304,424

Accumulated deficit (130,764,548) (119,527,336)

Stockholders' Equity 19,323,244 29,807,396

Total Liabilities and Stockholders' Equity $ 21,900,999 $ 31,393,309

X

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3-4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a(1)

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Concepts (CON)

-Number 6

-Paragraph 25

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 9

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6801-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 8, 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7, 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7

-Footnote 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.(a),19)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 25

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14326-108349

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 8, 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 17

-Article 9

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.17)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Net amount of long-term deferred finance costs capitalized at the end of the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 17

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 21

-Paragraph 16

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28555-108399

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DeferredFinanceCostsNoncurrentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.8)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 340

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6955238&loc=d3e105025-122735

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section A

+ Details

Name: us-gaap_DeferredOfferingCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Technical Bulletin (FTB)

-Number 85-3

-Paragraph 2

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.26(c))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 20

-Section 25

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=7501430&loc=d3e39927-112707

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 13

-Paragraph 19

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_DeferredRentCreditNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section A

-Paragraph 7, 8

-Chapter 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=6600647&loc=d3e214044-122780

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6935-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section A

-Paragraph 7, 8

-Chapter 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 48

-Paragraph 6

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=6600647&loc=d3e214044-122780

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6935-107765

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph ((a)(1),(b))

-URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16323-109275

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 142

-Paragraph 42, 45

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying amount (lower of cost or market) as of the balance sheet date of inventories less all valuation and other allowances. Excludes noncurrent inventory balances (expected to remain on hand past one year or one operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6386567&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 32

-Article 5

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 21

-Article 5

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Total obligations incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22, 23, 24, 25, 26, 27

-Article 5

+ Details

Name: us-gaap_LiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 17

-Article 5

+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate carrying amount of current liabilities (due within one year or within the normal operating cycle if longer) not separately disclosed in the balance sheet. Includes costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section A

-Paragraph 8

-Chapter 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6904-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 6

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6911-107765

+ Details

Name: us-gaap_OtherLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The total of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer, and the aggregate carrying amount of current assets, as of the balance sheet date, not separately presented elsewhere in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section A

-Paragraph 4

-Chapter 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount, net of accumulated depreciation, depletion and amortization, of long-lived physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 12

-Paragraph 5

-Subparagraph b, c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The cumulative amount of the reporting entity's undistributed earnings or deficit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A3

-Appendix A

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 26 R6.htm IDEA: XBRL DOCUMENT v2.4.0.6

Organization and Basis of Presentation
6 Months Ended

Jun. 30, 2012

Organization and Basis of Presentation [Abstract]

ORGANIZATION AND BASIS OF PRESENTATION
1. ORGANIZATION AND BASIS OF PRESENTATION

MELA Sciences, Inc., a Delaware corporation (the “Company”), is a medical device company focused on the commercialization of our flagship product, MelaFind^®, and the further design and development of MelaFind ^® and our technology. MelaFind^® is a non-invasive, point-of-care (in the doctor’s office) instrument to aid in the detection of melanoma. MelaFind ^® features a hand-held component that emits light of multiple wavelengths to capture digital data from clinically atypical pigmented skin lesions. The data are then analyzed utilizing sophisticated classification algorithms, ‘trained’ on our proprietary database of melanomas and benign lesions, to provide information to assist in the management of the patient’s disease, including information useful in the decision of whether to biopsy the lesion.

The Company received the Food and Drug Administration’s (“FDA”) approval of the Pre-Market Approval (“PMA”) application for Melafind^® in November 2011 and in September 2011 the Company received Conformite Europeenne (“CE”) Mark approval for MelaFind ^®. The Company initiated a controlled launch of MelaFind^® in selected U.S. and German markets in March 2012. Prior to March of 2012 the Company had not generated any revenues from MelaFind ^®.

During the second quarter of 2012, the Company continued the MelaFind^® controlled launch with additional installations of MelaFind ^® systems in both the U.S. and Germany. In the U.S., MelaFind^® systems were placed principally in the Northeast with additional installations in certain Southeastern, Southwestern and Middle-Atlantic states.

The Company anticipates that it will continue to incur net losses for the foreseeable future in the commercialization of the Melafind ^® device, the conduct of a Post Approval Study (“PAS”) evaluating the sensitivity of physicians in diagnosing melanomas and high-grade lesions and the false positive rate after using MelaFind^®, the further development of Melafind^® and the Company’s technology and the expansion of its corporate infrastructure. From inception, the Company has financed operations initially through the sale of convertible preferred stock prior to becoming a public company in 2005 and subsequently through the sale of common stock

On June 15, 2012, the Company entered into a sales agreement (the “Sales Agreement”) with Cowen and Company, LLC (“Cowen”) to sell shares of its common stock with aggregate gross proceeds of up to $20,000,000, from time to time, through an “at-the-market” equity offering program (“ATM Program”) under which Cowen will act as sales agent. There were no shares of the Company’s common stock sold through the ATM Program as of June 30, 2012.

The Company faces certain risks and uncertainties which are present in many emerging medical device companies regarding future profitability, ability to obtain future capital, protection of patents and intellectual property rights, competition, rapid technological change, government regulations, changing health care marketplace, recruiting and retaining key personnel, and reliance on third party manufacturing organizations.

As of June 30, 2012, the Company’s total of cash and cash equivalents was approximately $17.2 million. Management believes that this cash balance along with anticipated revenues and the utilization of the Company’s ATM Program will be sufficient to fund the Company’s anticipated level of operations for at least the next twelve months. However, the Company will need substantial funds to broaden the commercial expansion of MelaFind^®, including further development of a direct sales force and expansion of the Company’s contract manufacturing capacity.

The net proceeds anticipated from the ATM Program are intended to be used to continue the commercial launch of MelaFind^® in the U.S. and the European Union, for continued research & development activities and for general corporate purposes, including working capital. There can be no assurances that the Company will be able to obtain additional financing in the future. Additional funds may not become available on acceptable terms, and there can be no assurance that any additional funding that the Company does obtain will be sufficient to meet the Company’s needs in the long term. In the event that the Company is unable to raise additional funds, the Company has the ability and intent to reduce certain discretionary expenditures.

The unaudited condensed financial statements included herein have been prepared from the books and records of the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for reporting on Form 10-Q. The information and note disclosures normally included in complete financial statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) have been condensed or omitted pursuant to such rules and regulations. The interim financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2011.

The Company’s management is responsible for the financial statements included in this document. The Company’s interim financial statements are unaudited. Interim results may not be indicative of the results that may be expected for the year. However, the Company believes all adjustments considered necessary for a fair presentation of these interim financial statements have been included and are of a normal and recurring nature.

X

- Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 852

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2209116

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2122150

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7668296&loc=d3e288-107754

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2134480

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 720

-SubTopic 15

-URI http://asc.fasb.org/subtopic&trid=2122524

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Staff Position (FSP)

-Number FAS140-4/FIN46(R)-8

-Paragraph 8, C1, C7

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2197480

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Statement of Position (SOP)

-Number 94-6

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Interpretation (FIN)

-Number 46R

-Paragraph 4, 14, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 272

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=7880789&loc=SL6228881-111685

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 2-6

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 235

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 27 R35.htm IDEA: XBRL DOCUMENT v2.4.0.6

Warrants (Details)

Jun. 30, 2012

Dec. 31, 2011

Schedule Of Warrants Issued

Outstanding at December 31, 2011 546,781 546,781

Issued On 2007 [Member]

Schedule Of Warrants Issued

Outstanding at December 31, 2011 346,781 346,781

Issued On 2009 [Member]

Schedule Of Warrants Issued

Outstanding at December 31, 2011 200,000 200,000

X

- Details

Name: mela_ScheduleOfWarrantsIssuedAbstract

Namespace Prefix: mela_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of shares reserved for issuance under non-option equity instrument agreements awarded that validly exist and are outstanding, including vested instruments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 28 R22.htm IDEA: XBRL DOCUMENT v2.4.0.6

Stock-Based Compensation (Tables)
6 Months Ended

Jun. 30, 2012

Stock-Based Compensation [Abstract]

Schedule of fair value of each option award granted
The fair value of each option award granted is estimated on the date of grant using the Black-Scholes option valuation model and assumptions as noted in the following table:

For the Six Months
Ended June 30, 2012 For the Six Months
Ended June 30, 2011

Expected life
6.5 years 6.5 years

Expected volatility
73.55-79.68% 70.54-76.32%%

Risk-free interest rate
0.93-1.60% 2.47-3.34%

Dividend yield
0% 0%

Schedule of stock option plans
The status of the Company’s stock option plans at June 30, 2012 is summarized in the following:

Number of
Shares Weighted
Average
Exercise
Price per
Share Weighted
Average
Remaining
Contractual
Term in
Years Aggregate
Intrinsic
Value

Outstanding at December 31, 2011
2,057,104 $ 4.35 6.6

Granted
350,563 3.93 —

Exercised
(53,123 ) — —

Forfeited or expired
(159,238 ) 6.12 —

Outstanding at June 30, 2012
2,195,306 $ 4.18 7.0 $ 211

Vested and exercisable at June 30, 2012
1,562,681 $ 4.01 6.4 $ 149

Schedule of stock option plans quantitative information

 Number
Outstanding Options Outstanding
Weighted-
Average
Remaining
Contractual
Life Weighted
Average
Exercise
Price Options Exercisable

Range of Exercise Prices
Number
Exercisable Weighted-
Average
Exercise
Price

$.01-$1.00
43,329 0.6 years $ 1.00 43,329 $ 1.00

$1.01-$4.50
1,696,502 7.4 years $ 3.58 1,346,152 $ 3.63

$4.51-$11.11
455,475 6.2 years $ 6.70 173,200 $ 7.73

$.01-$11.11
2,195,306 7.0 years $ 4.18 1,562,681 $ 4.01

X

- Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of components of a stock option or other award plan under which equity-based compensation is awarded to employees, typically comprised of the amount of unearned compensation (deferred compensation cost), compensation expense, and changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan. Disclosure may also include nature and general terms of such arrangements that existed during the period and potential effects of those arrangements on shareholders, effect of compensation cost arising from equity-based payment arrangements on the income statement, method of estimating the fair value of the goods or services received, or the fair value of the equity instruments granted, during the period, cash flow effects resulting from equity-based payment arrangements and, for registrants that accelerate vesting of out of the money share options, reasons for the decision to accelerate.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 64, 65, A240

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 29 R36.htm IDEA: XBRL DOCUMENT v2.4.0.6

Warrants (Details Textual) (USD $)
1 Months Ended 6 Months Ended 1 Months Ended 6 Months Ended

Aug. 31, 2007

Jun. 30, 2012

Dec. 31, 2011

Aug. 31, 2012

Issued On 2007 [Member]

Aug. 31, 2007

Issued On 2007 [Member]

Jun. 30, 2012

Issued On 2007 [Member]

Dec. 31, 2011

Issued On 2007 [Member]

Jun. 30, 2012

Issued On 2009 [Member]

Dec. 31, 2011

Issued On 2009 [Member]

May 07, 2009

Issued On 2009 [Member]

Warrants (Textual) [Abstract]

Warrants Issued to purchase common stock 500,041 500,041

Warrant Outstanding 546,781 546,781 346,781 346,781 200,000 200,000

Exercise price of warrants outstanding $ 8.00

Warrant expiration period 60 months

Contractual Term of Warrant 5 years 5 years

Common Stock shares issued for warrants exercisable 200,000

Common Stock shares issued for warrants, Exercise Price $ 11.35

Expiry Date for the Warrants Outstanding May 01, 2014

X

- Definition

Share based compensation arrangement by share based payment award non option equity instruments exercisable.

+ References

No definition available.

+ Details

Name: mela_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable

Namespace Prefix: mela_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Share based compensation arrangement by share based payment award non option equity instruments exercisable weighted average exercise price.

+ References

No definition available.

+ Details

Name: mela_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice

Namespace Prefix: mela_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Share based compensation arrangement by share based payment award non option equity instruments outstanding weighted average exercise price.

+ References

No definition available.

+ Details

Name: mela_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice

Namespace Prefix: mela_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Warrant expiration period.

+ References

No definition available.

+ Details

Name: mela_WarrantExpirationPeriod

Namespace Prefix: mela_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Warrants issued to purchase common stock.

+ References

No definition available.

+ Details

Name: mela_WarrantsIssuedToPurchaseCommonStock

Namespace Prefix: mela_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: mela_WarrantsTextualAbstract

Namespace Prefix: mela_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Date the equity-based award expires, in CCYY-MM-DD format.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of shares reserved for issuance under non-option equity instrument agreements awarded that validly exist and are outstanding, including vested instruments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 30 R24.htm IDEA: XBRL DOCUMENT v2.4.0.6

Warrants (Tables)
6 Months Ended

Jun. 30, 2012

Warrants [Abstract]

Schedule of warrants issued

Issued Issued

2007 2009 Total

Outstanding at December 31, 2011
346,781 200,000 546,781

Outstanding at June 30, 2012
346,781 200,000 546,781

X

- Definition

Schedule of warrants issued.

+ References

No definition available.

+ Details

Name: mela_ScheduleOfWarrantsIssuedTableTextBlock

Namespace Prefix: mela_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_WarrantsAndRightsNoteDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 31 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "
"+ text.join( "

\n" ) +"
"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "
" + text[p] + "
\n"; } } }else{ formatted = '
' + raw + '
'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'
'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'
'+ "\n"+'
'+formatted+'
'+ "\n"+'
'+ "\n"+'
'+raw+'
'+ "\n"+'
'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } } XML 32 R7.htm IDEA: XBRL DOCUMENT v2.4.0.6

Revenue Recognition
6 Months Ended

Jun. 30, 2012

Revenue Recognition [Abstract]

REVENUE RECOGNITION
2. REVENUE RECOGNITION

The Company considers revenue to be earned when all of the following criteria are met: persuasive evidence a sales arrangement exists; delivery has occurred or services have been rendered; the price is fixed or determinable; and collectability is reasonably assured. The Company’s agreements with dermatologists regarding the MelaFind ^® system combines the elements noted above with a future service obligation. While the Company is required to place the MelaFind^® system with dermatologists for their exclusive use, ownership of the MelaFind ^® system remains with the Company.

In the U.S., the Company generates revenue primarily from the sale of single-use electronic patient record cards. These cards activate the MelaFind^® system, capture data and store the data for each patient visit. Additionally, the Company typically charges an initial installation fee for each MelaFind ^® system which covers training, delivery, supplies, maintenance and the right to use MelaFind ^®. In accordance with the accounting guidance regarding multiple-element arrangements, the Company defers revenue for the undelivered service element based upon the relative standalone selling prices, and recognizes the associated revenue over the related service period, generally expected to be two years.

In Germany, the typical contract with dermatologists calls for a fixed monthly fee and a per patient usage charge. Revenue generated from German contracts is recognized when earned.

X

- Details

Name: mela_RevenueRecognitionDisclosureAbstract

Namespace Prefix: mela_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

REVENUE RECOGNITION

+ References

No definition available.

+ Details

Name: mela_RevenueRecognitionDisclosureTextBlock

Namespace Prefix: mela_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R3.htm IDEA: XBRL DOCUMENT v2.4.0.6

Condensed Balance Sheets (Parenthetical) (USD $)

Jun. 30, 2012

Dec. 31, 2011

Condensed Balance Sheets [Abstract]

Accounts payable, related parties $ 50,000 $ 36,027

Preferred stock, par value $ 0.10

Preferred stock, shares authorized 10,000,000

Preferred stock, shares issued 0

Preferred stock, shares outstanding 0

Common stock, par value $ 0.001

Common stock, shares authorized 45,000,000

Common stock, shares issued 30,332,217 30,307,538

Common stock, shares outstanding 30,332,217 30,307,538

X

- Definition

Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 57

-Paragraph 2

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Subparagraph 1

-Article 4

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

+ Details

Name: us-gaap_AccountsPayableRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Face amount or stated value per share of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 34 R17.htm IDEA: XBRL DOCUMENT v2.4.0.6

Other Income
6 Months Ended

Jun. 30, 2012

Other Income [Abstract]

OTHER INCOME
12. OTHER INCOME

During April 2005, the Company discontinued all operations associated with its DIFOTI ^® product in order to focus its resources and attention on the development and commercialization of MelaFind ^®. During December 2006, the Company entered into a sale and exclusive licensing agreement with KaVo Dental GmbH (“KaVo”), a leading dental equipment manufacturer, which provides for KaVo to further develop and commercialize DIFOTI^®. Beginning in July 2008, KaVo is required to pay to the Company a royalty stream based upon the worldwide aggregate net sales of the licensed product, as defined in the license agreement, or a set minimum. During the three and six months ended June 30, 2012 and June 30, 2011, respectively, the Company earned $5 and $10 as the pro-rated portion of the minimum royalty as KaVo has not re-launched the product as of June 30, 2012.

X

- Definition

The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.3,6,7,9)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 3, 6, 7, 9

-Article 5

+ Details

Name: us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_OtherNonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 35 R1.htm IDEA: XBRL DOCUMENT v2.4.0.6

Document and Entity Information
6 Months Ended

Jun. 30, 2012

Jul. 31, 2012

Document and Entity Information [Abstract]

Entity Registrant Name MELA SCIENCES, INC. /NY

Entity Central Index Key 0001051514

Document Type 10-Q

Document Period End Date Jun. 30, 2012

Amendment Flag false

Document Fiscal Year Focus 2012

Document Fiscal Period Focus Q2

Current Fiscal Year End Date --12-31

Entity Filer Category Accelerated Filer

Entity Common Stock, Shares Outstanding 30,519,319

X

- Definition

If the value is true, then the document is an amendment to previously-filed/accepted document.

+ References

No definition available.

+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".

+ References

No definition available.

+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.

+ References

No definition available.

+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: mela_DocumentAndEntityInformationAbstract

Namespace Prefix: mela_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 36 R18.htm IDEA: XBRL DOCUMENT v2.4.0.6

Subsequent Events
6 Months Ended

Jun. 30, 2012

Subsequent Events [Abstract]

SUBSEQUENT EVENTS
13. SUBSEQUENT EVENTS

During July 2012, 187,102 shares of Company common stock, for gross proceeds of approximately $0.7 million, were sold through the Company’s ATM Program. Approximately $19.3 million remains available under the ATM Program as of July 31, 2012. The Company had 30,519,319 shares of common stock issued and outstanding as of July 31, 2012.

In connection with the Company’s private placement in August 2007, the Company issued 5-year warrants to purchase up to 500,041 shares of the Company’s common stock. At June 30, 2012, there were 346,781 of the 2007 warrants outstanding and exercisable at a price of $8.00 per share. On August 3, 2012, 5 years after their effective date, all 346,781 of the 2007 outstanding warrants expired.

X

- Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

+ References

No definition available.

+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6

Condensed Statements of Operations (Unaudited) (USD $)
3 Months Ended 6 Months Ended

Jun. 30, 2012

Jun. 30, 2011

Jun. 30, 2012

Jun. 30, 2011

Condensed Statements of Operations [Abstract]

Revenue $ 75,757 $ 87,007

Cost of revenue 372,048 502,458

Gross profit (296,291) (415,451)

Operating expenses:

Research and development 1,673,338 2,620,554 4,108,096 5,196,682

General and administrative 3,528,575 2,208,059 6,746,066 4,601,179

Operating loss (5,498,204) (4,828,613) (11,269,613) (9,797,861)

Interest income 9,021 13,934 22,405 34,465

Other income 4,996 5,022 9,996 11,670

Net loss $ (5,484,187) $ (4,809,657) $ (11,237,212) $ (9,751,726)

Basic and diluted net loss per common share $ (0.18) $ (0.19) $ (0.37) $ (0.39)

Basic and diluted weighted average number of common shares outstanding 30,332,217 25,262,538 30,323,061 25,262,538

X

- Definition

Basic and diluted weighted average number of common shares outstanding

+ References

No definition available.

+ Details

Name: mela_BasicAndDilutedWeightedAverageNumberOfSharesOutstanding

Namespace Prefix: mela_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The aggregate cost of goods produced and sold and services rendered during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 2

-Article 5

+ Details

Name: us-gaap_CostOfRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

No definition available.

+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1,2)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_GrossProfit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Income derived from investments in debt securities and on cash and cash equivalents the earnings of which reflect the time value of money or transactions in which the payments are for the use or forbearance of money.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 115

-Paragraph 14

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 7

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7(b))

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_InvestmentIncomeInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 10, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 87-21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28, 29, 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A7

-Appendix A

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 9

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.9)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141

-Paragraph 51

-Subparagraph g

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 86

-Paragraph 11, 12

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 2

-Paragraph 12, 13

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Aggregate revenue recognized during the period (derived from goods sold, services rendered, insurance premiums, or other activities that constitute an entity's earning process). For financial services companies, also includes investment and interest income, and sales and trading gains.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 38 R12.htm IDEA: XBRL DOCUMENT v2.4.0.6

Stock-Based Compensation
6 Months Ended

Jun. 30, 2012

Stock-Based Compensation [Abstract]

STOCK-BASED COMPENSATION
7. STOCK-BASED COMPENSATION

The Company has one stock-based compensation plan, the 2005 Stock Incentive Plan (“2005 Plan”), under which the Board of Directors may currently grant incentives to employees, consultants, directors, officers and collaborating scientists in the form of incentive stock options, nonqualified stock options and restricted stock awards. The Company also has one other stock-based compensation plan pursuant to which stock options are outstanding but no new grants may be made.

Stock awards under the Company’s stock option plans have been granted at prices which are no less than the market value of the stock on the date of the grant. Options granted under the 2005 Plan are generally time-based or performance-based, and vesting varies accordingly. Options under this plan expire in up to a maximum of ten years from the date of grant.

The compensation expense recognized in the Statement of Operations in the second quarter of 2012 and 2011 for stock options amounted to $426 (of which $199 relates to performance milestones) and $564 (of which $13 relates to performance milestones), respectively. For the six months ended June 2012 and 2011, compensation expense for stock options amounted to $774 (of which $345 relates to performance milestones) and $734 (of which $28 relates to performance milestones), respectively. No cash was received from options and warrants exercised under all share-based payment arrangements for the three month periods ended June 30, 2012 and 2011, respectively, and for the six month periods ended June 30, 2012 and 2011 cash received was $33 and $0, respectively.

The fair value of each option award granted is estimated on the date of grant using the Black-Scholes option valuation model and assumptions as noted in the following table:

For the Six Months
Ended June 30, 2012 For the Six Months
Ended June 30, 2011

Expected life
6.5 years 6.5 years

Expected volatility
73.55-79.68% 70.54-76.32%%

Risk-free interest rate
0.93-1.60% 2.47-3.34%

Dividend yield
0% 0%

The expected life of the options is based on the expected time to full-vesting, forfeiture and exercise. The expected volatility assumptions were determined based upon the historical volatility of the Company’s daily closing stock price. The risk-free interest rate is based on the continuous rates provided by the U.S. Treasury with a term equal to the expected life of the option. The expected dividend yield is zero as the Company has never paid dividends and does not currently anticipate paying any in the foreseeable future.

At June 30, 2012, stock options to purchase 2,195,306 shares of common stock at exercise prices ranging from $1.00 to $11.11 per share are outstanding and exercisable at various dates through 2022.

During the three months and six months ended June 30, 2012, the weighted average fair value of options granted, estimated as of the grant date using the Black-Scholes option valuation model, was $2.71 and $2.68, respectively. For the three month and six month periods ended June 30, 2011, the weighted average fair value of options granted was $2.18 and $2.20, respectively. There were no options exercised in the three month period ended June 30, 2012. For the six months ended June 30, 2012 the total intrinsic value of options exercised was $74. For the three month and six month periods ended June 30, 2011 no options were exercised.

The status of the Company’s stock option plans at June 30, 2012 is summarized in the following:

Number of
Shares Weighted
Average
Exercise
Price per
Share Weighted
Average
Remaining
Contractual
Term in
Years Aggregate
Intrinsic
Value

Outstanding at December 31, 2011
2,057,104 $ 4.35 6.6

Granted
350,563 3.93 —

Exercised
(53,123 ) — —

Forfeited or expired
(159,238 ) 6.12 —

Outstanding at June 30, 2012
2,195,306 $ 4.18 7.0 $ 211

Vested and exercisable at June 30, 2012
1,562,681 $ 4.01 6.4 $ 149

 Number
Outstanding Options Outstanding
Weighted-
Average
Remaining
Contractual
Life Weighted
Average
Exercise
Price Options Exercisable

Range of Exercise Prices
Number
Exercisable Weighted-
Average
Exercise
Price

$.01-$1.00
43,329 0.6 years $ 1.00 43,329 $ 1.00

$1.01-$4.50
1,696,502 7.4 years $ 3.58 1,346,152 $ 3.63

$4.51-$11.11
455,475 6.2 years $ 6.70 173,200 $ 7.73

$.01-$11.11
2,195,306 7.0 years $ 4.18 1,562,681 $ 4.01

As of June 30, 2012, of the total 2,195,306 options outstanding, 632,625 have not vested. Of this total unvested amount, 235,425 options will vest upon the attainment of certain milestones, and the balance will vest over the requisite service period. The weighted average vesting period for the non-milestone, non-vested awards not yet recognized is 1.9 years.

As of June 30, 2012, of the $986 of total unrecognized compensation cost related to unvested options to be recognized, $433 is to be recognized over a period to be determined by performance-based milestones, and $553 is to be recognized over the requisite service period through 2016.

As of June 30, 2012, there were 1,462,639 shares available for future grants under the Company’s 2005 Plan.

X

- Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Statement of Position (SOP)

-Number 93-6

-Paragraph 53

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 40

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 64, 65, A240

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 39 R11.htm IDEA: XBRL DOCUMENT v2.4.0.6

Net Loss Per Common Share
6 Months Ended

Jun. 30, 2012

Net Loss Per Common Share [Abstract]

NET LOSS PER COMMON SHARE
6. NET LOSS PER COMMON SHARE

Basic net loss per common share excludes dilution for potentially dilutive securities and is computed by dividing loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share gives effect to dilutive options, warrants and other potential common shares outstanding during the period. Diluted net loss per common share is equal to the basic net loss per common share since all potentially dilutive securities are anti-dilutive for each of the periods presented. Potential common stock equivalents excluded consist of stock options and warrants which are summarized as follows:

June 30,

2012 2011

Common stock options
2,195,306 2,107,429

Warrants
546,781 546,781

Total
2,742,087 2,654,210

X

- Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for earnings per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=16381557&loc=d3e4984-109258

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1278-109256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 40

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 40 R23.htm IDEA: XBRL DOCUMENT v2.4.0.6

Commitments, Contingencies and Litigation (Tables)
6 Months Ended

Jun. 30, 2012

Commitments, Contingencies and Litigation [Abstract]

Schedule of approximate aggregate minimum future payments
The approximate aggregate minimum future payments due under this lease are as follows:

Year ended December 31,

2012 Remaining six months
$ 216

2013
461

2014
478

2015
478

2016
478

$ 2,111

X

- Definition

Schedule of approximate aggregate minimum future payments.

+ References

No definition available.

+ Details

Name: mela_ScheduleOfApproximateAggregateMinimumFuturePaymentsTableTextBlock

Namespace Prefix: mela_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 41 R19.htm IDEA: XBRL DOCUMENT v2.4.0.6

Inventories (Policies)
6 Months Ended

Jun. 30, 2012

Inventories [Abstract]

INVENTORIES
Inventories are stated at the lower of cost (first-in, first-out) or market value. Inventory costs only include material purchases as the Company does not manufacture its products.

X

- Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for the basis and manner that goods are added and removed from inventory (for example, average cost, LIFO or FIFO) that are to be consumed, either directly or indirectly, in the production of goods or services to be available for sale (raw materials). If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory and how cost is determined (such as, FIFO, LIFO, average).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2126999

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Subparagraph Statement 8

-Chapter 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section A

-Paragraph 9

-Chapter 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Paragraph 3, 5, 15

-Chapter 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Inventory

-URI http://asc.fasb.org/extlink&oid=6516093

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph b

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6386783&loc=d3e4492-108314

+ Details

Name: us-gaap_InventoryRawMaterialsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 42 R15.htm IDEA: XBRL DOCUMENT v2.4.0.6

Warrants
6 Months Ended

Jun. 30, 2012

Warrants [Abstract]

WARRANTS
10. WARRANTS

Issued Issued

2007 2009 Total

Outstanding at December 31, 2011
346,781 200,000 546,781

Outstanding at June 30, 2012
346,781 200,000 546,781

In connection with the Company’s private placement in August 2007, the Company issued 5-year warrants to purchase up to 500,041 shares of the Company’s common stock. At June 30, 2012, 346,781 of the 2007 warrants were outstanding and exercisable at a price of $8.00 per share. At August 3, 2012, 60 months from their effective date, all 346,781 of the outstanding 2007 warrants expired.

In addition, in connection with the May 7, 2009 CEFF with Kingsbridge Capital, the Company issued a 5-year warrant to Kingsbridge to purchase up to 200,000 shares of the Company’s common stock at an exercise price of $11.35 per share. These 200,000 warrants are outstanding at June 30, 2012 and, if not exercised, will expire in May of 2014.

No warrants were exercised during the three and six month periods ended June 30, 2012 and June 30, 2011, respectively.

X

- Definition

WARRANTS

+ References

No definition available.

+ Details

Name: mela_ScheduleOfStockholdersEquityNoteWarrantsTextBlock

Namespace Prefix: mela_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_WarrantsAndRightsNoteDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 43 R13.htm IDEA: XBRL DOCUMENT v2.4.0.6

Commitments, Contingencies and Litigation
6 Months Ended

Jun. 30, 2012

Commitments, Contingencies and Litigation [Abstract]

COMMITMENTS, CONTINGENCIES AND LITIGATION
8. COMMITMENTS, CONTINGENCIES and LITIGATION

The Company is obligated under a non-cancelable operating lease for office, lab, and manufacturing space expiring December 2016. The lease is subject to escalations for increases in operating expenses. The approximate aggregate minimum future payments due under this lease are as follows:

Year ended December 31,

2012 Remaining six months
$ 216

2013
461

2014
478

2015
478

2016
478

$ 2,111

Rental payments are recognized as rent expense on a straight-line basis over the term of the lease. In April 2012, the Company entered into an agreement, effective May 1, 2012, which amended the existing lease for laboratory, assembly and office space which runs through December 2016. This amendment increases the previously leased space by 1,700 square feet at an annual rental of $22.

ASKION GmbH (“ASKION”), located in Gera Germany, which specializes in precision optics, is an integral member of the MelaFind^® manufacturing and development team. ASKION produced the MelaFind ^® hand-held devices used in our pivotal clinical trials. In January of 2012, the Company entered into an expanded manufacturing agreement with ASKION to continue developmental engineering, production and testing of our hand-held device, and to assemble and test the integrated finished MelaFind^® system to be placed within the European Union.

The Company, primarily through ASKION, engages Carl Zeiss Jena GmbH (“Zeiss”) to build the lenses and assemblies, as well as provide certain technical consulting, for the MelaFind ^® units that had been used in the Company’s clinical trials and the commercial units currently being manufactured. This work is expected to continue on commercial MelaFind^® units beyond 2012.

In addition, we are utilizing Nexcore Technology Inc., an FDA GMP compliant and ISO 9001 certified and ISO 13485 original equipment manufacturer of medical devices in New Jersey, to provide the assembled and tested MelaFind^® systems for installation in the U.S.

The Company has an employment agreement with its President and Chief Executive Officer, Dr. Gulfo, which provides for an annual base salary, stock options and discretionary performance bonuses. The agreement, which provides for automatic one-year renewal terms, currently runs through the end of 2012.

On November 19, 2010, a purported securities class action complaint was filed in the U.S. District Court for the Southern District of New York, naming as defendants the Company and certain of its officers and directors, entitled Randall J. Pederson, Individually and on Behalf of All Others Similarly Situated v. MELA Sciences, Inc., Joseph V. Gulfo, Richard I. Steinhart, and Breaux Castleman, No. 7:10-cv-08774-JFM. Two similar complaints were also filed, one on December 2, 2010 and the other on January 20, 2011, in the same District Court, entitled Amy Steigman, Individually and on Behalf of All Others Similarly Situated v. MELA Sciences, Inc., Joseph V. Gulfo, Richard I. Steinhart, and Breaux Castleman, No. 7:10-cv-09024-JFM; and Martin Slove and Linda Slove, Individually and on Behalf of All Others Similarly Situated v. MELA Sciences, Inc., Joseph V. Gulfo, Richard I. Steinhart, and Breaux Castleman, No. 1:11 cv-00429-JFM. These three securities class actions were consolidated into one action on February 15, 2011, entitled In re MELA Sciences, Inc. Securities Litigation, No. 10-Civ-8774-JFM (“securities class action”).

The securities class action plaintiffs assert violations of the Securities Exchange Act of 1934, alleging, among other things, that defendants made misstatements and omissions regarding the Company’s product, MelaFind^®, and its prospects for FDA approval, on behalf of stockholders who purchased the Company’s common stock during the period from February 13, 2009 through November 16, 2010, and seek unspecified damages. On May 2, 2011, the securities class action plaintiffs filed their amended consolidated complaint, alleging similar claims to their prior complaints. On July 29, 2011, defendants filed a motion to dismiss the consolidated amended complaint in its entirety. Plaintiff’s opposition to the motion to dismiss was filed on September 23, 2011. In light of the Company’s receipt of the Approvable Letter from the FDA for the MelaFind^® PMA Application on September 22, 2011, the parties filed a stipulation on October 19, 2011 in which plaintiff stated its intention to file a motion seeking leave to amend its complaint. Defendants withdrew the outstanding motion to dismiss the current Amended Complaint without prejudice to renew it at a later date. On November 18, 2011, plaintiffs filed their motion for leave to amend the consolidated amended complaint. On December 18, 2011, defendants filed an opposition to plaintiff’s motion for leave to amend the consolidated amended complaint. On February 8, 2012, plaintiffs filed their reply to defendants’ opposition to the motion. On March 16, 2012, plaintiffs filed a revised proposed second amended complaint. On March 30, 2012, defendants filed a surreply in further opposition to the motion. On April 16, 2012, plaintiffs filed a surreply in further support of the motion.

The Company believes that it has meritorious defenses and intends to vigorously defend against the securities class action; however, as with any litigation, we cannot predict with any degree of certainty the eventual outcome of this litigation. An adverse outcome could have a material adverse effect on our business and our business could be materially harmed.

From time to time, we may be a party to certain legal proceedings, incidental to the normal course of our business. These may include controversies relating to contract claims and employment related matters, some of which claims may be material in which case we will make separate disclosure as required.

X

- Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Interpretation (FIN)

-Number 14

-Paragraph 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 9, 10, 11, 12

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 44 R14.htm IDEA: XBRL DOCUMENT v2.4.0.6

Stockholders' Equity
6 Months Ended

Jun. 30, 2012

Stockholders' Equity [Abstract]

STOCKHOLDERS' EQUITY
9. STOCKHOLDERS’ EQUITY

In May 2009, the Company entered into a committed equity financing facility (“CEFF”) with Kingsbridge Capital Limited, pursuant to which Kingsbridge committed to purchase from time to time at the Company’s sole discretion, up to the lesser of $45 million or 3,327,000 shares of the Company’s common stock, prior to May 25, 2012. In connection with this CEFF, the Company issued a 5 year warrant, exercisable as of November 7, 2009, to Kingsbridge to purchase up to 200,000 shares of the Company’s common stock at an exercise price of $11.35 per share.

The CEFF terminated in May 2012 with 1,095,315 shares of common stock remaining unsold. Legal, accounting, and other costs associated with this agreement approximating $62 have been charged to operations in the quarter ended June 30, 2012 as the CEFF expired. The 200,000 warrants held by Kingsbridge remain outstanding and, if not exercised, will expire in May 2014.

In May 2010, the Company filed a Form S-3 shelf registration statement for an indeterminate number of shares of common stock, warrants to purchase shares of common stock and units consisting of a combination thereof having an aggregate initial offering price not to exceed $75 million. The registration statement was declared effective by the SEC on June 1, 2010. On June 30, 2010, the Company entered into an underwriting agreement, relating to the public offering of 2,200,000 shares of the Company’s common stock, at a price to the public of $7.50 per share less underwriting discounts and commissions. The common stock was offered and sold pursuant to the Company’s Prospectus dated June 1, 2010 and the Company’s Prospectus Supplement filed with the SEC on June 30, 2010, in connection with a takedown from the Company’s effective shelf registration statement.

On December 15, 2011, the Company entered into an underwriting agreement, relating to the public offering of 5,000,000 shares of the Company’s common stock, at a price to the public of $3.25 per share less underwriting discounts and commissions. The common stock was offered and sold pursuant to the Company’s Prospectus dated June 1, 2010 and the Company’s Prospectus Supplement filed with the SEC on December 16, 2011, in connection with a takedown from the Company’s effective shelf registration statement. The gross proceeds to the Company from the sale of the common stock totaled approximately $16.3 million. After deducting the underwriters’ discounts and commissions and other offering expenses payable by the Company, net proceeds were approximately $15 million. This offering closed on December 21, 2011. Approximately $42.2 million remained available under the Company’s 2010 shelf registration at December 31, 2011.

On June 15, 2012 the Company entered into a sales agreement with Cowen and Company, LLC to sell shares of its common stock with aggregate gross proceeds of up to $20 million, from time to time, through an ATM Program. The common stock was offered and will be sold pursuant to the Company’s Prospectus dated June 1, 2010 and the Company’s Prospectus Supplement filed with the SEC on June 15, 2012, in connection with a takedown from the Company’s effective shelf registration statement, leaving $22.2 million available under the shelf registration. There were no shares of Company common stock sold through this ATM Program as of June 30, 2012. During July 2012, there were 187,102 shares of Company common stock sold through the ATM for gross proceeds of approximately $0.7 million.

As of June 30, 2012, the Company had 45,000,000 shares of $0.001 par value common stock authorized and 30,332,217 shares issued and outstanding; and had 10,000,000 shares of $0.10 par value preferred stock authorized with no preferred shares issued and outstanding.

X

- Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section B

-Paragraph 7, 11A

-Chapter 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph d

-Article 4

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 20: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 21: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 22: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 23: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 45 R16.htm IDEA: XBRL DOCUMENT v2.4.0.6

Related Party Consulting Agreements
6 Months Ended

Jun. 30, 2012

Related Party Consulting Agreements [Abstract]

RELATED PARTY CONSULTING AGREEMENTS
11. RELATED PARTY CONSULTING AGREEMENTS

The Company has in place the following consulting agreements with related parties:

Consulting Agreement with Breaux Castleman

In June 2003, the Company entered into a consulting agreement with Breaux Castleman, a former member and the former Chairman of the Company’s Board of Directors, for consulting services related to the FDA approval of MelaFind^® PMA application and the Company’s business and financial strategy. Under this agreement, Mr. Castleman received compensation for each month of services rendered. The Company made payments pursuant to this consulting agreement of $6 and $12 in the three and six month periods ended June 30, 2011. This consulting agreement was terminated in December 2011 at the time of Mr. Castleman’s resignation from the Company’s Board of Directors.

Consulting Agreement with Gerald Wagner, Ph.D

In January 2007, Dr. Wagner, Ph.D., a former member of the Company’s Board of Directors, entered into an amended and restated consulting contract with the Company for consulting services related to the Company’s operations. Under the terms of the amended contract, Dr. Wagner is paid a monthly retainer of $2.5 and will be paid $2.5 for each additional consulting day. This amended agreement may terminate at the option of Dr. Wagner or the Company at any time, by providing fifteen days’ prior written notice, or immediately upon the mutual agreement of the Company and Dr. Wagner. The Company paid consulting costs pursuant to this agreement of $7.5 and $15 in the three and six month periods ended June 30, 2012 and June 30, 2011, respectively. Dr. Wagner resigned from the Company’s Board of Directors in December 2011, with his consulting contract remaining in effect.

Consulting Agreement with Anne Egger

In March 2009, the Company entered into a consulting agreement with Anne Egger for certain consulting services primarily focusing on physician advocacy. The agreement was for an initial term of three months, and has subsequently been extended to run through September 2012, and may be terminated by either party with 30 days’ notice. Under the terms of the agreement, Ms. Egger is entitled to receive a consulting fee of $1.6 per day. The Company did not pay any amount to Ms. Egger for consulting in the three and six month periods ended June 30, 2012 and June 30, 2011, respectively. Ms. Egger was appointed to the Company’s Board of Directors in June 2009.

X

- Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 57

-Paragraph 1-4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph b

-Article 3A

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Article 4

+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 46 R34.htm IDEA: XBRL DOCUMENT v2.4.0.6

Stockholders' Equity (Details) (USD $)
6 Months Ended 6 Months Ended

Jun. 30, 2012

Jul. 31, 2012

Dec. 31, 2011

Jun. 30, 2012

Committed Equity Financing Facility [Member]

May 31, 2012

Committed Equity Financing Facility [Member]

May 25, 2012

Committed Equity Financing Facility [Member]

Nov. 07, 2009

Committed Equity Financing Facility [Member]

Dec. 15, 2011

Shelf Registration Statement [Member]

Jun. 30, 2010

Shelf Registration Statement [Member]

Jun. 01, 2010

Shelf Registration Statement [Member]

Jun. 30, 2012

Atm Program [Member]

Jun. 15, 2012

Atm Program [Member]

Dec. 31, 2011

Atm Program [Member]

Stockholders' Equity (Textual) [Abstract]

Common Stock Purchase by Kingsbridge 3,327,000

Common Stock Shares, Purchase by Kingsbridge $ 45,000,000

Common Stock shares issued for warrants exercisable 200,000

Common Stock shares issued for warrants, Exercise Price $ 11.35

Contractual Term of Warrant 5 years 5 years

Common Stock Shares unsold on termination of CEFF 1,095,315

Legal, accounting, and other costs associated with CEFF agreement 62

Warrants Outstanding 200,000

Aggregate Initial Offering Price on Self Registration Statement 75,000,000

Public Offering Of Common Stock Shares under underwriting agreement 5,000,000 2,200,000

Initial Public offering price Per Share $ 3.25 $ 7.50

Gross proceeds from sale of common stock 16,300,000 700,000 20,000,000

Net Proceeds From Sale of Common Stock 15,000,000

Amount Available Under Shelf Registration Statement $ 22,200,000 $ 42,200,000

Common stock, shares issued 30,332,217 30,519,319 30,307,538 187,102

Stockholders Equity (Additional Textual) [Abstract]

Preferred stock, par value $ 0.10

Preferred stock, shares authorized 10,000,000

Preferred stock, shares issued 0

Preferred stock, shares outstanding 0

Common stock, par value $ 0.001

Common stock, shares authorized 45,000,000

Common stock, shares outstanding 30,332,217 30,519,319 30,307,538

X

- Definition

Amount available under shelf registration statement.

+ References

No definition available.

+ Details

Name: mela_AmountAvailableUnderShelfRegistrationStatement

Namespace Prefix: mela_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Common stock purchase agreement shares.

+ References

No definition available.

+ Details

Name: mela_CommonStockPurchaseAgreementShares

Namespace Prefix: mela_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Common stock purchase agreement value.

+ References

No definition available.

+ Details

Name: mela_CommonStockPurchaseAgreementValue

Namespace Prefix: mela_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Common stock shares unsold on termination of committed equity financing facility.

+ References

No definition available.

+ Details

Name: mela_CommonStockSharesUnsoldOnTerminationOfCommittedEquityFinancingFacility

Namespace Prefix: mela_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Gross proceeds from sale of the common stock.

+ References

No definition available.

+ Details

Name: mela_GrossProceedsFromSaleOfCommonStock

Namespace Prefix: mela_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Initial offering price.

+ References

No definition available.

+ Details

Name: mela_InitialOfferingPrice

Namespace Prefix: mela_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Legal, accounting, and other costs.

+ References

No definition available.

+ Details

Name: mela_LegalAccountingAndOtherCosts

Namespace Prefix: mela_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Net proceeds from sale of common stock.

+ References

No definition available.

+ Details

Name: mela_NetProceedsFromSaleOfCommonStock

Namespace Prefix: mela_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Price of public offering of common stock shares.

+ References

No definition available.

+ Details

Name: mela_PriceOfPublicOfferingOfCommonStockShares

Namespace Prefix: mela_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Public offering of common stock shares.

+ References

No definition available.

+ Details

Name: mela_PublicOfferingOfCommonStockShares

Namespace Prefix: mela_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Share based compensation arrangement by share based payment award non option equity instruments exercisable.

+ References

No definition available.

+ Details

Name: mela_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable

Namespace Prefix: mela_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Share based compensation arrangement by share based payment award non option equity instruments exercisable weighted average exercise price.

+ References

No definition available.

+ Details

Name: mela_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice

Namespace Prefix: mela_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Details

Name: mela_StockholdersEquityAdditionalTextualAbstract

Namespace Prefix: mela_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: mela_StockholdersEquityTextualAbstract

Namespace Prefix: mela_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Aggregate amount of each class of warrants or rights outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph i

-Article 4

+ Details

Name: us-gaap_ClassOfWarrantOrRightOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Face amount or stated value per share of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

XML 47 R21.htm IDEA: XBRL DOCUMENT v2.4.0.6

Net Loss Per Common Share (Tables)
6 Months Ended

Jun. 30, 2012

Net Loss Per Common Share [Abstract]

Schedule of stock options and warrants
Potential common stock equivalents excluded consist of stock options and warrants which are summarized as follows:

June 30,

2012 2011

Common stock options
2,195,306 2,107,429

Warrants
546,781 546,781

Total
2,742,087 2,654,210

X

- Definition

Schedule of stock options and warrants.

+ References

No definition available.

+ Details

Name: mela_ScheduleOfStockOptionsAndWarrantsTableTextBlock

Namespace Prefix: mela_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 48 R26.htm IDEA: XBRL DOCUMENT v2.4.0.6

Revenue Recognition (Details)
6 Months Ended

Jun. 30, 2012

Revenue Recognition (Textual) [Abstract]

Associated revenue over the related service period 2 years

X

- Definition

Associated revenue over the related service period.

+ References

No definition available.

+ Details

Name: mela_AssociatedRevenueOverRelatedServicePeriod

Namespace Prefix: mela_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: mela_RevenueRecognitionTextualAbstract

Namespace Prefix: mela_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 49 R5.htm IDEA: XBRL DOCUMENT v2.4.0.6

Condensed Statements of Cash Flows (Unaudited) (USD $)
6 Months Ended

Jun. 30, 2012

Jun. 30, 2011

Cash flows from operating activities:

Net loss $ (11,237,212) $ (9,751,726)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization 330,395 283,785

Noncash compensation 774,493 734,222

Write off of unamortized financing costs 62,391

Changes in operating assets and liabilities:

Increase in accounts receivable (68,360)

Increase in inventory (383,181)

Decrease (Increase) in prepaid expenses and other current assets 306,814 (410,357)

Increase (decrease) in accounts payable and accrued expenses 888,813 (419,525)

Increase in deferred rent 2,778 16,956

Increase in other assets (6,751)

Increase in deferred revenue 87,974

Increase (decrease) in other current liabilities 12,277 (647)

Net cash used in operating activities (9,229,569) (9,547,292)

Cash flows from investing activities:

Purchases of property and equipment (1,390,572) (30,811)

Net cash used in investing activities (1,390,572) (30,811)

Cash flows from financing activities:

Proceeds from exercise of stock options 33,310

Expenses related to Public Offerings (198,942)

Net cash provided by financing activities (165,632)

Net decrease in cash and cash equivalents (10,785,773) (9,578,103)

Cash and cash equivalents at beginning of period 27,996,871 30,520,812

Cash and cash equivalents at end of period 17,211,098 20,942,709

Non-cash investing activity:

Reclassification of MelaFind components from other assets to property and equipment $ 522,014

X

- Definition

Reclassification of MelaFind components from other assets to property and equipment

+ References

No definition available.

+ Details

Name: mela_ReclassificationFromOtherAssetsToPropertyAndEquipment

Namespace Prefix: mela_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Write off of unamortized financing costs.

+ References

No definition available.

+ Details

Name: mela_WriteOffOfUnamortizedFinancingCosts

Namespace Prefix: mela_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 8, 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7, 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7

-Footnote 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 5

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_DepreciationAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Change during the period in carrying value for all deferred liabilities due within one year or operating cycle.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDeferredLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in other assets used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current assets, other noncurrent assets, or a combination of other current and noncurrent assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in other liabilities used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current liabilities, other noncurrent liabilities, or a combination of other current and noncurrent liabilities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInOtherOperatingLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The net cash inflow or outflow from financing activity for the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3574-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net cash inflow or outflow from investing activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3574-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3536-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 10, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 87-21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28, 29, 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A7

-Appendix A

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow for cost incurred directly with the issuance of an equity security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18, 19, 20

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3291-108585

+ Details

Name: us-gaap_PaymentsOfStockIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3213-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 17

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph i

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 19

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (j)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ProceedsFromStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 50 R10.htm IDEA: XBRL DOCUMENT v2.4.0.6

Recent Accounting Pronouncements
6 Months Ended

Jun. 30, 2012

Recent Accounting Pronouncements [Abstract]

RECENT ACCOUNTING PRONOUNCEMENTS
5. RECENT ACCOUNTING PRONOUNCEMENTS

In June, 2011, the FASB issued Accounting Standard Update No 2011-05 “Presentation of Comprehensive Income” (ASU 2011-05). Under ASU 2011-05, an entity has the option to present the total of comprehensive income either in a single continuous statement of comprehensive income or in two separate but continuous statements of income and comprehensive income. The option of presentation of the components of other comprehensive income as part of the statement of change in the stockholders’ equity has been eliminated. This update was applied retrospectively and was effective for the Company for the fiscal year beginning January 1, 2012. For the periods ended June 30, 2011 and June 30, 2012, comprehensive loss was equal to net loss as the Company had no other comprehensive income or loss to report in either period.

X

- Details

Name: us-gaap_AccountingChangesAndErrorCorrectionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for reporting accounting changes and error corrections. It includes the conveyance of information necessary for a user of the Company's financial information to understand all aspects and required disclosure information concerning all changes and error corrections reported in the Company's financial statements for the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6801783&loc=d3e22499-107794

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 1.N.Q3)

-URI http://asc.fasb.org/extlink&oid=6369664&loc=d3e30840-122693

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=6801783&loc=d3e22644-107794

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 1

-Section N

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section 45

-Paragraph 23

-URI http://asc.fasb.org/extlink&oid=6368906&loc=d3e21914-107793

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6801783&loc=d3e22595-107794

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 154

-Paragraph 17, 22, 25, 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_AccountingChangesAndErrorCorrectionsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 51 R27.htm IDEA: XBRL DOCUMENT v2.4.0.6

Net Loss Per Common Share (Details)
6 Months Ended

Jun. 30, 2012

Jun. 30, 2011

Schedule of stock options and warrants

Potential common stock equivalents 2,742,087 2,654,210

Common stock options [Member]

Schedule of stock options and warrants

Potential common stock equivalents 2,195,306 2,107,429

Warrants [Member]

Schedule of stock options and warrants

Potential common stock equivalents 546,781 546,781

X

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 07-4

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Diluted Earnings Per Share

-URI http://asc.fasb.org/extlink&oid=6510752

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Contingent Stock Agreement

-URI http://asc.fasb.org/extlink&oid=6508534

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Antidilution

-URI http://asc.fasb.org/extlink&oid=6505113

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 171

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 40

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 13, 14

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 52 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.6 Html 66 174 1 false 16 0 false 6 false false R1.htm 00 - Document - Document and Entity Information Sheet http://melasciences.com/role/DocumentAndEntityInformation Document and Entity Information true false R2.htm 0110 - Statement - Condensed Balance Sheets Sheet http://melasciences.com/role/BalanceSheets Condensed Balance Sheets false false R3.htm 0111 - Statement - Condensed Balance Sheets (Parenthetical) Sheet http://melasciences.com/role/BalanceSheetsParenthetical Condensed Balance Sheets (Parenthetical) false false R4.htm 0120 - Statement - Condensed Statements of Operations (Unaudited) Sheet http://melasciences.com/role/StatementsOfOperations Condensed Statements of Operations (Unaudited) false false R5.htm 0130 - Statement - Condensed Statements of Cash Flows (Unaudited) Sheet http://melasciences.com/role/StatementsOfCashFlows Condensed Statements of Cash Flows (Unaudited) false false R6.htm 0201 - Disclosure - Organization and Basis of Presentation Sheet http://melasciences.com/role/OrganizationAndBasisOfPresentation Organization and Basis of Presentation false false R7.htm 0202 - Disclosure - Revenue Recognition Sheet http://melasciences.com/role/RevenueRecognition Revenue Recognition false false R8.htm 0203 - Disclosure - Inventories Sheet http://melasciences.com/role/Inventories Inventories false false R9.htm 0204 - Disclosure - Use of Estimates Sheet http://melasciences.com/role/UseOfEstimates Use of Estimates false false R10.htm 0205 - Disclosure - Recent Accounting Pronouncements Sheet http://melasciences.com/role/RecentAccountingPronouncements Recent Accounting Pronouncements false false R11.htm 0206 - Disclosure - Net Loss Per Common Share Sheet http://melasciences.com/role/NetLossPerCommonShare Net Loss Per Common Share false false R12.htm 0207 - Disclosure - Stock-Based Compensation Sheet http://melasciences.com/role/StockBasedCompensation Stock-Based Compensation false false R13.htm 0208 - Disclosure - Commitments, Contingencies and Litigation Sheet http://melasciences.com/role/CommitmentsContingenciesAndLitigation Commitments, Contingencies and Litigation false false R14.htm 0209 - Disclosure - Stockholders' Equity Sheet http://melasciences.com/role/StockholdersEquity Stockholders' Equity false false R15.htm 0210 - Disclosure - Warrants Sheet http://melasciences.com/role/Warrants Warrants false false R16.htm 0211 - Disclosure - Related Party Consulting Agreements Sheet http://melasciences.com/role/RelatedPartyConsultingAgreements Related Party Consulting Agreements false false R17.htm 0212 - Disclosure - Other Income Sheet http://melasciences.com/role/OtherIncome Other Income false false R18.htm 0213 - Disclosure - Subsequent Events Sheet http://melasciences.com/role/SubsequentEvents Subsequent Events false false R19.htm 0403 - Disclosure - Inventories (Policies) Sheet http://melasciences.com/role/InventoriesPolicies Inventories (Policies) false false R20.htm 0405 - Disclosure - Recent Accounting Pronouncements (Policies) Sheet http://melasciences.com/role/RecentAccountingPronouncementsPolicies Recent Accounting Pronouncements (Policies) false false R21.htm 0506 - Disclosure - Net Loss Per Common Share (Tables) Sheet http://melasciences.com/role/NetLossPerCommonShareTables Net Loss Per Common Share (Tables) false false R22.htm 0507 - Disclosure - Stock-Based Compensation (Tables) Sheet http://melasciences.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) false false R23.htm 0508 - Disclosure - Commitments, Contingencies and Litigation (Tables) Sheet http://melasciences.com/role/CommitmentsContingenciesAndLitigationTables Commitments, Contingencies and Litigation (Tables) false false R24.htm 0510 - Disclosure - Warrants (Tables) Sheet http://melasciences.com/role/WarrantsTables Warrants (Tables) false false R25.htm 0601 - Disclosure - Organization and Basis of Presentation (Details) Sheet http://melasciences.com/role/OrganizationAndBasisOfPresentationDetails Organization and Basis of Presentation (Details) false false R26.htm 0602 - Disclosure - Revenue Recognition (Details) Sheet http://melasciences.com/role/RevenueRecognitionDetails Revenue Recognition (Details) false false R27.htm 0606 - Disclosure - Net Loss Per Common Share (Details) Sheet http://melasciences.com/role/NetLossPerCommonShareDetails Net Loss Per Common Share (Details) false false R28.htm 0607 - Disclosure - Stock Based Compensation (Details) Sheet http://melasciences.com/role/StockBasedCompensationDetails Stock Based Compensation (Details) false false R29.htm 06071 - Disclosure - Stock Based Compensation (Details 1) Sheet http://melasciences.com/role/StockBasedCompensationDetails1 Stock Based Compensation (Details 1) false false R30.htm 06072 - Disclosure - Stock Based Compensation (Details 2) Sheet http://melasciences.com/role/StockBasedCompensationDetails2 Stock Based Compensation (Details 2) false false R31.htm 06073 - Disclosure - Stock Based Compensation (Details Textual) Sheet http://melasciences.com/role/StockBasedCompensationDetailsTextual Stock Based Compensation (Details Textual) false false R32.htm 0608 - Disclosure - Commitments, Contingencies and Litigation (Details) Sheet http://melasciences.com/role/CommitmentsContingenciesAndLitigationDetails Commitments, Contingencies and Litigation (Details) false false R33.htm 06081 - Disclosure - Commitments, Contingencies and Litigation (Details Textual) Sheet http://melasciences.com/role/CommitmentsContingenciesAndLitigationDetailsTextual Commitments, Contingencies and Litigation (Details Textual) false false R34.htm 0609 - Disclosure - Stockholders' Equity (Details) Sheet http://melasciences.com/role/StockholdersEquityDetails Stockholders' Equity (Details) false false R35.htm 0610 - Disclosure - Warrants (Details) Sheet http://melasciences.com/role/WarrantsDetails Warrants (Details) false false R36.htm 06101 - Disclosure - Warrants (Details Textual) Sheet http://melasciences.com/role/WarrantsDetailsTextual Warrants (Details Textual) false false R37.htm 0611 - Disclosure - Related Party Consulting Agreements (Details) Sheet http://melasciences.com/role/RelatedPartyConsultingAgreementsDetails Related Party Consulting Agreements (Details) false false R38.htm 0612 - Disclosure - Other Income (Details) Sheet http://melasciences.com/role/OtherIncomeDetails Other Income (Details) false false R39.htm 0613 - Disclosure - Subsequent Events (Details) Sheet http://melasciences.com/role/SubsequentEventsDetails Subsequent Events (Details) false false All Reports Book All Reports Element us-gaap_ProceedsFromIssuanceOfCommonStock had a mix of decimals attribute values: -5 -3. 'Monetary' elements on report '0601 - Disclosure - Organization and Basis of Presentation (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '0609 - Disclosure - Stockholders' Equity (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '0613 - Disclosure - Subsequent Events (Details)' had a mix of different decimal attribute values. Process Flow-Through: 0110 - Statement - Condensed Balance Sheets Process Flow-Through: Removing column 'Jun. 30, 2011' Process Flow-Through: Removing column 'Dec. 31, 2010' Process Flow-Through: 0111 - Statement - Condensed Balance Sheets (Parenthetical) Process Flow-Through: Removing column 'Jul. 31, 2012' Process Flow-Through: 0120 - Statement - Condensed Statements of Operations (Unaudited) Process Flow-Through: 0130 - Statement - Condensed Statements of Cash Flows (Unaudited) mela-20120630.xml mela-20120630.xsd mela-20120630_cal.xml mela-20120630_def.xml mela-20120630_lab.xml mela-20120630_pre.xml true true XML 53 R38.htm IDEA: XBRL DOCUMENT v2.4.0.6

Other Income (Details) (USD $)
3 Months Ended 6 Months Ended

Jun. 30, 2012

Jun. 30, 2011

Jun. 30, 2012

Jun. 30, 2011

Other Income [Abstract]

Royalty Earned From KaVo Dental GmbH to develop and commercialize DIFOTI $ 5 $ 5 $ 10 $ 10

X

- Details

Name: us-gaap_OtherNonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(e))

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_RoyaltyRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 54 R20.htm IDEA: XBRL DOCUMENT v2.4.0.6

Recent Accounting Pronouncements (Policies)
6 Months Ended

Jun. 30, 2012

Recent Accounting Pronouncements [Abstract]

RECENT ACCOUNTING PRONOUNCEMENTS
In June, 2011, the FASB issued Accounting Standard Update No 2011-05 “Presentation of Comprehensive Income” (ASU 2011-05). Under ASU 2011-05, an entity has the option to present the total of comprehensive income either in a single continuous statement of comprehensive income or in two separate but continuous statements of income and comprehensive income. The option of presentation of the components of other comprehensive income as part of the statement of change in the stockholders’ equity has been eliminated. This update was applied retrospectively and was effective for the Company for the fiscal year beginning January 1, 2012. For the periods ended June 30, 2011 and June 30, 2012, comprehensive loss was equal to net loss as the Company had no other comprehensive income or loss to report in either period.

X

- Details

Name: us-gaap_AccountingChangesAndErrorCorrectionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of the adoption of new accounting pronouncements that may impact the entity's financial reporting.

+ References

No definition available.

+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

Organization and Basis of Presentation (Details) (USD $)	6 Months Ended
	Jun. 30, 2012	Dec. 31, 2011	Jun. 30, 2011	Dec. 31, 2010
Organization and Basis of Presentation (Textual) [Abstract]
Proceeds from issue of common stock through ATM program	$ 20,000,000,000
Total cash and cash equivalents	$ 17,211,098	$ 27,996,871	$ 20,942,709	$ 30,520,812

Related Party Consulting Agreements (Details) (USD $)	3 Months Ended		6 Months Ended
Related Party Consulting Agreements (Details) (USD $)	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011
Consulting Agreement with Breaux Castleman [Member]
Related Party Transaction (Textual) [Abstract]
Amount payable under consulting agreement		$ 6		$ 12
Termination of consulting agreement			Dec. 01, 2011
Monthly retaining fee			2.5
Additional retaining fee			2.5
Consulting Agreement with Gerald Wagner, Ph.D [Member]
Related Party Transaction (Textual) [Abstract]
Amount payable under consulting agreement	7.5	7.5	15	15
Consulting Agreement with Anne Egger [Member]
Related Party Transaction (Textual) [Abstract]
Consulting fee payable			1.6
Consulting fees outstanding	$ 0	$ 0	$ 0	$ 0

Stock Based Compensation (Details 1) (USD $)	6 Months Ended	12 Months Ended
Stock Based Compensation (Details 1) (USD $)	Jun. 30, 2012	Dec. 31, 2011
Schedule of stock option plans
Number of Shares Outstanding at December 31, 2011	2,057,104
Number of Shares Granted	350,563
Number of Shares Exercised	(53,123)
Number of shares Forfeited or expired	(159,238)
Number of Shares Outstanding at June 30, 2012	2,195,306	2,057,104
Number of Shares Vested and exercisable at June 30, 2012	1,562,681
Weighted Average Exercise Price per Share Outstanding at December 31, 2011	$ 4.35
Weighted Average Exercise Price per Share Granted	$ 3.93
Weighted Average Exercise Price per Share Forfeited or expired	$ 6.12
Weighted Average Exercise Price per Share Outstanding at June 30, 2012	$ 4.18	$ 4.35
Weighted Average Exercise Price per Share Vested and exercisable at June 30, 2012	$ 4.01
Weighted Average Remaining Contractual Term in Years Outstanding	7 years	6 years 7 months 6 days
Weighted Average Remaining Contractual Term in Years Vested and exercisable at June 30, 2012	6 years 4 months 24 days
Aggregate Intrinsic Value Outstanding	$ 211
Aggregate Intrinsic Value Outstanding Vested and exercisable at June 30, 2012	$ 149

Stock Based Compensation (Details)	6 Months Ended
Stock Based Compensation (Details)	Jun. 30, 2012	Jun. 30, 2011
Schedule of fair value of each option award granted
Expected life	6 years 6 months	6 years 6 months
Expected volatility - Minimum	73.55%	70.54%
Expected volatility - Maximum	79.68%	76.32%
Risk-free interest rate - Minimum	0.93%	2.47%
Risk-free interest rate - Maximum	1.60%	3.34%
Dividend yield	0.00%	0.00%

Stock Based Compensation (Details 2) (USD $)	6 Months Ended
Stock Based Compensation (Details 2) (USD $)	Jun. 30, 2012
Range One [Member]
Schedule of stock option plans quantitative information
Range of Exercise Prices, Lower Range Limit	$ 0.01
Range of Exercise Prices, Upper Range Limit	$ 1.00
Number Outstanding	43,329
Options Outstanding Weighted-Average Remaining Contractual Life	7 months 6 days
Options Outstanding Weighted Average Exercise Price	$ 1.00
Options Exercisable Number Exercisable	43,329
Options Exercisable Weighted-Average Exercise Price	$ 1.00
Range Two [Member]
Schedule of stock option plans quantitative information
Range of Exercise Prices, Lower Range Limit	$ 1.01
Range of Exercise Prices, Upper Range Limit	$ 4.50
Number Outstanding	1,696,502
Options Outstanding Weighted-Average Remaining Contractual Life	7 years 4 months 24 days
Options Outstanding Weighted Average Exercise Price	$ 3.58
Options Exercisable Number Exercisable	1,346,152
Options Exercisable Weighted-Average Exercise Price	$ 3.63
Range Three [Member]
Schedule of stock option plans quantitative information
Range of Exercise Prices, Lower Range Limit	$ 4.51
Range of Exercise Prices, Upper Range Limit	$ 11.11
Number Outstanding	455,475
Options Outstanding Weighted-Average Remaining Contractual Life	6 years 2 months 12 days
Options Outstanding Weighted Average Exercise Price	$ 6.70
Options Exercisable Number Exercisable	173,200
Options Exercisable Weighted-Average Exercise Price	$ 7.73
Net Range [Member]
Schedule of stock option plans quantitative information
Range of Exercise Prices, Lower Range Limit	$ 0.01
Range of Exercise Prices, Upper Range Limit	$ 11.11
Number Outstanding	2,195,306
Options Outstanding Weighted-Average Remaining Contractual Life	7 years
Options Outstanding Weighted Average Exercise Price	$ 4.18
Options Exercisable Number Exercisable	1,562,681
Options Exercisable Weighted-Average Exercise Price	$ 4.01

Stock Based Compensation (Details Textual) (USD $) In Thousands, except Share data, unless otherwise specified			3 Months Ended		6 Months Ended		3 Months Ended		6 Months Ended
	Jun. 30, 2012	Dec. 31, 2011	Jun. 30, 2012 2005 Stock Incentive Plan [Member]	Jun. 30, 2011 2005 Stock Incentive Plan [Member]	Jun. 30, 2012 2005 Stock Incentive Plan [Member]	Jun. 30, 2011 2005 Stock Incentive Plan [Member]	Jun. 30, 2012 2005 Stock Incentive Plan [Member] Performance Milestones [Member]	Jun. 30, 2011 2005 Stock Incentive Plan [Member] Performance Milestones [Member]	Jun. 30, 2012 2005 Stock Incentive Plan [Member] Performance Milestones [Member]	Jun. 30, 2011 2005 Stock Incentive Plan [Member] Performance Milestones [Member]
Shared Based Compensation (Textual) [Abstract]
Expiry period of option plan					Up to 10 years
Compensation expense			$ 426	$ 564	$ 774	$ 734	$ 199	$ 13	$ 345	$ 28
Cash received from options and warrants exercised			0	0	33	0
Number of stock options to purchase			2,195,306		2,195,306
Range of Exercise Prices, Lower Range Limit					$ 1.00
Range of Exercise Prices, Upper Range Limit					$ 11.11
Weighted average fair value of options granted			$ 2.71	$ 2.18	$ 2.68	$ 2.20
Total intrinsic value of options exercised			0	0	74	0
Total options outstanding	2,195,306	2,057,104	2,195,306		2,195,306
Options nonvested					632,625
Share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, Number							235,425		235,425
Employee Service Share-Based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition					1 year 10 months 24 days
Employee Service Share-Based Compensation Nonvested Awards, Total Compensation Cost Not yet Recognized, Stock Options			986		986		433		433
Total unrecognized compensation cost to be recognized over the requisite service period					$ 553
Shares available for future grants under ESOP			1,462,639		1,462,639

Commitments, Contingencies and Litigation (Details) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2011
Schedule of approximate aggregate minimum future payments
2012 Remaining six months	$ 216
2013	461
2014	478
2015	478
2016	478
Total	$ 2,111

Warrants (Details)	Jun. 30, 2012	Dec. 31, 2011
Schedule Of Warrants Issued
Outstanding at December 31, 2011	546,781	546,781
Issued On 2007 [Member]
Schedule Of Warrants Issued
Outstanding at December 31, 2011	346,781	346,781
Issued On 2009 [Member]
Schedule Of Warrants Issued
Outstanding at December 31, 2011	200,000	200,000

Warrants (Details Textual) (USD $)	1 Months Ended	6 Months Ended		1 Months Ended				6 Months Ended
Warrants (Details Textual) (USD $)	Aug. 31, 2007	Jun. 30, 2012	Dec. 31, 2011	Aug. 31, 2012 Issued On 2007 [Member]	Aug. 31, 2007 Issued On 2007 [Member]	Jun. 30, 2012 Issued On 2007 [Member]	Dec. 31, 2011 Issued On 2007 [Member]	Jun. 30, 2012 Issued On 2009 [Member]	Dec. 31, 2011 Issued On 2009 [Member]	May 07, 2009 Issued On 2009 [Member]
Warrants (Textual) [Abstract]
Warrants Issued to purchase common stock	500,041				500,041
Warrant Outstanding		546,781	546,781			346,781	346,781	200,000	200,000
Exercise price of warrants outstanding						$ 8.00
Warrant expiration period				60 months
Contractual Term of Warrant		5 years						5 years
Common Stock shares issued for warrants exercisable										200,000
Common Stock shares issued for warrants, Exercise Price										$ 11.35
Expiry Date for the Warrants Outstanding								May 01, 2014

Condensed Balance Sheets (Parenthetical) (USD $)	Jun. 30, 2012	Dec. 31, 2011
Condensed Balance Sheets [Abstract]
Accounts payable, related parties	$ 50,000	$ 36,027
Preferred stock, par value	$ 0.10
Preferred stock, shares authorized	10,000,000
Preferred stock, shares issued	0
Preferred stock, shares outstanding	0
Common stock, par value	$ 0.001
Common stock, shares authorized	45,000,000
Common stock, shares issued	30,332,217	30,307,538
Common stock, shares outstanding	30,332,217	30,307,538

Document and Entity Information	6 Months Ended
Document and Entity Information	Jun. 30, 2012	Jul. 31, 2012
Document and Entity Information [Abstract]
Entity Registrant Name	MELA SCIENCES, INC. /NY
Entity Central Index Key	0001051514
Document Type	10-Q
Document Period End Date	Jun. 30, 2012
Amendment Flag	false
Document Fiscal Year Focus	2012
Document Fiscal Period Focus	Q2
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		30,519,319

Condensed Statements of Operations (Unaudited) (USD $)	3 Months Ended		6 Months Ended
Condensed Statements of Operations (Unaudited) (USD $)	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011
Condensed Statements of Operations [Abstract]
Revenue	$ 75,757		$ 87,007
Cost of revenue	372,048		502,458
Gross profit	(296,291)		(415,451)
Operating expenses:
Research and development	1,673,338	2,620,554	4,108,096	5,196,682
General and administrative	3,528,575	2,208,059	6,746,066	4,601,179
Operating loss	(5,498,204)	(4,828,613)	(11,269,613)	(9,797,861)
Interest income	9,021	13,934	22,405	34,465
Other income	4,996	5,022	9,996	11,670
Net loss	$ (5,484,187)	$ (4,809,657)	$ (11,237,212)	$ (9,751,726)
Basic and diluted net loss per common share	$ (0.18)	$ (0.19)	$ (0.37)	$ (0.39)
Basic and diluted weighted average number of common shares outstanding	30,332,217	25,262,538	30,323,061	25,262,538

Inventories (Policies)	6 Months Ended
Inventories (Policies)	Jun. 30, 2012
Inventories [Abstract]
INVENTORIES	Inventories are stated at the lower of cost (first-in, first-out) or market value. Inventory costs only include material purchases as the Company does not manufacture its products.

Stockholders' Equity (Details) (USD $)	6 Months Ended			6 Months Ended
Stockholders' Equity (Details) (USD $)	Jun. 30, 2012	Jul. 31, 2012	Dec. 31, 2011	Jun. 30, 2012 Committed Equity Financing Facility [Member]	May 31, 2012 Committed Equity Financing Facility [Member]	May 25, 2012 Committed Equity Financing Facility [Member]	Nov. 07, 2009 Committed Equity Financing Facility [Member]	Dec. 15, 2011 Shelf Registration Statement [Member]	Jun. 30, 2010 Shelf Registration Statement [Member]	Jun. 01, 2010 Shelf Registration Statement [Member]	Jun. 30, 2012 Atm Program [Member]	Jun. 15, 2012 Atm Program [Member]	Dec. 31, 2011 Atm Program [Member]
Stockholders' Equity (Textual) [Abstract]
Common Stock Purchase by Kingsbridge						3,327,000
Common Stock Shares, Purchase by Kingsbridge						$ 45,000,000
Common Stock shares issued for warrants exercisable							200,000
Common Stock shares issued for warrants, Exercise Price							$ 11.35
Contractual Term of Warrant	5 years			5 years
Common Stock Shares unsold on termination of CEFF					1,095,315
Legal, accounting, and other costs associated with CEFF agreement				62
Warrants Outstanding				200,000
Aggregate Initial Offering Price on Self Registration Statement										75,000,000
Public Offering Of Common Stock Shares under underwriting agreement								5,000,000	2,200,000
Initial Public offering price Per Share								$ 3.25	$ 7.50
Gross proceeds from sale of common stock										16,300,000	700,000	20,000,000
Net Proceeds From Sale of Common Stock										15,000,000
Amount Available Under Shelf Registration Statement											$ 22,200,000		$ 42,200,000
Common stock, shares issued	30,332,217	30,519,319	30,307,538								187,102
Stockholders Equity (Additional Textual) [Abstract]
Preferred stock, par value	$ 0.10
Preferred stock, shares authorized	10,000,000
Preferred stock, shares issued	0
Preferred stock, shares outstanding	0
Common stock, par value	$ 0.001
Common stock, shares authorized	45,000,000
Common stock, shares outstanding	30,332,217	30,519,319	30,307,538

Revenue Recognition (Details)	6 Months Ended
Revenue Recognition (Details)	Jun. 30, 2012
Revenue Recognition (Textual) [Abstract]
Associated revenue over the related service period	2 years

Condensed Statements of Cash Flows (Unaudited) (USD $)	6 Months Ended
Condensed Statements of Cash Flows (Unaudited) (USD $)	Jun. 30, 2012	Jun. 30, 2011
Cash flows from operating activities:
Net loss	$ (11,237,212)	$ (9,751,726)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	330,395	283,785
Noncash compensation	774,493	734,222
Write off of unamortized financing costs	62,391
Changes in operating assets and liabilities:
Increase in accounts receivable	(68,360)
Increase in inventory	(383,181)
Decrease (Increase) in prepaid expenses and other current assets	306,814	(410,357)
Increase (decrease) in accounts payable and accrued expenses	888,813	(419,525)
Increase in deferred rent	2,778	16,956
Increase in other assets	(6,751)
Increase in deferred revenue	87,974
Increase (decrease) in other current liabilities	12,277	(647)
Net cash used in operating activities	(9,229,569)	(9,547,292)
Cash flows from investing activities:
Purchases of property and equipment	(1,390,572)	(30,811)
Net cash used in investing activities	(1,390,572)	(30,811)
Cash flows from financing activities:
Proceeds from exercise of stock options	33,310
Expenses related to Public Offerings	(198,942)
Net cash provided by financing activities	(165,632)
Net decrease in cash and cash equivalents	(10,785,773)	(9,578,103)
Cash and cash equivalents at beginning of period	27,996,871	30,520,812
Cash and cash equivalents at end of period	17,211,098	20,942,709
Non-cash investing activity:
Reclassification of MelaFind components from other assets to property and equipment	$ 522,014

Net Loss Per Common Share (Details)	6 Months Ended
Net Loss Per Common Share (Details)	Jun. 30, 2012	Jun. 30, 2011
Schedule of stock options and warrants
Potential common stock equivalents	2,742,087	2,654,210
Common stock options [Member]
Schedule of stock options and warrants
Potential common stock equivalents	2,195,306	2,107,429
Warrants [Member]
Schedule of stock options and warrants
Potential common stock equivalents	546,781	546,781

Other Income (Details) (USD $)	3 Months Ended		6 Months Ended
Other Income (Details) (USD $)	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011
Other Income [Abstract]
Royalty Earned From KaVo Dental GmbH to develop and commercialize DIFOTI	$ 5	$ 5	$ 10	$ 10

Recent Accounting Pronouncements (Policies)	6 Months Ended
Recent Accounting Pronouncements (Policies)	Jun. 30, 2012
Recent Accounting Pronouncements [Abstract]
RECENT ACCOUNTING PRONOUNCEMENTS	In June, 2011, the FASB issued Accounting Standard Update No 2011-05 “Presentation of Comprehensive Income” (ASU 2011-05). Under ASU 2011-05, an entity has the option to present the total of comprehensive income either in a single continuous statement of comprehensive income or in two separate but continuous statements of income and comprehensive income. The option of presentation of the components of other comprehensive income as part of the statement of change in the stockholders’ equity has been eliminated. This update was applied retrospectively and was effective for the Company for the fiscal year beginning January 1, 2012. For the periods ended June 30, 2011 and June 30, 2012, comprehensive loss was equal to net loss as the Company had no other comprehensive income or loss to report in either period.